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Abstract 
Recently, it has emerged that the NO metabolites, nitrite and nitrate can be chemically 
reduced in vivo to biologically active nitric oxide (NO). This generation of NO is 
dependent on reduction of nitrate to nitrite by facultative anaerobes on the dorsal 
surface of the tongue, entry of the nitrite into the enterosalivary circuit, transit to the 
stomach, and absorption through the gut wall into the circulation. Conversion of nitrite 
to NO is then facilitated by vascular nitrite reductase enzymes. This nitrate-nitrite-NO 
pathway has been shown to exert a number of beneficial effects in healthy volunteers 
e.g. lowering of blood pressure, however whether this pathway is affected by 
cardiovascular disease (CVD) is currently unknown. 
 
Ozone chemiluminescence was used to determine and compare nitrite and nitrate 
levels in 2 models of CVD. To study atherosclerosis wild type (WT) and apolipoprotein 
E knock out (ApoE KO) mice were used and for hypertension wistar kyoto (WKY) rats as 
controls vs. spontaneously hypertensive rats (SHR). Assessment of nitrite reductase 
activity was conducted in the compartment which showed the most consistent 
differences in distribution, the red blood cell (RBC) and in homogenates of liver tissue. 
The impact of dietary nitrite and nitrate on distribution of the 2 anions throughout the 
cardiovascular system was assessed to determine the utility of this approach in 
restoring levels of these anions in CVD. Finally, using flow cytometry I investigated 
whether dietary nitrate supplementation could be used to influence inflammatory 
responses as a mechanism to improve CVD. 
 
Compared to WT mice, nitrate levels were reduced in ApoE KO mice in the plasma and 
across most of the tissues. In contrast in SHRs, reduction of the anions was only 
apparent in RBCs with no differences compared to WKY in all other tested tissues. 
Furthermore I have demonstrated that the most efficient way to restore nitrate levels 
back up to baseline is through a dietary nitrate strategy and that a dose of 15mM 
nitrate in the drinking water is sufficient to achieve this. In addition I have shown that 
nitrite reductase activity is enhanced in CVD particularly at the level of the RBC in both 
[3] 
 
 
atherosclerosis and hypertension and that this enhanced activity is due, in part, to 
upregulation of xanthine oxidoreductase (XOR). Finally I have shown that dietary 
nitrate is an effective way to modulate an acute inflammatory response. This 
modulation is mediated through interfering with the ability of the neutrophil to firmly 
adhere to the vascular endothelium. These changes were shown to be dose-
dependent and concomitant with dose-dependent increases in plasma nitrite and 
plasma nitrate. These data suggest that utilization of the nitrate-nitrite-NO pathway 
with dietary nitrate may represent an effective approach for the treatment of CVD. 
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1.1 Preface 
Cardiovascular disease (CVD) occurred most commonly in industrialized countries 
where the standard of living is particularly high in comparison to other nations, 
however in low- and middle-income countries (LMIC) CVD is rising. Globally, CVD is the 
main cause of death with approximately 17 million deaths occurring worldwide with 
over 80% taking place in LMICs (Chan, 2013) and over 4 million deaths occurring in 
Europe (Nichols et al., 2012). In Europe, the UK is one of the worst affected countries 
with CVD accounting for almost 180,000 deaths with the majority (80,568) resulting 
from coronary heart disease (CHD). England alone accounts for almost 83% of these 
CVD-related deaths (Townsend et al., 2012).   
 
CVD is an umbrella term encompassing several diseases including CHD, stroke and 
myocardial infarction. A key risk factor for many CVDs is hypertension and it has been 
suggested that by 2027 30% of the population will likely present with hypertension. 
This is despite many available options in terms of pharmacotherapy (Law et al., 2009). 
In addition a common underlying pathology for many CVDs, particularly stroke and 
myocardial infarction is atherosclerosis (Mendis et al., 2011). The actual pathology for 
atherosclerosis is extremely complex. It involves all of the structural elements of the 
arterial wall, the circulating cells e.g. platelets and leukocytes, as well as a number of 
inflammatory cells in particular monocytes/macrophages (Lusis, 2000). Previously, 
atherosclerosis was considered to be the result of passive lipid accumulation in the 
vessel wall but the current reality is far more complex. In terms of therapeutics, whilst 
the introduction of angioplasty with stent insertion followed by anti-platelet therapy 
has resulted in substantial improvements in mortality following an event (Keeley et al., 
2006), limited options in primary or secondary prevention are available underlying the 
huge demands of increasing morbidity. Inorganic nitrate and nitrite via provision of 
nitric oxide (NO) may offer an option and is the focus of this thesis. 
1.2 Overview of hypertension 
The pathogenesis of hypertension is multifactorial, highly complex and much 
uncertainty still remains. Indeed, approximately 2-5% of patients have underlying renal 
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or adrenal disease as the cause of their raised blood pressure (Beevers et al., 2001). 
For the remaining patients there is no single factor that is attributable for disease and 
in these particular circumstances the condition is termed essential hypertension. 
Essential, primary or idiopathic hypertension is defined as high blood pressure in which 
secondary causes such as renovascular disease, renal failure, aldosteronism or other 
causes of secondary hypertension are not present. Essential hypertension accounts for 
95% of all causes of hypertension and is a heterogeneous disorder with different 
patients having various apparent causal factors that lead to high blood pressure 
(Carretero et al., 2000). It is likely that a multitude of interrelated factors contribute to 
disease and the relative roles that these factors play differ from individual to 
individual. Salt intake, obesity, insulin resistance and the renin-angiotensin system are 
contributing factors that have gained much attention. Furthermore, additional 
contributors such as genetics and endothelial dysfunction are being evaluated 
(Beevers et al., 2001). 
 
The disease burden of arterial hypertension accounts for approximately 7.1 million 
deaths per year, which is equivalent to 13% of the total worldwide deaths (WHO, 
2010). Indeed most cases of hypertension can be effectively treated with lifestyle 
changes, drugs or in some cases both, however within this population there is a cohort 
at one end of the spectrum i.e. those with hypertension that are resistant to 
treatment. Resistant hypertension has been defined as a raised blood pressure (seated 
clinic blood pressure >140/90mmHg) despite treatment with at least 3 
antihypertensive agents at optimal or best tolerated doses. In the 2006 Health Survey 
for England, 20% of hypertensive patients had uncontrolled blood pressure despite the 
administration of at least 3 drugs, therefore in England alone it was estimated that 0.5-
1 million people present with resistant hypertension (Falaschetti et al., 2009), although 
recent estimates suggest that this ‘resistance’ may in part be accounted for by non-
compliance. Indeed the recent assessment of global burden of disease (1990-2010) 
demonstrates that systemic hypertension remains the largest attributable risk factor 
for mortality worldwide (Lim et al., 2010). In 2010 raised blood pressure was the 
second greatest and amongst the top 5 risk factors in the UK (Murray et al., 2010) and 
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US  (Murray, 2013) respectively. Worryingly, the scale of the problem is increasing, 
with the proportion of adults with hypertension predicted to increase to almost 1 in 3 
(1.57 billion) by 2025 (Kearney et al., 2005). Despite more than 60 years of innovation 
in the pharmacotherapy of hypertension (Laurent et al., 2012), only ~25% of 
hypertensives are treated for their BP and of those treated only ~30-40% are 
controlled to guideline-driven targets (Falaschetti et al., 2009; Egan et al., 2010; 
Persell, 2011). Amongst the many facets linked to poor BP control, non-adherence to 
pharmacotherapy is commonly reported (Burnier et al., 2013). A recent meta-analysis 
suggests that adherence (based upon prescription refill) to certain anti-hypertensive 
medications in primary prevention is ~50% (Naderi et al., 2012), and direct 
measurement of this by spot urine testing has supported this view where of those 
patients categorised with resistant hypertension, 53% were non-adherent to their 
pharmacotherapy regimes (Jung et al., 2013). Dislike of life-long pharmacotherapy, 
adverse medication effects and lack of hypertension symptoms are some of the 
reasons thought to underlie this non-adherence (Svensson et al., 2000). Thus, 
therapeutic strategies that offer non-medication approaches are of great interest.  
1.3 The basic aetiology of atherosclerosis 
Atherosclerosis is considered a slowly progressing chronic inflammatory disease that 
results in the formation of lesions (plaques) in large and mid-sized arteries. Risk factors 
include hypertension, diabetes, smoking and excessive food intake. Previous infection 
(e.g. influenza, oral pathogens), underlying autoimmune diseases (e.g. lupus) or 
rheumatoid arthritis increase ones susceptibility for the development of 
atherosclerosis  (Rosenfeld et al., 2011; Gonzalez-Gay et al., 2012; Sozeri et al., 2012). 
Even though plaques can grow to sufficiently large size to compromise blood flow, 
most of its clinical complications are attributable to arterial occlusion due to plaque 
erosion or rupture (Lusis, 2000). Plaques form at predisposed regions characterized by 
disturbed blood flow such as curvatures and bifurcations i.e. branch points. When 
plaques are damaged and rupture, prothrombotic material from the plaque is exposed 
to the coagulation system in the blood resulting in sudden thrombotic occlusion of the 
artery at the site of disruption leading to inhibition of blood flow and ultimately an 
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event (Lusis, 2000). In the heart, atherosclerosis can lead to myocardial infarction and 
heart failure whereas in the arteries that perfuse the brain, it can cause ischaemic 
stroke and transient ischaemic attacks. If atherosclerosis affects other arterial 
branches, renal impairment, hypertension, abdominal aortic aneurysms and critical 
limb ischaemia may result (Mendis et al., 2011). 
1.4 Atherosclerosis as a disease of inflammation  
The notion of atherosclerosis as an inflammatory disease is based on the finding that 
immune competent cells are abundant in atherosclerotic lesions, and that lesions are 
also sites for cytokine synthesis, in particular pro-inflammatory cytokines (Frostegard 
et al., 1999). Cells of both the innate and the adaptive immune system play a crucial 
role in atherosclerosis development. Through the transformation of immune cells into 
pro- and anti-inflammatory chemokine- and cytokine-producing cells as well as guiding 
the interactions between the different immune cells, the immune system critically 
influences the tendency of a plaque to rupture and cause clinical symptoms such as 
myocardial infarction and stroke.  
 
The development of atherosclerosis is initiated by activation, dysfunction and 
structural alterations of the endothelium, which is critical to the pathology of 
atherosclerosis. Activated endothelium with the expression of adhesion molecules is 
an early event in atherosclerosis (Drexler et al., 1991; Celermajer et al., 1992; 
Blankenberg et al., 2003; Halcox et al., 2009). Adhesion molecule expression allows 
mononuclear leukocytes, such as monocytes and T-cells, to attach to the endothelium 
and penetrate into the intima. Dendritic cells, mast cells, neutrophils, B-cells, smooth 
muscle cells (SMCs) may also be present in lesions. Contractile SMCs undergo 
phenotypic changes into synthetic SMCs and migrate into the intima from the media 
(Weber et al., 2011). 
 
The vascular endothelium essentially acts as a dynamic interface/barrier between the 
circulation and the arterial wall. The artery wall changes throughout ones life but the 
process of atherosclerosis is considered to be different from ageing. The inflammatory 
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nature of atherosclerosis and therefore CVD has been accepted for a long time. 
However, even with this understanding of the disease process there is no anti-
inflammatory or immune modulatory treatment available to ameliorate disease. The 
high incidence of atherosclerosis-related CVDs naturally causes an enormous and 
sustained burden on healthcare systems (Weber et al., 2011). Current therapeutics 
largely target alleviating hypertension and hyperlipidemia or controlling haemostasis 
to prevent thrombotic complications. Furthermore lifestyle changes can be 
implemented e.g. eating a healthier diet, exercising more, and use of medications such 
as cholesterol-lowering statins can be used in the treatment of atherosclerosis. In 
some cases surgery may be required to widen or bypass a section of a blocked or 
narrow artery. Unfortunately these strategies do not directly address the inflammatory 
processes that drive disease progression (Weber et al., 2011). 
 
As the immune response is a highly complex system numerous subtle targets for 
therapeutic manipulation are offered. As research uncovers the specifics of the host 
response to atherosclerosis more selective interventions might prove more 
appropriate for longer term atherosclerosis treatment. Clearly strategies that look to 
modulate the inflammatory response in atherosclerosis have potential therapeutic 
utility.  
1.5 The healthy endothelium 
In 1966 (Florey, 1966) it was suggested that vascular endothelium is more than a 
simple monolayer of cells and in the last few decades the importance of the 
endothelium in the regulation of cardiovascular physiology has been uncovered. The 
endothelial cell surface in an adult human is comprised of approximately 1 to 6x1013 
cells, weighs approximately 1kg and covers a surface area of approximately 1 to 7m2 
(Augustin et al., 1994). The healthy endothelium regulates vascular tone and structure 
as well as exhibiting anticoagulant, antiplatelet and fibrinolytic properties. The 
maintenance of these effects is accomplished by the release of numerous substances 
(Villar et al., 2006; Roberts et al., 2013). In the healthy endothelium there are 3 main 
substances thought to provide many of the beneficial properties of the endothelium 
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called endothelium-derived relaxing factors (EDRFs) that include prostaglandins, 
endothelium-derived hyperpolarizing factor (EDHF) (Chen et al., 1988) and nitric oxide 
(NO) (Furchgott et al., 1980), which is possibly the most important of all of the EDRFs 
(figure 1.1). 
 
These beneficial factors are released by the endothelium in response to physiological 
forces such as shear stress (Sessa et al., 1994) and by recirculation of locally generated 
hormones including bradykinin (BK), adenosine and vascular endothelial growth factor 
(VEGF) (Govers et al., 2001) (figure 1.1). NO (discussed in section 1.6) generated from 
the amino acid substrate L-arginine by the action of endothelial nitric oxide synthase 
(eNOS), is freely able to diffuse and crosses the underlying vascular SMCs as well as 
pass into the lumen where it acts upon platelets and leukocytes. It produces most of 
its effects in target cells by activating soluble guanylate cyclase (sGC), which leads to 
elevations in cyclic guanosine monophosphate (cGMP). 
Endothelial 
cell
Smooth muscle 
cell
Blood vessel 
lumen
Relaxation
Platelet 
aggregation
Leukocyte 
adherence
.
..
. ..
.
..
.. ....
....
Shear stress
EDRF
Adenosine
VEGF
BK
 
Figure 1.1: Production and release of EDRF from the endothelium to promote smooth muscle cell 
relaxation and exert anti-platelet and anti-inflammatory properties in the blood vessel lumen. BK, 
bradykinin; EDRF, endothelium-derived relaxing factor; VEGF, vascular endothelial growth factor. 
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EDHF activity is most well defined with respect to its hyperpolarizing effect on vascular 
SMCs resulting in potassium conductance and subsequent relaxation of vascular SMCs 
thus playing a critical role in maintaining vascular tone (Busse et al., 2002). The identity 
of EDHF is uncertain and may differ between vascular beds. It is however, well 
recognized that EDHF can compensate for loss of NO-mediated vasodilator tone in 
certain disease states including hypertension (Taddei et al., 1994), particularly in the 
microcirculation, and this appears important when NO bioavailability is reduced 
(Halcox et al., 2001). More recently there has been the suggestion that similarly to NO, 
EDHF might also influence inflammatory cell recruitment (Villar et al., 2011) and that 
EDHF pathways may play a greater role in determining vascular health in females 
compared to males (Scotland et al., 2005; Bubb et al., 2012).  
 
Prostacyclin, generated from arachidonic acid by the action of the cyclooxygenase 
enzymes, is another endothelium-derived mediator that expresses many 
characteristics displayed by NO (Moncada et al., 1977). The effects of prostacyclin are 
dependent upon the expression of its receptor, the prostacyclin receptor (IP) and 
consequent activation of adenylate cyclase. Prostacyclin is a dilator that inhibits 
platelet activation (Mustard et al., 1980) and some evidence supports a role in 
reducing leukocyte activation (Lefer et al., 1994; Thomson et al., 1994). Figure 1.2 
details the 3 main endothelial factors and their pathways, thought to underlie normal 
vascular health. 
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Figure 1.2: Schematic summarizing the release of relaxing factors from endothelial cells and their effect 
on vascular SMCs. AA, arachidonic acid; ATP, adenosine triphosphate; Ca
2+
, calcium; cAMP, cyclic 
adenosine monophosphate; cGMP, cyclic guanosine monophosphate; Cox, cyclooxygenase; EDHF, 
endothelium-derived hyperpolarizing factor; eNOS, endothelial nitric oxide synthase; GTP, guanosine 
triphosphate; IKCa, intermediate conductance Ca
2+
-activated K
+ 
channel; IP, IP receptor; K
+
, potassium; L-
Arg, L-arginine; Na
+
, sodium; NO, nitric oxide; PGI2, prostacyclin; PKA, protein kinase A; PKG, protein 
kinase G; sGC, soluble guanylate cyclase; SKCa, small conductance Ca
2+
-activated K
+ 
channel. 
  
Critically in CVD there is endothelial dysfunction. This dysfunction, however, 
represents not only a deficit of the bioavailability of the aforementioned mediators but 
also expression of damaging factors. For example, evidence demonstrates the 
generation of the potent constrictor and pro-hypertrophic mediator endothelin-1 as 
well as a switch from the generation of vasoprotective prostacyclin to damaging 
prostanoids including prostaglandin E₂ (PGE₂), and enhanced conversion of angiotensin 
I to angiotensin II (Saye et al., 1984; Kinlay et al., 2001). These changes underlie the 
switch in phenotype of the endothelium from beneficial to damaging. Perhaps the 
most prominent and well described change is the reduction in bioavailable NO. Indeed 
a loss in NO-mediated dilation (induced by shear stress) is used to characterize 
endothelial dysfunction (Celermajer et al., 1992; Celermajer et al., 1994).  
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1.6 Nitric oxide (NO) 
Nitric oxide (NO) was discovered in 1772 by Joseph Priestley as a clear, colourless gas 
with a half-life of 6-10 seconds (Priestley et al., 1772). In 1977 it was shown that 
sodium nitroprusside, nitroglycerin, sodium azide and hydroxylamine all increased 
guanylate cyclase activity in particulate and/or soluble preparations from various 
tissues (Katsuki et al., 1977). Activation of guanylate cyclase by these compounds 
consequently resulted in increases in cGMP levels. At the time the precise mechanism 
of activation was unknown, however it was postulated that activation may be due to 
the formation of NO since NO also increased guanylate cyclase activity (Katsuki et al., 
1977).  
 
It wasn’t until 1979 that the vascular smooth muscle relaxant properties of NO were 
discovered. Using bovine arterial strips in an organ bath Gruetter saw that the 
carcinogenic nitrosamine also known to liberate NO 1-methyl-3-nitro-1-
nitrosoguanidine (MNNG), nitroprusside and NO all caused concentration-dependent 
relaxation of precontracted strips  (Gruetter et al., 1979). Relaxation in response to NO 
was rapid but returned spontaneously to the initial level of induced tone. Coronary 
arterial relaxation by NO was abolished by agents that attenuated NO reactivity such 
as haemoglobin, methaemoglobin, myoglobin and the oxidant methylene blue 
(Gruetter et al., 1979).  
 
In 1980, Furchgott discovered that endothelial cells produce EDRF in response to 
stimulation by acetylcholine (ACh) in vessels with intact endothelium. In this study it 
was demonstrated that relaxation of isolated preparations of rabbit thoracic aorta, and 
other blood vessels, by ACh required the presence of an intact endothelium as 
disruption of the integrity of the endothelium (through rubbing it) caused a loss of 
ACh-dependent relaxation (Furchgott et al., 1980). ACh acting on muscarinic receptors 
of the endothelial cells stimulated release of a substance (or substances), which in turn 
acted on the SMCs in the media to activate relaxation. At the time, the substance was 
not identified to be NO, however other candidates such as bradykinin, prostacyclin and 
AMP were all ruled out (Furchgott et al., 1980). 
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In 1987, separately, Moncada et al. and Ignarro et al. proved that EDRF is NO. Prior to 
the discovery of EDRF as NO it was actually suggested by Furchgott that EDRF may be 
NO. Moncada et al. examined this suggestion by studying the release of EDRF and NO 
from endothelial cells in culture (Palmer et al., 1987). NO was determined by 
chemiluminescence and the biological activity of EDRF and NO was determined using 
bioassay tissues. The relaxations of bioassay tissues induced by EDRF and NO were 
indistinguishable. Bradykinin caused concentration-dependent release of amounts of 
NO sufficient to account for the relaxations that were induced by EDRF (Palmer et al., 
1987). In the study by Ignarro et al. similar patterns were seen in that the effects of 
EDRF were indistinguishable to the effects produced by NO. Their study, however, 
looked at the vascular effects of EDRF released from perfused bovine intrapulmonary 
artery and vein and subsequently compared them to the effects of NO delivered by 
superfusion and over endothelium-denuded arterial and venous strips arranged in a 
cascade (Ignarro et al., 1987). 
 
A year later, Moncada demonstrated that NO is synthesized from the amino acid L-
arginine in porcine aortic endothelial cells in culture. In this study, NO detection was 
achieved by bioassay, chemiluminescence and mass spectrometry. Release of NO from 
the endothelial cells was induced by bradykinin or the calcium ionophore A23187 
(Palmer et al., 1988a). Infusions of L-arginine and L-citrulline but not D-arginine (or 
other close structural analogues) reversibly enhanced the release of NO. Finally using 
15N-labelled L-arginine, mass spectrometry analysis indicated that the enhanced 
release of NO was due to the formation of NO from the terminal guanidine nitrogen 
atom(s) of L-arginine (Palmer et al., 1988a). As the importance of L-arginine in the 
generation of NO was determined this opened up opportunities for investigation of the 
pathways of the synthesis of NO.  
1.7 Nitric oxide synthase (NOS) family of enzymes 
The enzymatic production of NO from L-arginine is catalysed by 1 of 3 nitric oxide 
synthases (NOS) in a 2 step process via the formation of N-hydroxyl L-arginine (Dawson 
et al., 1994). NO has a multitude of functions throughout the body and 3 different 
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enzymes exist to tailor for its different locations and functions. The enzymes are all the 
same with respect to the fact that they all produce NO, however differences in 
structure and location allowing them to cater for the various functions of NO (the 
similarities and differences are summarized in table 1.1). 
 
The 3 isoforms have been characterized, purified and cloned in the order of their 
discovery: neuronal nitric oxide synthase (nNOS) or NOS1, inducible nitric oxide 
synthase (iNOS) or NOS2 and endothelial nitric oxide synthase (eNOS) or NOS3. The 3 
isoforms are actually encoded by 3 different genes on different chromosomes 
although they share between 50-60% homology in the amino acid sequence and in the 
amino acid sequence in the oxidase and reductase domains (Marletta, 1994; Govers et 
al., 2001).  
 
The first isoform isolated of NOS was reported in the brain. Initially the authors 
showed that nitric oxide synthase required CaM (calmodulin) as NO formation 
required calcium. They observed that CaM restored unrecovered enzymatic activity (in 
diethylaminoethyl eluate fractions). Furthermore it was shown that NO formation was 
dependent on the conversion of arginine to citrulline (Bredt et al., 1990). This was 
done by utilizing an assay that monitors the conversion of [3H]arginine to [3H]citrulline. 
Finally, based on the discovery that enzymatic activity was CaM-dependent and 
converted arginine to citrulline, it was possible to purify NO synthase to homogeneity 
from rat cerebellum. The purified enzyme was shown to exist as a monomer 150kDa in 
size (Bredt et al., 1990) and was termed neuronal NOS (nNOS). 
 
Soon after the discovery of nNOS, iNOS was isolated from macrophages. In a 2-column 
procedure using an affinity column and anion exchange column iNOS was purified 
from activated murine macrophages. Enzymatic activity was dependent on L-arginine 
and reduced nicotinamide adenine dinucleotide phosphate (NADPH) (Hevel et al., 
1991). Moreover factors such as tetrahydrobiopterin (BH₄) and flavin adenine 
dinucleotide (FAD) enhanced activity whereas magnesium and flavin mononucleotide 
(FMN) had no effect. The molecular weight of the protein was estimated to be 
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260

30kDa suggesting that the enzyme exists as a dimer (Hevel et al., 1991). iNOS is 
an enzyme that can be found in a number of cell types normally after several hours of 
exposure to cytokines and/or microbial products. The final isomer of NOS identified 
was endothelial NOS (eNOS) described in section 1.10. 
 
  NOS1/NOS3 NOS2 
Ca²⁺/calmodulin-dependent √ x 
Constitutive/inducible constitutive inducible 
Cytosolic √ √ 
Period of NO release short long 
Amount of NO released picomoles nanomoles 
Type of stimulation receptor/physical 
induced after macrophage 
activation, endothelial cells 
and a number of other 
cytokines 
Induction inhibited by 
glucocorticoids 
x √ 
Role 
transduction 
mechanism 
effector molecule whose 
release is induced during 
immunological reactions 
Table 1.1: Summary of the similarities, differences and differing functions of the 3 NOS isoforms 
1.8 Overview of NOS inhibitors 
In the literature numerous NOS inhibitors have been described. Inhibitors of NOS have 
been described which interact with the NOS enzymes in a variety of ways, for example 
at different sites, as well as different time- and substrate-dependence and mechanism 
of inhibition. Of these the most widely used have been NG-monomethyl L-arginine (L-
NMMA), N-nitro L-arginine (L-NNA) and N-nitro L-arginine methyl ester (L-NAME). 
Simple arginine derivatives were first considered as inhibitors for experimental use 
because they were expected to compete with arginine for the active site of NOS. L-
NMMA occurs naturally in living organisms as it is the product of the degradation of 
arginine-methylated proteins (Bedford et al., 2009). It is one of the first compounds 
which were intuitively employed to inhibit NOS’s at the end of the 80s (Palmer et al., 
1988b). L-NMMA has been widely used as a tool to decrease NO bioavailability or to 
establish the NO dependency of a physiological process. As the structure of L-NMMA is 
very close to arginine it acts as a competitive inhibitor of all NOS enzymes (Griffith et 
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al., 1996). An additional feature of L-NMMA is that it is easily taken up into cells via the 
action of cationic amino acid transporters since it has a similar affinity to arginine 
transport systems as L-arginine (McDonald et al., 1997). 
 
L-NNA was one of the first synthetic NOS inhibitors produced being demonstrated to 
block NO synthesis in the early 90s (Moore et al., 1990). Initially L-NNA was thought to 
act as a competitive inhibitor of all NOS isoforms with high selectivity for eNOS and 
nNOS rather than iNOS (Furfine et al., 1993). However a later study indicated only 
minor selectivity to nNOS and eNOS (Moore et al., 1996). Such a pattern of selectivity 
correlates with a different mechanism of L-NNA binding to individual isoforms. The 
binding of L-NNA to eNOS and nNOS is a time-dependent process with a relatively slow 
reversal (Furfine et al., 1994; Klatt et al., 1994). The only limiting factor of L-NNA 
application in biological systems is poor solubility (approximately 4mmol/L) at neutral 
pH. This issue was addressed by introducing L-NAME. L-NAME may act as a weak NOS 
inhibitor, however it is readily hydrolyzed by ubiquitously present esterases to L-NNA 
in a biological system (Griffith et al., 1996). The application of L-NAME in experiments 
in vitro and in vivo provides an advantage over L-NNA as there is no major limitation 
on solubility in an aqueous environment.  
 
The vast majority of this work contributed to the establishment of NO as a critical 
signalling molecule in the cardiovascular system. By 1993, NO had been implicated in 
the pathogenesis of diseases ranging from hypertension to septic shock (Moncada et 
al., 1993) and it is the wide-ranging importance of this molecule that ultimately led to 
the Nobel prize in Physiology or Medicine in 1998 being awarded to Robert Furchgott, 
Louis Ignarro and Ferid Murad. Over the last 2 decades NO research has crossed into 
almost every area of biomedicine that as such it is now hard to find a physiological 
system in which NO does not play a regulatory role. The wide biological significance of 
NO comes from the fact that it is widely synthesized but also because it is a very 
reactive molecule.  
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1.9 Endothelial NOS (eNOS) 
eNOS was purified from cultured and primary bovine aortic endothelial cells. The 
resultant protein was approximately 135kDa in size (Pollock et al., 1991). The activity 
of the enzyme was confirmed through its effect on sGC of rat fetal lung fibroblasts by 
measuring nitrite/nitrate formation and by bioassay on endothelium-denuded vascular 
strips. Furthermore activity was shown to be dependent on L-arginine, NADPH, calcium 
(Ca²⁺), CaM and BH₄ (Pollock et al., 1991) as with other isoforms. 
 
We now know that the 3 NOS isoforms are homodimeric proteins that require L-
arginine as the substrate as well as molecular oxygen and NADPH as co-substrates as 
well as FAD, FMN and BH₄ as essential cofactors (Marletta, 1994). Between the 3 of 
them the NOS enzymes cover a range of functions but of particular relevance to the 
cardiovascular system is eNOS as it is the predominant isoform in the vasculature and 
is therefore responsible for most of the NO produced within this system. 
1.9.1 The structure of eNOS 
eNOS is composed of 2 globular protein modules (reductase and oxygenase domains) 
connected via a flexible protein strand. The C-terminal reductase domain contains 
binding sites for NADPH, FMN and FAD whereas the N-terminal oxygenase domain, 
which subtracts 1 electron from L-arginine, has binding sites for heme iron, BH₄ and L-
arginine (see figure 1.3 for the structure of eNOS) (Knowles et al., 1994). From the 
carboxy-terminal reductase domain a normal functioning NOS enzyme generates the 
electrons required for NO synthesis by binding reduced NADPH and catalyzing its 
dehydrogenation. The electrons are transferred across the flexible protein strand from 
NADPH, via FAD and FMN, to the haem in the amino-terminal oxygenase domain. The 
electron transfer is activated by calcium-dependent binding of CaM to a specific 
binding site on the flexible protein strand (Knowles et al., 1994). The oxygenase 
domain consists of the catalytic center responsible for NO production. At the 
oxygenase domain the cofactors BH₄, molecular oxygen and L-arginine can also be 
bound. At the haem site of the oxygenase domain electrons are used to reduce and 
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activate oxygen and to oxidize L-arginine to L-citrulline and NO (Knowles et al., 1994; 
Forstermann et al., 2006; Dias et al., 2009). 
NADPH FMNFAD
FENO Arg
BH₄
O₂
Zn
HOOC
FE NOArg
BH₄
O₂
FMN NADPHFAD COOH
Zn
Reductase Domain
Oxygenase Domain
e⁻ e⁻
e⁻e⁻  
Figure 1.3: A model for the dimeric structure of eNOS. Electron (e⁻) transfer between cofactors and 
substrates is represented by the red arrows. The electrons flow from NADPH to FAD to FMN in the 
reductase domain of 1 monomer to iron (Fe) in the oxygenase domain of the adjacent monomer. 
Electron flow and catalysis is shown for both sides of the enzyme. Electron flow from 1 domain to the 
other is mediated by calmodulin (CAM) (adapted from (Munzel et al., 2005b)).  
1.9.2 Biochemistry of eNOS-derived NO 
eNOS is mostly expressed in endothelial cells but its expression is not restricted to this 
cell type. Indeed eNOS has been detected in cardiac myocytes, platelets and certain 
neurons of the brain (Forstermann et al., 1994). Importantly eNOS (as well as nNOS) is 
inactive at basal intracellular Ca²⁺ concentrations and requires an increase in 
intracellular Ca²⁺, through stimulation by hemodynamic shear stress or by the 
activation of G-protein coupled cell surface receptors to trigger activation. 
 
eNOS is usually found in regions of the plasma membrane called caveolae (small 
invaginations of the plasma membrane). Caveolae are structures associated with 
compartmentalizing signal transduction molecules that regulate endothelial cell 
functions including the generation of NO by eNOS (Drab et al., 2001). The initial step in 
NO production requires localization of eNOS to caveolae and requires cotranslational 
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myristoylation as well as posttranslational palmitoylation of eNOS (Liu et al., 1995). 
Only a fraction of eNOS is sequestered in the caveolae and it is this fraction that can 
interact with the caveolae protein caveolin-1. Caveolin-1 (a major coat protein of 
caveolae) is critical in regulating enzymic function as it tonically inhibits eNOS function 
by directly interacting with the enzyme (Garcia-Cardena et al., 1997). Indeed in 
caveolin-1 gene disrupted mice, blood vessels show enhanced endothelium-dependent 
relaxation (Drab et al., 2001). Displacement and therefore interruption of caveolin-1 
interaction with eNOS leads to activation of eNOS.     
 
As with nNOS, calcium-activated CaM is one of the key pathways for the regulation of 
eNOS activity. An increase in intracellular Ca²⁺ leads to enhanced binding of CaM to the 
enzyme (Forstermann et al., 1991; Pollock et al., 1991). Binding of CaM to its specific 
binding site increases the rate of electron transfer from the reductase domain to the 
catalytic centre of eNOS. The enhanced binding dislodges the auto-inhibitory loop 
leading to the facilitation of electron flow from NADPH (located in the reductase 
domain) to haem (located in the oxygenase domain) (Forstermann et al., 2012).  
 
eNOS activity is also regulated by phosphorylation. eNOS can be phosphorylated on 
several serine (Ser), threonine (Thr) and tyrosine (Tyr) residues. There are 2 critically 
established, functionally important phosphorylation sites in human eNOS, namely 
Ser1177 and Thr495 (Fleming et al., 2001). In a resting endothelial cell Ser1177 is not 
normally phosphorylated. Exposure to oestrogens, VEGF, insulin, bradykinin or fluid 
shear stress can induce phosphorylation (Michel et al., 1993; Papapetropoulos et al., 
1997; Dimmeler et al., 1999; Fulton et al., 1999). This activating phosphorylation 
requires recruitment of the kinase Akt and of heat shock protein 90 (Hsp90) (Garcia-
Cardena et al., 1998). Hsp90 functions as a scaffold for eNOS and Akt. Conversely 
phosphorylation at Thr495 inactivates eNOS (Fleming et al., 2001; Fleming et al., 
2003).  
 
BH₄ is a required cofactor of NO synthesis as it is a critical determinant of eNOS 
activity. Importantly depletion of BH₄ may result in ‘uncoupling’ (see figure 1.4) of 
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eNOS with a consequent reduction in NO synthesis and production of superoxide 
instead of NO by eNOS. Even when NO is produced from the healthy endothelium it 
can be rapidly inactivated by superoxide, particularly under conditions of high oxidant 
stress (Alp et al., 2004).  
NADPH FMNFAD
FE O₂
HOOC
FEO₂
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Diabetes
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Figure 1.4: Potential risk factors that may cause depletion of BH₄ ultimately leading to eNOS uncoupling 
and production of superoxide (O₂∙⁻) and potentially endothelial dysfunction. In many types of vascular 
disease, products of vascular disease (such as peroxynitrite) combine to oxidize BH₄, the essential 
cofactor of eNOS and/or produces damage to eNOS. Subsequently, O₂ reduction by eNOS is uncoupled 
from NO formation and a functional NOS is converted into a dysfunctional O₂∙⁻ generating enzyme that 
contributes to vascular oxidative stress (adapted from (Munzel et al., 2005b).  
1.10 Biochemistry of NO reactions 
The steady-state concentration of NO is determined by its rate of formation and its 
rate of decomposition. The metabolic pathway of NO depends strongly on its site of 
administration or formation. In biological systems, the mode and rate of NO 
metabolism is dependent on its own concentration, its diffusibility and the surrounding 
concentration of other bioreactants. Diffusion is essential for understanding the ability 
of NO to act as a local modulator and is a major determinant of biological life time 
(Lancaster, 1994; Beckman et al., 1996a). In the absence of haemoglobin, NO rapidly 
diffuses along the vasculature and reaches vascular SMCs and mitochondria of 
cardiomyocytes in sufficiently bioactive amounts to affect coronary blood flow and left 
[44] 
 
 
ventricular function (Kelm et al., 1995; Kelm et al., 1997). Within the myocardial tissue, 
endothelial NO is avidly bound to myoglobin, resulting in steady-state concentration of 
0.1-0.3µM, which exerts inhibitory effects on cytochrome oxidase and the electron 
transfer of the respiratory chain in the mitochondria (Poderoso et al., 1998). Thus in 
agreement with its function as a paracrine mediator, NO can travel significant 
distances to reach target cells neighbouring the NO generating cell with little 
consumption or direct reaction. Along this migration, in particular at higher 
concentration, NO can interact with molecular oxygen, thiols and reduced 
hemoproteins. The extent of either of these reactions largely depends on the 
microenvironmental conditions in which NO is released, most important, the 
concentration of other bioreactants (Heinrich et al., 2013). 
 
Aside from molecular oxygen, several reactive oxygen derived species (ROS), such as 
superoxide anion (O₂⁻), hydrogen peroxide (H₂O₂) and hydroxyl radical (HO∙) interact 
with NO. The main biological targets for NO within the cell are oxygen-centred radicals, 
metal-, thiol- and amine containing proteins and low molecular weight thiols. Many of 
these targets are biologically active and are involved with a diverse array of normal 
cellular and physiological processes. Although the chemical reactions in which NO 
participate are quite varied, the constraints imposed by biological conditions narrow 
the relevant reactions considerably. It is possible to view these reactions as either 
direct or indirect reactions of NO (Wink et al., 1996; Thomas et al., 2008). 
 
Direct reactions refer to those interactions in which NO binds directly with biological 
targets, predominantly metal complexes, radical species and oxygen. These reactions 
are generally rapid, require low concentrations of NO and are the basis for the 
majority of NO-related biological effects. The reaction of NO with certain metals to 
form nitrosyl complexes occurs in vivo mainly with iron-containing proteins (Thomas et 
al., 2003). The reaction between NO and haem proteins represents a critical signaling 
pathway, the most well studied example being NO’s interaction with sGC, a key 
enzyme in the pathway of NO-mediated vascular dilation (Denninger et al., 1999; 
Munzel et al., 2003) and discussed later. The reaction between NO and haem proteins 
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represents an important signaling pathway which is influenced by the redox state of 
the haem and the structure of the protein. For example, in terms of redox state, the 
rate constant for NO dissociation from a ferric (iron (III), Fe3⁺) haem protein is 4 times 
that of the corresponding ferrous (iron (II), Fe²⁺) haem (Kharitonov et al., 1997; Sharma 
et al., 1999). Ferrous haem also has a comparably faster association rate, making these 
complexes relatively stable and ferric haem protein complexes reversible in many 
cases (Ford et al., 2002; Thomas et al., 2003). The most well studied example of NO 
interaction with haem is the reaction with sGC. sGC is an obligate heterodimer 
consisting of 1 α and 1 β subunit and a non-covalently bound haem (Wedel et al., 
1995). More than 1 model of sGC activation/deactivation have been suggested 
(Poulos, 2006), however it is generally agreed that nitrosylation of the haem severs the 
proximal histidine bond, triggering intramolecular rearrangements which influence the 
catalytic centre and result in a significant increase in cGMP levels (Ignarro et al., 1982; 
Zhao et al., 1999). The severing of the histidine bond converts the haem from an initial 
6-coordinate Fe²⁺-nitrosyl intermediate to a 5-coordinate Fe²⁺-nitrosyl species (Stone 
et al., 1994; Stone et al., 1996; Ballou et al., 2002), a process that may be accelerated 
by additional non-haem NO (Cary et al., 2006). Increased levels of cGMP resulting from 
sGC activation decrease the intracellular calcium concentration resulting in 
dephosphorylation of myosin light chains and subsequent relaxation of vascular 
smooth muscle, eliciting the classic pathway of NO-dependent vasodilation (Munzel et 
al., 2003). Other NO-mediated nitrosylation pathways also inhibit metalloproteins such 
as cytochrome P-450, NOS, cytochrome oxidase and catalase (Wink et al., 1997).  
 
Furthermore, NO can react directly with high energy radicals such as carbon-, oxygen- 
and nitrogen-centred radicals. Arguably the most significant reaction is with 
superoxide (O₂⁻, formed from the 1 electron reduction of molecular oxygen) forming 
the nitrogen oxide peroxynitrite (ONOO⁻, equation 1.1) (Beckman et al., 1990). 
NO O₂⁻+ ONOO⁻
 
Equation 1.1: The reaction of nitric oxide (NO) with superoxide (O₂⁻) to generate peroxynitrite (ONOO⁻). 
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Peroxynitrite can cause severe tissue damage through its reactions with proteins, lipids 
and DNA (Szabo et al., 2007). Peroxynitrite decays rapidly once protonated forming 
peroxynitrous acid (ONOOH) and eventually nitrate (Beckman et al., 1990). This 
interaction of NO with superoxide is thought to play a critical role in the phenomenon 
of endothelial dysfunction (Channon et al., 2002). The reaction between NO and 
oxygen (commonly referred to as autoxidation) forms nitrogen dioxide (NO₂, equation 
1.2) and other nitrogen oxides such as N₂O₃ and N₂O₄ (termed reactive nitrogen oxide 
species, equation 1.3).  
2NO + O₂ 2NO₂
 
Equation 1.2: The autoxidation reaction of nitric oxide (NO) with oxygen (O₂) forming nitrogen dioxide 
(NO₂). 
 
NO + NO₂ N₂O₃
 
2NO₂ N₂O₄
 
Equation 1.3: The formation of other nitrogen oxides (N₂O₃ and N₂O₄) from the reaction of NO with 
NO₂. 
  
The autoxidation reaction is second order with respect to NO and first order with 
respect to oxygen and therefore third order overall and involves 2 NO molecules with 
1 oxygen (equation 1.2). The reaction is relatively slow at physiological NO 
concentrations in health but is more relevant in certain environments such as in the 
immediate vicinity of NO production or activated macrophages and neutrophils or 
under pathophysiological conditions where the NO concentration is raised. 
 
The indirect reactions of NO are often mediated by products of the direct reactions in 
particular reactive nitrogen oxide species derived from the interactions of NO with 
molecular oxygen or superoxide. It is the reactive intermediates and not NO itself that 
ultimately react with target specific motifs. Indirect reactions tend to require initial 
higher concentrations of NO due to the lower relative concentrations of the reactants. 
Nitrogen oxides range from the fully oxidized nitrate (NO₃⁻) to the fully reduce 
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ammonia (NH₃) and in between these 2 states exists a range of partially reduced 
nitrogen oxides (Wink et al., 1996; Thomas et al., 2008). 
 
In the vascular system on production in the endothelium, NO diffuses into the 
underlying smooth muscle and reacts directly with sGC to elicit vasodilation. NO 
diffusing into the blood stream is rapidly metabolized to various reaction products. In 
blood the formation of NO metabolites is dependent on the environmental conditions 
at a given moment. Key factors that require consideration are the concentration of NO 
itself, the surrounding conditions (e.g. partial pressure of oxygen, pH, and type and 
amount of free radicals), concentration of thiols and the presence of haem proteins 
(e.g. guanylate cyclase, haemoglobin, superoxide dismutase and xanthine 
oxidoreductase) (Stamler et al., 1996; Kelm, 1999). In the plasma compartment 
autoxidation of NO produces NO₂ (equation 1.2), which can either dimerise to form 
N₂O₄ or couple with unreacted NO to form N₂O₃ (equation 1.3) (Stamler et al., 1996). 
These nitrogen oxides then either nitrosate low molecular weight thiols including 
cysteine, thiol groups, amines to produce N-nitroamines or they can be further 
hydrolysed to produce nitrite (NO₂⁻) and nitrate (NO₃⁻) (Lewis et al., 1994). Due to the 
concentration of reactants the primary pathway through which NO is metabolized in 
blood is reaction with the haem group of oxy- and deoxyhaemoglobin contained in the 
red blood cells (RBCs). The reaction between NO and oxygenated haemoglobin forms 
nitrate and methaemoglobin (equation 1.4).  
NO HbO₂+ MetHb + NO₃⁻
 
Equation 1.4: The primary reaction pathway of NO in blood involves reaction with oxygenated 
haemoglobin (HbO₂) to generate methaemoglobin (MetHb) and nitrate (NO₃⁻). 
 
The reaction between NO and deoxygenated haemoglobin forms iron-nitrosyl 
haemoglobin (equation 1.5).  
NO Hb+ HbNO
 
Equation 1.5: Formation of iron-nitrosyl haemoglobin (HbNO) from the reaction of NO with 
deoxygenated haemoglobin (Hb). 
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The major NO metabolite species observed in blood under normal physiological 
conditions are nitrate and nitrite with smaller amounts of S-nitrosothiols, N-
nitroamines and HbNO (Kelm, 1999). 
1.11 Functional effects of NO 
In addition to its effects on vascular tone NO also exerts other functions that underlie 
its critical role in sustaining vascular health. The endothelial response to platelets is 
controlled by 3 major mediators, serotonin, ADP and thrombin, which act on 5-HT1D 
serotonin and P2Y purinergic receptors respectively. The endothelial action of 
thrombin and platelet products is crucial for the protective role played by the normal 
healthy endothelium against unwanted coagulation. Local platelet aggregation along 
with the release of serotonin, ADP and the production of thrombin (from the local 
activation of the coagulation cascade), leads to a significant local release of NO that 
diffuses into the underlying vascular SMCs inducing relaxation and dilation of the 
artery. This process aids elimination of the microaggregate. In addition to vasodilation 
NO exerts a number of effects directly on the platelet, which also attenuate platelet 
reactivity. Furthermore, release of NO toward the blood vessel lumen also inhibits 
platelet adhesion to the endothelium. Thus the tonic NO generation in a healthy blood 
vessel, in synergy with prostacyclin, is thought to eliminate the potential danger of 
vascular occlusion (Radomski et al., 1990). 
 
The direct actions of NO to inhibit platelet activation (Stamler et al., 1989; Cooke et al., 
1990) and prevent thrombosis are thought to be mediated in part through inhibition of 
the normal activation-dependent increase in the expression of platelet surface 
glycoproteins such as P-selectin and the integrin glycoprotein IIb/IIIa complex 
(Michelson et al., 1996). These effects of NO have been shown to be due to sGC 
stimulation resulting in cGMP-dependent protein kinase stimulation leading to a 
reduction in binding of fibrinogen to glycoprotein IIb/IIIa and modulation of 
phospholipase A2- and C-mediated responses (Radomski et al., 1993). However, there 
is some controversy regarding this issue with some suggestions in sGC deficient mice 
that cGMP increases platelet activation (Marjanovic et al., 2005; Stojanovic et al., 
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2006; Zhang et al., 2011). However, contrasting publications also in sGC knock outs 
(KOs) and several other studies demonstrating NO-mediated repression of platelets 
support NO-mediated reductions in platelet reactivity (Dangel et al., 2010; 
Rukoyatkina et al., 2011). Perhaps most relevant to this thesis are the effects of NO in 
inflammation. Strong evidence suggests that in health the NO released tonically by the 
endothelium plays a critical role in repressing inflammation within the blood vessel 
wall. 
1.11.1 NO and its role in inflammation 
The inflammatory response is the response of the host that is required to inactivate or 
destroy invading pathogens, remove irritants as well as preparing the site of damage 
for tissue repair. The response consists of specific immunological attack and non-
specific immune reactions. The primary drivers in the process of inflammation include 
an increase in vascular permeability, release of lipid-derived autacoids or release of 
cytokines such as interleukin-1 (IL-1), release of small peptides such as bradykinin as 
well as amines such as histamine from injured tissues and migrating cells. NO has been 
proposed to play an influential role at almost every stage in the development of 
inflammation (table 1.2). In particular NO has been implicated in each step of the 
inflammatory cell recruitment process which is a sequential, multistep cascade that 
initially requires the rolling of leukocytes to endothelial cells (Rao et al., 2007). The 
initial process is a mechanism that supports leukocyte tethering and rolling (step 1), 
firm adhesion (step 2) and transmigration (step 3) under laminar shear stress. Each of 
these steps invites interplay between soluble mediators including chemoattractants 
and adhesion molecules. 
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 Symptom Mediators 
Vascular permeability 
Vasoactive amines, Bradykinin, Leukotrienes 
(C₄, D₄, E₄), PAF, Complement (C3a and C5a), 
NO 
Vasodilatation 
NO, PGI₂, PGE₁, PGE₂, PGD₂, Hydrogen 
peroxide  
Vasoconstriction 
Thromboxane A₂, Leukotrienes (C₄, D₄, E₄), 
Superoxide 
Chemotaxis and leukocyte adhesion 
Chemokines, LTB₄, Complement (C5a), 
Superoxide 
Pain Bradykinin, Prostaglandins, Superoxide 
Fever IL-1, TNF, IL-6, Prostaglandins 
Tissue and endothelial damage 
Reactive oxygen species, Nitric oxide (iNOS), 
Lyzosomal enzymes 
Table 1.2: Summary of the various processes in inflammation that NO might contribute to (adapted 
from (Guzik et al., 2003)). 
 
NO produced by the endothelium acts as an endogenous inhibitor of neutrophil 
adhesion to vascular endothelium. In 1991, it was first proposed that inhibition of NOS 
in the microvasculature would lead to an increase in leukocyte recruitment. 
Quantification, using intravital microscopy of NO-dependent leukocyte (mostly 
neutrophil) adhesion was conducted in cat mesenteric venules superfused with the NO 
synthase inhibitor L-NAME or L-NMMA (Kubes et al., 1991). Use of either inhibitor 
caused a significant increase (L-NMMA=16-fold; L-NAME=21-fold) in leukocyte 
adherence with promotion of emigration, 2 events generally associated with 
microvascular dysfunction. Reversal of L-NAME-induced inhibition was possible with L-
arginine. In this particular study the authors also used the CD18-specific antibody IB₄ 
and demonstrated attenuation of the adherence properties of the leukocyte in the 
presence of blockade of the adhesion glycoprotein CD11/CD18. The authors suggested 
that NO also targets this adhesion molecule since the effect of the NOS inhibitor L-
NMMA or L-NAME were prevented in the presence of antibody (Kubes et al., 1991). 
Furthermore pretreatment of cats with L-arginine prevented L-NAME-induced 
increases in microvascular protein and fluid flux as well as vascular protein clearance 
(Kubes et al., 1992). Similar observations have also been shown in rat and mouse 
mesentery (Davenpeck et al., 1994; Ahluwalia et al., 2004) 
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Similarly, in rat mesentery exposure to L-NAME initially caused leakage into the 
interstitial space that was also followed by leukocyte adherence and emigration. In this 
study, as previously, attenuation of expression of the adhesion molecules CD11/18 
was observed but the authors also demonstrated suppression of intercellular adhesion 
molecule-1 (ICAM-1) or P-selectin (CD62P) (Kurose et al., 1993) an observation 
supported by others (Davenpeck et al., 1994) but also by studies in mice. Ahluwalia et 
al demonstrated elevated leukocyte rolling at rest and following IL-1β in eNOS KO mice 
vs. WT mice: an effect that was associated with upregulated P-selectin expression at 
the level of the endothelial cell (Ahluwalia et al., 2004). In line with this, NO donors 
such as nitroprusside also exhibit anti-inflammatory effects. Superfusion with 
nitroprusside reversed L-NAME induced vascular protein and fluid leakage in cat 
mesentery (Kubes et al., 1992). 
 
These effects of endogenous and exogenously delivered NO upon cell recruitment 
appear to be mediated by activation of cGMP. In the study of Kurose et al L-NAME 
induced adhesion in rat mesenteric venules was reversed with a cGMP analogue 
(Kurose et al., 1993). Furthermore, studies in mice demonstrate that activators of sGC 
such as the Bayer compound BAY 41-2272 mimic the effect of endothelial-derived NO 
and reduce the raised leukocyte rolling evident in eNOS deficient mice (Ahluwalia et 
al., 2004). 
 
The inhibitory action of NO on leukocytes has been shown to extend to monocytes as 
well as neutrophils. The interaction of endothelial cells with circulating monocytes is a 
key part of the normal host-defense pathways in normal vascular biology. Indeed, the 
constant on/off interaction of monocytes with the endothelium has been described as 
a mechanism of survival and the particular subset of monocytes that do this are 
termed ‘patrolling’ monocytes in some instances (Shi et al., 2011). However, prolonged 
interactions between these cells and the endothelium are implicated in the 
pathogenesis of vascular disease. Monocyte adhesion to porcine aortic endothelial 
cells was shown to increase in response to the chemoattractant N-formyl-methionyl-
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leucyl-phenylalanine (fMLP). However, bubbling of pure NO into the bathing medium 
resulted in a reduction of adhesion. Since no change in the leukocyte adhesion 
molecule CD11b/18 was evident in these experiments it was suggested that the effects 
were related to changes at the level of the endothelium rather than on the monocyte 
itself. In the presence of superoxide dismutase (SOD) the effects of NO were enhanced 
and this was associated with increased levels of endothelial cGMP, demonstrating that 
prevention of NO scavenging by superoxide lead to repression of monocyte adhesion 
by influencing the endothelium (Bath et al., 1991). In another study IL-1α-stimulated 
human saphenous vein endothelial cells were used to investigate NO-mediated 
monocyte adhesion. It was shown that 3 structurally unrelated NO donors (SNP, SIN-1 
and GSNO) inhibited VCAM-1 expression (De Caterina et al., 1995). For maximal 
inhibition of adhesion molecule expression the presence of the NO donors throughout 
the period of stimulation was required. This reduction in VCAM-1 expression was 
paralleled by reduced monocyte adhesion to endothelial monolayers. Furthermore 
inhibition of endogenous NO production induced VCAM-1 expression (De Caterina et 
al., 1995). Finally, it has been suggested that at least part of the suppression of 
monocyte adhesion relates to a suppression of chemokine expression. In human 
studies a specific suppression of monocyte chemoattractant protein-1 (MCP-1) has 
been demonstrated (Desai et al., 2006). Thus, endothelial-derived NO prevents 
leukocyte adhesion and their subsequent migration into the subendothelial space. The 
anti-leukocyte properties of NO are mediated through inhibition of the expression of 
endothelial cell surface adhesion molecules P-selectin, vascular adhesion molecule-1 
(VCAM-1), ICAM-1 as well as repression of leukocyte CD11/18 and prevention of the 
expression of monocyte chemoattractant protein-1 (MCP-1). 
 
Interestingly, it has been suggested that during vascular adherence a number of 
phenomena occur that influence endothelial NO-induced repression of cell 
recruitment. The adhesion of monocytes to the endothelium itself was shown to 
suppress the release of biologically active NO in a monocyte concentration- and time-
dependent manner (Marczin et al., 1996). Investigations of the effects of monocytes 
on the NO pathway on cultured endothelial cells have revealed that the attenuation of 
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NO release is also due to reduced levels of eNOS. It was suggested that such an effect 
would naturally predispose a vessel to form atherosclerotic lesions due to a 
combination of effects such as thrombosis and increased recruitment of platelets and 
leukocytes to the site of inflammation (Marczin et al., 1996). 
 
Thus it is clear that NO plays an important role in keeping the blood vessel in an anti-
inflammatory state that is repressive for inflammatory cell recruitment. In CVD the 
presence of endothelial dysfunction that is characterized by reduced bioavailability of 
endothelial NO thus places the blood vessel vulnerable to inflammatory cell 
recruitment.  
1.12 The key events in endothelial dysfunction 
The term ‘endothelial dysfunction’ stems from an observation that Ludmer and co-
workers made in 1986 when they reported that ACh-induced vasorelaxation was 
impaired, even reversed, in atherosclerotic coronary arteries in humans (Ludmer et al., 
1986). The investigators observed paradoxical constriction in the arteries of patients 
with CAD as well as in those with advanced CAD, indicating that endothelial 
dysfunction is present in the early stages of atherosclerosis (Ludmer et al., 1986). In 
addition in studies looking at either ACh-induced vasorelaxation or measurement of 
flow mediated dilatation (FMD), endothelial dysfunction was detected in both the 
conduit and microvascular blood vessels in patients with coronary risk factors 
(Celermajer et al., 1994; Reddy et al., 1994). Brachial artery ultrasound measurement 
of FMD is commonly used to assess endothelial function in humans and is the gold 
standard for demonstrating endothelial dysfunction in CVD patients (Corretti et al., 
2002). 
 
Atherosclerosis, and diseases which predispose to atherosclerosis such as 
hypercholesterolaemia, diabetes and hypertension, are characterized by endothelial 
dysfunction (Cai et al., 2000). Under this particular state endothelial cell function is 
compromised leading to altered activity of platelets, leukocytes and the underlying 
vascular SMCs. Experimentally endothelial dysfunction is commonly characterized by 
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demonstrations of defects in the normal vaso-relaxation response to mediators such 
as ACh and/or to increased blood flow. The underlying basis for endothelial 
dysfunction is thought to involve a reduction in bioavailable NO in the vasculature. 
There are several mechanisms that are thought to underlie the reduced bioavailability 
in NO and these can broadly be divided into 3 categories: reduced expression of eNOS, 
reduced eNOS enzymatic activity and rapid removal of NO. 
 
Expression of eNOS may be reduced at the vessel wall due to reduced transcription 
and/or increased instability of eNOS mRNA caused by cytokines (Oemar et al., 1998). 
Indeed there are numerous demonstrations of reduced eNOS expression in models of 
CVD, including atherosclerosis (Oemar et al., 1998; Won et al., 2007) and hypertension 
(Giaid et al., 1995; Chou et al., 1998). However, this issue is controversial since in 
several animal models of atherosclerosis an unchanged or even augmented expression 
of eNOS, at least in early atherosclerosis, despite the presence of impaired 
endothelium-dependent relaxations has been demonstrated (Kanazawa et al., 1996; 
d'Uscio et al., 2001). 
 
Under pathological conditions it is now well accepted that eNOS can switch from an 
NO-producing enzyme to an enzyme that generates ROS. This phenomenon is termed 
eNOS uncoupling (see figure 1.4) and results in superoxide formation if the key 
cofactor BH₄ is not present (Alp et al., 2004), or generation of hydrogen peroxide if the 
substrate L-arginine is deficient (Vasquez-Vivar et al., 1998; Cai et al., 2005; Crabtree et 
al., 2011). Laursen et al demonstrated the production of superoxide from eNOS. In 
apolipoprotein E knock out (ApoE KO) mice the authors showed the increased vascular 
superoxide production from the endothelium was associated with impaired 
endothelial function. Incubation of vessels with sepiapterin (a precursor to BH₄) 
decreased superoxide formation and improved endothelial function (Laursen et al., 
2001). The enzymatic activity of eNOS is inhibited by various mechanisms associated 
with atherosclerosis and hyperlipidemia. Pro-atherogenic lipids, such as oxidized low-
density lipoprotein (oxLDL) inhibit signal transduction from receptor activation to 
eNOS activation (Hirata et al., 1991). Hypercholesterolemia and LDL upregulate 
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caveolin abundance, augment the caveolin-eNOS complex and therefore attenuate NO 
production from the endothelial cell (Feron et al., 1999; Feron et al., 2001). 
Endogenous NOS inhibitors e.g. asymmetric dimethylarginine (ADMA) and N-
monomethylarginine (NMA) are also thought to contribute to a reduction in the 
endothelium-dependent relaxation response in CVD (Miyazaki et al., 1999; Cooke, 
2000) since levels of these are elevated in both atherosclerosis (Boger et al., 1997) and 
hypertension (Surdacki et al., 1999). 
 
Increased superoxide production causing accelerated NO degradation is another key 
mechanism in endothelial dysfunction (Harrison, 1997). In animal models of 
atherosclerosis and in patients there is evidence of an increase in superoxide 
production (Ohara et al., 1993; Rikitake et al., 2001). The endothelium is an important 
source of superoxide production and its denudation decreases superoxide production 
from vessels that have atherosclerosis compared to no effect being observed in normal 
vessels that do not have atherosclerosis (Ohara et al., 1993). As well as uncoupled 
eNOS additional important endothelial sources of superoxide in pathological 
conditions include XOR (Berry et al., 2004) and NADPH oxidase (Frey et al., 2009; 
Manea, 2010). In vivo models of hyperlipidemia and atherosclerosis are associated 
with excessive amounts of superoxide that is linked to reduced bioavailable NO. 
Excessive superoxide production has been confirmed by the use of antioxidants and 
superoxide dismutase in restoring impaired endothelium responses in atherosclerotic 
vessels (Mugge et al., 1991; Drexler, 1997). In rabbit aortae with high-cholesterol diet-
induced atherosclerosis, the impaired vasodilatory responses to ACh and A23187 
(calcium ionophore) were restored by chronic treatment with polyethylene-glycolated 
SOD (Mugge et al., 1991). Furthermore antioxidants improve endothelial function in 
human and animal models with atherosclerosis (Taddei et al., 1998; Beckman et al., 
2001) in particular vitamin C is effective in the restoration of endothelium dysfunction 
from risk factors such as hypercholesterolemia, hypertension and diabetes mellitus 
(Levine et al., 1996; Ting et al., 1996; Ting et al., 1997). 
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Endothelial dysfunction was first described in human hypertension in the forearm 
vasculature in 1990 (Panza et al., 1990). Impaired vasodilation in hypertension has 
been confirmed by many studies in different vascular beds, including small resistance 
vessels (Schiffrin et al., 2000; Park et al., 2001). Although human and animal studies 
have demonstrated that hypertension is accompanied by an increase in oxidative 
stress, the evidence for this in humans is not definitive (Oparil et al., 2003). Clinical 
studies have shown that there is an increase in production of oxygen-derived free 
radicals (Mehta et al., 1994), together with a decreased level of antioxidants (Sagar et 
al., 1992). Although studies in humans have not been as convincing as those in 
experimental models the increase in oxidative stress has been shown in various types 
of hypertension such as essential hypertension, renovascular hypertension, salt-
sensitive hypertension and preeclampsia (Higashi et al., 2002; Lee et al., 2003; Fortuno 
et al., 2004). Furthermore, plasma levels of ADMA and 13-hydroxyoctadecadienoic 
acid (a marker of ROS production) are both elevated in patients with hypertension, and 
microvessels from patients with the highest levels of these markers are least 
responsive in terms of NO-induced relaxation (Wang et al., 2009).     
 
Thus NO is a critical molecule in cardiovascular physiology. Release of NO from the 
endothelium regulates vascular homeostasis, however numerous CVDs or risk factors 
impair NO synthesis or increase NO destruction. The overall effect is the enhancement 
of vascular tone and reactivity as well as predisposition to atheroma formation. Thus 
development of novel strategies to replenish reduced NO levels have clear therapeutic 
potential. The identification of endogenous NO generating pathways independent of 
the conventional L-arginine/NOS pathway centres on the chemical reduction of nitrite 
and have recently offered new opportunities to deliver NO in CVD. 
1.13 Introduction to nitrite in physiology 
In 1953 Furchgott demonstrated that nitrite relaxed spirally cut strips of rabbit thoracic 
aorta, however this only occurred at high concentrations of nitrite (100 and 1000µM). 
Low concentrations were not actually tested therefore it was inferred that at least at 
physiological levels nitrite had no biological activity (Furchgott et al., 1953). 
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Thus in 2001 nitrite was generally viewed as having little physiological function and 
was largely viewed as a useful marker of endogenous NO production and reflective of 
NOS activity. Indeed studies in healthy volunteers confirm that nitrite rather than 
nitrate provides an accurate estimate of eNOS activity (Lauer et al., 2001). In blood 
collected from 24 healthy volunteers from the antecubital vein and the brachial artery 
at rest there was no difference in nitrite or nitrate levels between the arterial and 
venous circulations (Lauer et al., 2001). However, following infusion of the eNOS 
inhibitor L-NMMA dose-dependent decreases in blood flow were evident and 
associated with dose-dependent decreases in nitrite but no changes in nitrate. 
Furthermore stimulation of eNOS with ACh augmented forearm blood flow almost 4-
fold and the change was paralleled with increases in plasma nitrite concentration and 
no significant changes in plasma nitrate concentration. In this study the authors also 
infused nitrite into the forearm at doses of 0.01-36µmol/min, levels that resulted in 
elevations of venous nitrite, however no change in forearm blood flow was evident. 
Importantly the authors measured venous plasma nitrite concentrations, which 
exceeded 130µM and found that they were approximately 200 times greater than the 
concentrations measured during maximal eNOS stimulation with ACh. The results 
demonstrated that circulating levels of nitrite are a good reflection of eNOS activity 
but that nitrite per se was not responsible for change in blood flow and possessed no 
vasodilator activity, essentially confirming the view that Furchgott’s studies in 1953 
had established (Lauer et al., 2001). This view contradicted proposals that nitrite might 
play a role in NO delivery, however in 2003 this view was strongly challenged by 
studies demonstrating exactly the contrary. 
 
In 2000, work published by Gladwin and colleagues showed significant arterial-venous 
gradients for plasma nitrite demonstrating that at baseline arterial nitrite levels 
(54074nM) were significantly greater than venous nitrite levels (466±79nM) (Gladwin 
et al., 2000). Even though this work demonstrated the existence of the arterial-venous 
gradient, suggesting that nitrite is reduced to NO under normal physiological 
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conditions, others supported the view that the gradient was actually a result of 
differences in NOS activity (Luchsinger et al., 2005). 
 
In 2001, using rat aorta in vitro, the vasorelaxant effects of physiological levels of 
nitrite was demonstrated where in phenylephrine precontracted aortic segments 
sodium nitrite caused dose-dependent relaxation (Modin et al., 2001). In a neutral 
buffer (pH 7.45) the threshold dose was 10µM, the EC50 was 200µM and the aortic 
segment relaxed to almost basal tone following 1000µM nitrite, which was the highest 
concentration tested. In acidic buffer (pH 6.66) the threshold dose was 2.5µM and the 
EC50 was 40µM, therefore a leftward shift of the concentration-response curve was 
observed. The nitrite-derived relaxant effects were blocked by the sGC inhibitor 1H-
[1,2,4]oxadiazolo[4,3,-a]quinoxalin-1-one (ODQ). The results showed that nitrite is a 
more potent vasodilator in acidic conditions and its vasorelaxant effects were 
mediated through NO generation (Modin et al., 2001). 
 
The ability of nitrite to act as a vasodilator was further elucidated when it was shown 
that nitrite infusion into the human forearm brachial artery resulted in increased 
forearm blood flow (Cosby et al., 2003a). Forearm blood flow measurements were 
made in 18 healthy volunteers and nitrite infused at 36µmol/ml, into the brachial 
artery to achieve an intravascular nitrite concentration of approximately 200µM 
(Cosby et al., 2003a). Systemic nitrite concentration of 16µM, measured in the 
contralateral arm, was associated with a systemic decrease in mean arterial blood 
pressure of approximately 7mmHg. The physiological relevance of vascular nitrite as a 
vasodilator was tested. An infusion of 400nmol/ml significantly increased forearm 
blood flow in all subjects tested. Blood flow was significantly increased at rest and 
during NOS inhibition, with and without exercise to simulate hypoxia. Following a 5 
minute infusion of nitrite, venous nitrite levels initially increased from 17617nM to 
2,564462nM. Following exercise venous nitrite levels decreased to 909113nM 
(Cosby et al., 2003a). These observations lead to the acceptance that nitrite is 
functional and could act as a storage pool for NO. 
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Coupled with the observation that arteriovenous gradients exist in the human forearm 
was the knowledge that these gradients were enhanced during exercise and regional 
NOS inhibition. This lead to the suggestion that nitrite is consumed to liberate NO 
(Gladwin et al., 2000; Cosby et al., 2003a). Still, around that time the involvement of 
nitrite at physiological concentrations on vasodilation was disputed. It was thought 
that the nitrite gradient may be due to decreased production of nitrite on the venous 
side through a combination of decreased NOS activity and increased nitrite 
consumption (Luchsinger et al., 2005). Maher and colleagues therefore set out to 
determine whether nitrite would have a greater effect in capacitance vessels 
compared to resistance vessels due to lower oxygen tension. Furthermore, whether 
resistance-vessel dilation would be more pronounced during hypoxemia. The effect of 
intra-arterial infusion of nitrite on forearm blood flow was assessed during normoxia 
and hypoxia. There was no significant difference between dilation in the capacitance 
vessels under normoxia compared with hypoxia (35.83.4% for normoxia). In the 
resistance vessels nitrite-induced vasodilation, as assessed by the forearm blood flow 
ratio, was moderately increased from baseline (1.040.09 to 1.620.18FBF-R, p<0.05). 
In hypoxia, however, arterial blood flow was increased over 2 fold from baseline 
(1.070.09 to 2.370.15, p<0.005). In addition, in vitro studies using vessels isolated 
from rabbits confirmed the in vivo observations giving credence to the suggestion that 
hypoxia significantly influences nitrite-induced relaxation in both arteries and veins 
(Maher et al., 2008). 
1.14 Conversion of nitrite to NO 
In 1994 2 groups independently and for the first time demonstrated that nitrite can be 
reduced to NO in a biological system (Benjamin et al., 1994; Lundberg et al., 1994). In 
these studies NO production was measured in expelled air of healthy volunteers using 
the highly specific ozone chemiluminescence assay. At the time it was known that 
human saliva contained both nitrate and nitrite and that nitrate absorbed in the 
gastrointestinal tract is extracted by the salivary glands from plasma (Spiegelhalder et 
al., 1976; Tannenbaum et al., 1976). Furthermore most of the nitrite in the saliva 
resulted from the reduction of nitrate within the oral cavity, a process facilitated by 
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micro-organisms residing normally within the oral cavity (Tannenbaum et al., 1976). It 
was logical to postulate that swallowed saliva would enter the stomach and under the 
acidic environment presented by the stomach reduction of nitrite to NO may occur 
(Archer, 1993). Lundberg et al. demonstrated that basal NO concentration in expelled 
air after 10 hours of fasting was approximately 602ppb in healthy volunteers, however 
following ingestion of a dietary nitrate load (in the form of lettuce which is naturally 
rich in nitrate) exhaled NO levels were increased 4 fold, 5 minutes following the intake 
of lettuce. In vitro they demonstrated that NO formation from nitrite was pH 
dependent between pH 1 to 2 (Lundberg et al., 1994). The requirement of an acidic 
environment for NO formation from nitrite was confirmed by treating volunteers with 
the selective proton pump inhibitor omeprazole. Omeprazole inhibits gastric acid 
secretion and use of this inhibitor almost abolished NO in expelled air (Lundberg et al., 
1994). At these particularly high levels NO is toxic to a wide range of microorganisms 
and therefore this pathway may reflect a mechanism of host defense. Indeed Benjamin 
and colleagues investigated this hypothesis by exposing enteropathogens to different 
combinations of acid and nitrite (Benjamin et al., 1994). They proposed that 
acidification of nitrite in the stomach would result in the formation of nitrous acid 
followed by spontaneous decomposition to NO and other nitrogen oxides (see 
equations 1.6-1.8). Thus simple nitrite diproportionation, which increases under acidic 
conditions with abundant availability of H⁺ ions, favours the release of free NO.  
Equation 1.7: 2HNO₂ H₂O + N₂O₃
Equation 1.6: NO₂⁻ + H⁺ HNO₂
Equation 1.8: N₂O₃ NO∙ + NO₂∙
 
Equations 1.6, 1.7 and 1.8: Equations depicting conversion of nitrite to nitric oxide (NO) in the stomach. 
In the acidic environment of the stomach, nitrite (NO₂⁻) exists in equilibrium with nitrous acid (HNO₂) 
(equation 1.6). Both exist in equilibrium with oxygen intermediates including dinitrogen trioxide (N₂O₃) 
(equation 1.7), which breaks down to form NO and nitrogen dioxide (NO₂) (equation 1.8).  
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Very soon after these studies were published Zweier and colleagues demonstrated 
that nitrite reduction also occurs within the cardiovascular system in acidotic 
conditions (Zweier et al., 1995). The authors observed that in ischaemic tissues such as 
the heart, large quantities of NO, measured by EPR spectroscopy were produced via a 
pathway that was independent of the conventional L-arginine/NOS pathway. Using the 
ferrous iron complex of N-methyl—D-glucamine-dithiocarbamate (MGD), Fe(II)-MGD2 
(Fe-MGD) to trap NO rat hearts perfused at a pressure of 80mmHg infused with Fe-
MGD for 5 minutes and then subjected to 30 minutes global ischaemia (Zweier et al., 
1995). They demonstrated that inhibition of NOS reduced NO formation during the 
ischaemia by more than 60% although it was never fully blocked. However, this group 
demonstrated that fairly high levels of nitrite were present in the heart (20µM). They 
then investigated the possibility that this nitrite might be the source of NO since during 
ischaemia they showed that pH decreased down to pH 5.5 and hypothesized that this 
acidosis might be sufficient to chemically reduce nitrite to NO. Using 15N nitrite they 
demonstrated that during ischaemia nitrite could be directly reduced to NO and thus 
postulated that nitrite sequestered in the cardiac tissue was responsible for a 
considerable proportion of NO generation during the ischaemia as a consequence of 
acidic disproportionation (Zweier et al., 1995). 
1.15 Mechanism of nitrite conversion to NO 
As demonstrated, in an acidic environment simple chemical disproportionation 
encourages the release of free NO. In tissues, however, the process of chemical 
disproportionation accounts for only up to 20% of the total NO produced from nitrite 
and we now know that the rest is derived from enzymatic nitrite reduction. This view 
was first demonstrated in cardiac tissue where nitrite reduction facilitated by rat heart 
homogenates was reduced by ~75% after proteins were denatured (Webb et al., 
2004a). In this study it was shown that this dependency on protein relates to 
enzymatic activity that could be attributed to xanthine oxidoreductase (XOR). Since 
that time a number of mammalian nitrite reductases have been identified (figure 1.5) 
that can be broadly grouped into 3 categories. These are (1) haem based nitrite 
reductases e.g. haemoglobin (Huang et al., 2005), myoglobin (Hendgen-Cotta et al., 
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2008) and neuroglobin (Tiso et al., 2011), (2) the nitrite anhydrases e.g. carbonic 
anhydrase (Aamand et al., 2009), and (3) the molybdopterin reductases e.g. aldehyde 
oxidase (Li et al., 2009) and XOR (Millar et al., 1998a; Li et al., 2001b). In the work 
described in this thesis the focus has rested on the third group and the next section of 
this chapter describes in detail this activity. 
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Figure 1.5: The enzyme-mediated pathways for nitrite reduction. Conditions such as hypoxia and 
acidosis enhance the magnitude of nitrite reduction to NO, a process facilitated by numerous nitrite 
reductases. 
1.15.1 Enzymatic conversion by the molybdopterin reductases 
The family of molybdenum (Mo) containing reductase enzymes catalyse a wide range 
of reactions. These reactions are dependent on the oxidation states of Mo, which can 
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exist in a range of oxidation states from +4 to +6 (Mo(IV), Mo(V), Mo(VI) (Zhang et al., 
1998a). There are over 50 different Mo-containing enzymes, the vast majority of which 
are bacterial enzymes (Hille, 2013), however in mammals there are 4 known Mo-
containing enzymes: sulphite oxidase (SO), aldehyde oxidoreductase (AO), 
mitochondrial amidoxime reducing component (mARC) and XOR (figure 1.6). 
Interestingly, there is now evidence that all of these Mo-containing enzymes can act as 
nitrite reductases (Stirpe et al., 1969; Sparacino-Watkins et al., 2013; Wang et al., 
2013). However, the most well described and characterized of these enzymes is XOR. 
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Figure 1.6: Secondary structure of the 4 known mammalian molybdenum containing enzymes XOR, AO, 
SO and mARC. AO=aldehyde oxidase; SO=sulphite oxidase; mARC=mitochondrial amidoxime reducing 
component.   
1.15.2 Introduction to xanthine oxidoreductase (XOR) 
In 1902 the Austrian biochemist Franz Schardinger found an enzyme fraction in whole 
milk decolourizes methlyene blue in the presence of formaldehyde (Schardinger, 
1902). After this discovery, some 20 years later, the same enzyme fraction was found 
to produce urate (Morgan et al., 1922). Urate production was then shown to belong to 
the terminal rate-limiting steps in human purine catabolism from the degradation 
products hypoxanthine and xanthine by the same Schardinger enzyme, now known to 
be XOR. 
 
XOR refers to 2 interconvertible forms found in mammalian cells, xanthine oxidase 
(XO) and xanthine dehydrogenase (XDH) (Enroth et al., 2000). XOR exists as a 
[64] 
 
 
homodimer (Andrews et al., 1964) with a single monomer having a molecular weight 
of approximately 150kDa. Each monomer comprises a flavin adenine dinucleotide 
(FAD) site, 2 iron-sulphur (2Fe-2S) clusters (Richert et al., 1954) (residing at the N-
terminus of each monomer) and a molybdopterin (Mo) site that resides at the C-
terminus.  
 
Transcription of the gene encoding XOR results in the expression of XDH, which under 
physiological conditions is the predominant intracellular form whereas XO is a post-
translationally modified product of the initial XDH form. XDH can be reversibly 
converted to XO via sulphydryl oxidation or irreversibly due to proteolysis (Della Corte 
et al., 1968). Both forms of XOR catalyze the hydroxylation of purines at the Mo 
binding site but the difference between the enzymes lies in the activity of the flavin 
cofactor. The catabolism of purines occurs at the FAD site but for XDH the electron 
acceptor is NAD⁺ (although it can use molecular oxygen as well) whilst for XO the 
electron acceptor is only molecular oxygen (Hille et al., 1995; Enroth et al., 2000; 
Okamoto et al., 2013). 
 
Electron flow begins at the Mo site from a substrate that is either a purine or an 
aldehyde. The resultant electron flow changes the Mo oxidation state from +6 to +4 
(Stockert et al., 2002). The 2 electrons are distributed sequentially to the nearest Fe-S 
cluster positioned 10-15Å away. Following transfer to the next Fe-S cluster (Eger et al., 
2000) the electrons are passed onto the FAD site (located 10-12Å away from the Fe-S 
cluster) resulting in the formation of FADH and then FADH₂ prior to reduction of the 
final exogenous oxidant. This process of electron transfer occurs independently in each 
monomer (Massey et al., 1969). Depending on the form of XOR, electrons are either 
transferred to NAD⁺ or molecular oxygen (figure 1.6). As XO only uses molecular 
oxygen as its terminal electron acceptor substantial superoxide generation occurs 
when this form of XOR is active (Hille et al., 1981). The hypoxic environment prevalent 
in I/R injury causes XDH to preferentially utilize NADH as substrate to generate 
electrons. Upon reperfusion molecular oxygen uses the electrons to make superoxide 
and hydrogen peroxide. Studies with XOR in endothelial cells show that superoxide 
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generation as a consequence of reperfusion is not blocked by the Mo site targeted 
inhibitor allopurinol but by the FAD site targeted inhibitor diphenyleneiodonium 
(Harris et al., 1997).  
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Figure 1.7: Electron flux through 1 monomer of XOR. Arrows show the direction of electron flow. 
Depending on the form of XOR the reduced FAD site reacts with either NAD⁺ or molecular oxygen to 
produce NADH or hydrogen peroxide (H₂O₂) or superoxide (O₂⁻). FADH₂ reacts with O₂ to produce H₂O₂, 
while FADH produces O₂⁻. 
1.15.3 How does XOR function as a nitrite reductase? 
Under anaerobic conditions and in the presence of either NADH or xanthine, purified 
XOR can also catalyse the reduction of nitrite to NO (Godber et al., 2000; Li et al., 
2001a). The process of nitrite reduction was first described to occur under hypoxic 
conditions and as a process functioning optimally in the presence of NADH as the 
reducing substrate (Millar et al., 1998b; Millar et al., 1998a; Zhang et al., 1998b). 
Interestingly, it has been known for almost 90 years that XOR can catalyze the 
reduction of nitrate to nitrite (Dixon et al., 1924). In these early studies it was not 
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considered whether nitrite might also be reduced by the enzyme and neither what 
might be the biological significance of this activity. Indeed, these observations were 
described by the authors as simply identifying another oxidizing agent that might be 
used to study ‘Schardinger’ enzyme.     
 
Two groups in 1998 published observations with purified enzyme demonstrating the 
nitrite reductase activity of XOR. Using a chemiluminescence NO detector to measure 
NO production, Millar and co-workers (Millar et al., 1998a) demonstrated that under 
<1% oxygen conditions, purified bovine XOR catalyzed NO production from nitrite 
(using mM concentrations of nitrite), a phenomenon abolished with the introduction 
of oxygen. However, it is notable that this reduction of nitrite did not occur if NADH 
was substituted with xanthine or hypoxanthine. Indeed, if either of the purines were 
introduced into the reaction mixture concomitantly with NADH, nitrite reduction was 
inhibited, although the authors provided no explanation for why this might be the 
case. Zhang et al also published their observations in 1998 using bovine XOR (Zhang et 
al., 1998b). However, unlike Millar et al they suggested that the capacity of XOR to 
generate nitrite for NO was not altered by the presence of oxygen (ambient air). In 
addition, this group demonstrated that NO production from nitrite was completely 
blocked by the Mo-directed inhibitor, allopurinol, or the FAD-directed inhibitor, DPI. 
They concluded that nitrite is likely to interact with the Mo centre, whilst NADH 
interacts with the FAD site. Essentially the mechanism of this reduction is the reverse 
of xanthine oxidation but with NADH as the reducing substrate. NADH donates 
electrons to FAD to form FADH₂. FADH₂ then reduces Mo, which goes from oxidation 
state +6 to +4. This reduced Mo then accepts O⁻ from nitrite to give Mo(V) and 
consequently releases NO. The Mo returns to its original oxidation state by obtaining 
an electron from the FADH₂ centre restoring FAD for the next cycle of nitrite reduction. 
Importantly, Zhang and co-workers demonstrated that this profile of activity of XOR 
was also shown to hold true for XOR in homogenates of inflamed human synovium. 
Interestingly, this group had also previously published observations using human XOR 
purified from human breast milk (Zhang et al., 1997). In that particular study they 
demonstrated that allopurinol had no effect on the nitrite reductase activity of the 
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enzyme (Zhang et al., 1997). Exactly why this difference occurred between the studies 
is uncertain, however, in the study with human XOR a concentration of allopurinol of 
only 10μM was used as opposed to mM concentrations of nitrite. Allopurinol is a 
reversible inhibitor of the enzyme with an IC50 reported to lie between 0.2 to 50μM 
(for review see (Pacher et al., 2006)). A simple explanation for this observation is that 
insufficient amounts of allopurinol were used. Further extensive analysis of the nitrite 
reductase activity of bovine XOR was then conducted by Jay Zweier and his group (Li et 
al., 2001a; Li et al., 2004a). Collectively, the studies demonstrated that xanthine, 
aldehyde (in the form of 2,3-dithdroxybenz-aldehyde) and NADH all act as electron 
donors for nitrite reduction, but importantly with xanthine having the highest Km (See 
Table 1.3) (Li et al., 2001a). Additionally, whilst oxypurinol (the active form of 
allopurinol) inhibited nitrite reduction with all three reducing substrates, DPI only 
inhibited the response with NADH. Furthermore, in agreement with Millar et al (Millar 
et al., 1998b), these studies show that high concentrations of the purines attenuate 
nitrite reduction and the authors suggest that this inhibition likely relates to binding of 
the molybdenum in the reduced form preventing access to nitrite. Finally this group 
also demonstrate the exquisite sensitivity of the nitrite reductase activity of XOR to 
oxygen, whereby xanthine or aldehyde (substrates that provide electrons at the Mo 
site) catalysed nitrite production competes with oxygen whilst NADH-driven nitrite 
reduction still occurs under aerobic conditions with ~70% of the activity evident in 
anoxia (Li et al., 2004a).  
Electron Donor Target Site Condition Km 
Xanthine Molybdenum Anoxia 1.5µM 
Aldehyde Molybdenum Anoxia 35.0µM 
NADH FAD Anoxia 0.9mM 
Xanthine Molybdenum Air (21% O₂) 58.6mM 
Aldehyde Molybdenum Air (21% O₂) 48.5mM 
NADH FAD Air (21% O₂) 0.2nmols⁻¹mg⁻¹ 
(does not follow 
Michaelis-
Menten kinetics)  
Table 1.3: Effect of electron donors on Km values for purified XO-mediated NO generation from nitrite 
(Li et al., 2001b; Li et al., 2003).   
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In addition to substrate availability there are a number of environmental factors that 
also alter XOR’s ability to function as a nitrite reductase. Of particular relevance to 
ischaemic CVD, the activity of XOR is both increased with increasing hypoxia and by 
increasing acidosis. The latter has been shown to occur with purified enzyme but also 
with tissue homogenates. The relevance of this observation is better appreciated when 
one remembers that hypoxia is associated with increasing acidosis. Indeed it has been 
demonstrated in isolated rat heart preparations subjected to a simulated heart attack, 
that within 20 mins of ischaemia pH dropped from 7.4 to 5.5 (Zweier et al., 1999). 
Zweier and colleagues (Li et al., 2001a) demonstrated that irrespective of substrate, 
and using an excess of nitrite (1mM), the rate of NO generation was enhanced with 
decreasing pH. Interestingly, in this study the impact of pH upon nitrite reduction was 
assessed in the presence of different reducing substrates, showing that whilst a 
decrease in pH from 7.4 to 6 caused a small increase with xanthine (i.e. 1.1 fold) that 
the rate of NO generation was increased 2.3 and 2.6-fold respectively with NADH and 
aldehyde respectively. In homogenates of both rat and human heart tissue work in my 
lab has shown that decreasing pH (6.0-5.0) results in a pronounced increase in NO 
generation, although which reducing substrate might be involved in such responses 
was not assessed (Webb et al., 2004b). However, as oxygen tension decreases the 
levels of NADH will increase as mitochondrial oxidative phosphorylation is impaired, 
suggesting that NADH is likely to play a major role under such conditions. The 
mechanism of action of XOR-facilitated nitrite reduction to NO is depicted in figure 1.8. 
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Figure 1.8: The biochemistry of XOR-facilitated nitrite reduction to NO.   
1.15.4 XOR expression and distribution within the cardiovascular system 
XOR is thought to be widely distributed in mammals with evidence of expression in a 
range of organs, however the highest levels of expression and activity appear to occur 
within the liver, including in humans (Linder et al., 1999). Within the cardiovascular 
system XOR expression and activity have been identified in human heart (Abadeh et 
al., 1992; Abadeh et al., 1993). In addition, previous work in my lab has demonstrated 
significant nitrite reductase activity that is abolished in the presence of allopurinol in 
human atrial tissue, implicating XOR (Webb et al., 2004b). XOR is also thought to be 
expressed throughout the vasculature at the level of the endothelial cell. However, 
despite evidence of ubiquitous capillary endothelial expression in early studies in 
bovine tissues (Jarasch et al., 1981), in humans a more selective distribution of 
expression appears to be present. Early studies suggested that endothelial XOR could 
be found only within capillaries of certain organs including the liver, mesentery and 
mammary gland (Jarasch et al., 1981) with little to no expression in the heart, lung, 
kidneys or on the endothelium of larger blood vessels of any organs. In contrast, other 
studies suggest expression and activity in isolated human capillary endothelial cells of 
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both skeletal and cardiac tissue (Jarasch et al., 1986), and in addition more recent 
evidence suggests XOR expression in venular (human umbilical vein) endothelial cells 
(Kelley et al., 2006; Webb et al., 2008b), and in endothelial cells of small arteries 
(Hellsten-Westing, 1993). More recently XOR activity in terms of allopurinol-sensitive 
nitrite reductase activity has been demonstrated in human left internal mammary 
artery (Webb et al., 2008b). Thus, these data together support the view that significant 
functional XOR likely exists in human arteries in addition to capillaries. 
 
Interestingly, it seems that XOR is located within the cytoplasm (Jarasch et al., 1981; 
Jarasch et al., 1986) and on the outer cell membrane of human endothelial cells 
(Rouquette et al., 1998). Whilst the source for the intracellular expression is clearly the 
endothelial cell itself, the cell membrane bound expression relates to XOR shed from 
organs such as the liver and, as evidenced from studies in rodents, in periods of 
metabolic stress also from the intestine (Yokoyama et al., 1990; Terada et al., 1992a). 
Circulating XOR binds with high affinity to endothelial cells via glycosaminoglycans 
(Adachi et al., 1993; Radi et al., 1997; Houston et al., 1999). Once XOR has been 
released into the circulation, it is then free to be carried and bind to vascular 
endothelium, via these heparin sulphate proteoglycans, in distant parts of the 
circulatory tree. More recently, it has been demonstrated that not only is this binding 
occurring at the endothelial cell but also likely occurring at the level of the red blood 
cell too since using immunohistochemistry the presence of large amounts of XOR on 
the membrane of erythrocytes from healthy volunteers was demonstrated (Webb et 
al., 2008b). 
1.15.5 Upregulation of XOR in CVD 
XOR activity/expression is upregulated in CVD. In animal models of CVD including 
atherosclerosis, hypercholesterolaemia and reperfusion injury, XOR expression/activity 
increases and blockade of activity improves disease burden/outcome (Grum et al., 
1986; Tan et al., 1993; Nielsen et al., 1994b; White et al., 1996a). Similarly, in patients 
with CVD including coronary artery disease, hypertension and heart failure, both XOR 
expression and activity (in some cases identified as endothelium-bound activity) is 
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substantially increased (Spiekermann et al., 2003b; Guzik et al., 2006b; Landmesser et 
al., 2007). In patients undergoing upper limb surgery (~90 min ischaemia), plasma XO 
activity in the ipsilateral arm was found to increase from ~2nmol/ml/min before 
reperfusion to ~10nmol/ml/min shortly after reperfusion, suggesting release of XO 
from ischaemic vascular endothelium (Friedl et al., 1990). In addition to the stimulated 
release of XOR from organs such as the liver, expression/activity of XOR within 
endothelial cells can be upregulated by pro-inflammatory cytokines; specifically 
interferon gamma has been shown to elevate XDH levels in rat pulmonary artery and 
lung microvascular endothelial cells (Dupont et al., 1992). Furthermore, evidence also 
suggests that hypoxia is a potent stimulus for XDH transcription. In rat pulmonary 
microvascular endothelial cells XDH mRNA levels were increased 2-fold in hypoxic [3% 
oxygen] relative to normoxic controls [20% oxygen] (Lanzillo et al., 1996), although 
more moderate increases of ~50% have been demonstrated in bovine arterial 
endothelial cells using more moderate levels of hypoxia [10%] (Kelley et al., 2006) or 
indeed no change in expression at all (in response to 0-3% oxygen conditions) has also 
been reported in these cells (Poss et al., 1996). Interestingly in this latter study whilst 
no change in expression was observed, a doubling in activity was evident suggesting 
possibly post-translational alterations. Indeed, this possibility was confirmed in a study 
using cultured rat pulmonary microvascular endothelial cells in which hypoxia-induced 
post-translational phosphorylation of XDH was mediated by p38 kinase and casein 
kinase II (Kayyali et al., 2001). Such observations might suggest that the multiple 
modes of upregulation of XOR permit a continuum for the enzyme whereby 
phosphorylation might provide an acute response to stimuli, such as hypoxia; over 
longer periods of time, the release and upregulation of protein synthesis maintains a 
role for this enzyme, in the face of prolonged ischaemic or inflammatory stimuli.   
 
In all the above-mentioned CVD states whilst the changes in XOR expression and/or 
activity are deemed to be pathogenic, whether this pathogenic role relates to the 
activity of damaging superoxide or elevated uric acid generation is controversial and 
remains uncertain. In all of these disease states there is evidence that targeting XOR 
activity using either allopurinol or the more recently licensed non-purine based 2-(3-
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cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylic acid (febuxostat), (Okamoto 
et al., 2003; Tayar et al., 2012) results in improvement of surrogate measures of 
disease severity, however there are a number of observations that have also limited 
enthusiasm for this approach to CVD due to an absence of beneficial effect or indeed a 
worsening. An underlying cause for these uncertain data may be due to the fact that 
inhibition of XOR will result not only in a decrease in both superoxide and uric acid 
generation but also inhibit the generation of beneficial NO from nitrite. 
1.15.6 XOR in hypertension 
A role for XOR in mediating the elevated blood pressure (BP) and associated 
‘endothelial dysfunction’ in hypertension has been demonstrated in various animal 
models. Early experimental work assessing raised BP in the spontaneously 
hypertensive rat (SHR), the salt sensitive rat and in dexamethasone-induced 
hypertension in rats demonstrated that XOR expression and activity is upregulated in 
vivo in the kidney (Laakso et al., 1998a; Laakso et al., 2004). However, whilst 
allopurinol treatment completely blocked this elevated activity, it did not alter BP in 
these animals. In contrast, whilst others have also demonstrated elevated XOR activity 
in other tissues including the mesentery (Suzuki et al., 1998b) and cremaster 
(Wallwork et al., 2003) in the same models of hypertension i.e. the SHR and 
dexamethasone-induced hypertension respectively,  the selective XOR inhibitor 
sodium 8-(3-methoxy-4-phenylsulfinylphenyl)pyrazolo[1,5-α]-1,3,5-triazine-4-olate 
monohydrate (BOF-4272) or allopurinol did reduce BP. These pre-clinical studies have 
been followed up by others and rather than clearing up these anomalies continued 
investigation has fuelled the controversy further with equally opposing observations 
(Ong et al., 2007; Sánchez-Lozada et al., 2008; Szasz et al., 2013). Numerous ideas have 
been put forward for these findings but these differences might simply reflect an 
unconsidered effect of inhibition of beneficial nitrite reduction.  
 
In terms of the mechanisms involved in the pro-hypertensive effects of XOR, an 
increase in activity and/or expression will lead to an increase in uric acid and 
superoxide. It is elevation of the latter that, until recently, was thought to underlie the 
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role that XOR plays in both promoting raised BP and the endothelial dysfunction 
occurring in hypertension (Kojda et al., 1999). Superoxide produced by XOR reacts with 
NO to form peroxynitrite (Beckman et al., 1996b) and this scavenging of NO has been 
implicated in its reduced bioavailability in hypertensive states, and been shown to be 
reflected in measures of endothelial reactivity. In transgenic rats harbouring the  
human renin and human angiotensinogen genes, BP is elevated in an angiotensin II-
dependent fashion (Ganten et al., 1992). Endothelium- and NO-dependent 
vasorelaxation of renal arteries, isolated from such animals is impaired, however 
treatment of these vessels with oxypurinol reversed this effect, as also did treatment 
with superoxide dismutase (SOD), suggesting that XOR-derived superoxide was 
responsible for this effect. However, more recently there has been growing support for 
the view that the elevations in uric acid that characterize hypertension might have a 
more important role to play in the hypertensive pathology than previously suspected.  
 
Hyperuricemia is associated with hypertension although whether it is a risk factor or a 
consequence remains unclear (Mazzali et al., 2010). It has been postulated that uric 
acid might increase BP by two mechanisms; firstly an acute, reversible phase which 
involves an increase in the renin angiotensin system (Mazzali et al., 2001); secondly a 
chronic, irreversible phase in which the renal vasculature is permanently damaged due 
to elevations in local urate levels leading to hypertension (Kang et al., 2002). Uric acid 
has also been shown to reduce NO levels in bovine aortic endothelial cells and in a rat 
model of hyperuricemia, induced through administration of the uricase inhibitor, 
oxonic acid (Khosla et al., 2005). It is possible therefore that both uric acid and 
superoxide have a role to play in reducing the bioavailability of NO. Importantly 
scavenging of NO by either of these pathways will result in less NO that enters the 
usual metabolism pathways of this molecule i.e. oxidation (Fukuto et al., 2000). 
Evidence suggests that the levels of both the oxidative metabolites of NO, nitrite and 
nitrate, are lower in hypertensive individuals than in healthy volunteers; an effect the 
authors suggested in this study is a reflection of scavenging of NO due to oxidative 
stress (Forte et al., 1997). However, what has not been previously considered is that 
the reduced levels of nitrite not only reflect reduced availability of NO generated 
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through the conventional L-arginine/NOS pathway but also reflect reduced substrate 
for NO generation via the activity of XOR. 
1.15.7 Vasodilator and hypotensive effects of nitrite  
Systemic nitrite administration causes dose-dependent increases in blood flow and 
accordingly decreases in BP in both healthy animals and volunteers (Vleeming et al., 
1997b; Cosby et al., 2003b; Dejam et al., 2007b; Petersson et al., 2009b). In addition 
repeated nitrite administration (once daily dosing for 14 days), albeit intravenously 
administered and with supra-pharmacological dosing (12,000µg/Kg/min), lowered BP 
in primates (Dejam et al., 2007b). Similarly, studies in healthy volunteers assessing the 
pharmacokinetics of nitrite infusion largely support the vascular studies in healthy 
volunteers demonstrating that very large doses of nitrite (achieving circulating 
concentrations >20μM) do effect BP decreases (Dejam et al., 2007b; Pluta et al., 2011). 
A recent review comparing physiological plasma nitrite concentrations across studies, 
in healthy volunteers, suggests levels fall within the 200-500 nM range (Grau et al., 
2007b). However, published values range from non-detectable or as low as ~20nM 
(Pannala et al., 2003b) to as high as 5μM (Moshage et al., 1995b). Such variability may 
reflect true levels in plasma but are also likely to reflect differences in techniques used 
for measurement of nitrite; an issue debated in several reviews (Pelletier et al., 2006a; 
Grau et al., 2007b; Tsikas, 2007a). Irrespective of this, these acute infusion studies 
suggest a requirement for high circulating levels of nitrite to bring about significant BP-
lowering effects. More recently, an alternative approach to raising circulating nitrite 
levels has been taken in a bid to better and more easily investigate the effects of this 
anion on BP in humans and relies upon what has been termed the ‘enterosalivary 
circuit’ of nitrate.  
1.16 The enterosalivary circuit and its role in nitrate reduction to nitrite 
The enterosalivary circuit is required to facilitate the conversion of nitrate to nitrite. 
The bioactivation of orally ingested inorganic nitrate results in elevation of 
endogenous nitrite levels, a reaction that is facilitated by oral bacteria. This conversion 
is a complex process. After ingestion of a nitrate load, nitrate is rapidly absorbed from 
the proximal part of the gastrointestinal tract into the bloodstream (Mensinga et al., 
[75] 
 
 
2003). In the bloodstream, nitrate from the diet mixes with endogenously generated 
nitrate, produced from the NOS pathway.  
 
After dietary nitrate consumption there is a rapid rise in plasma nitrate concentration 
with rises in nitrate evident within 30 minutes (Webb et al., 2008c; Kapil et al., 2010). 
This elevation peaks at 1.5 hours and remains elevated for up to 6 hours after 
ingestion (Webb et al., 2008c; Kapil et al., 2010). Estimates suggest a half life between 
6-8 hours (Wagner et al., 1983; van Velzen et al., 2008). Most nitrate (60-75%) is 
ultimately excreted in the urine with peak excretion occurring around 6 hours after 
ingestion (Wennmalm et al., 1993; Pannala et al., 2003a). However the remaining 
nitrate, up to 25%, is actively taken up by the salivary glands and secreted with the 
saliva resulting in concentrations of salivary nitrate being 10-20 times higher than 
plasma nitrate concentrations (Spiegelhalder et al., 1976). In the oral cavity, 
commensal facultative bacteria reduce nitrate to nitrite (Doel et al., 2005). A study in 
1997 examined in much detail the nitrate-reducing bacteria on rat tongues. Rats were 
chosen as the model system since their tongues can be divided into 2 morphologically 
distinct zones, the anterior part, which has a smooth surface, and the posterior part 
that has deep clefts filled with bacterial biofilms. Up to 65% of bacteria were located in 
the deep clefts on the posterior surface of the tongue where only significant nitrite 
production was detected (Li et al., 1997). The conversion of nitrate to nitrite within the 
oral cavity is reflected by rises in the levels of salivary nitrite in parallel with nitrate 
(Webb et al., 2008c). However studies measuring oral nitrate reduction in healthy 
volunteers have confirmed this. Healthy volunteers treated with antiseptic mouthwash 
had a 90% reduction in oral nitrite production and a 25% reduction in plasma nitrite 
concentration. Interestingly the reduction in circulating nitrite concentration was 
concomitant with increased systolic and diastolic blood pressure (Kapil et al., 2013).  
 
In 2004 Lundberg and Govoni demonstrated that an oral load of sodium nitrate caused 
increases in circulating nitrite (Lundberg et al., 2004). Further work has also 
demonstrated that plasma nitrite is significantly elevated after dietary nitrate 
consumption. This elevation peaked at 3 hours following ingestion and remained at 
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this level up until 5 hours. This slow and sustained manner of circulatory nitrite 
elevation was proposed to be reflective of the ingestion and enterosalivary processing 
of dietary nitrate (Webb et al., 2008c). In support of the view that elevations of 
circulating nitrite following nitrate ingestion is dependent on the enterosalivary circuit, 
treatment of rodents or humans with antibacterial mouthwash as well as interruption 
of the enterosalivary circuit in humans by spitting, attenuate the increases in plasma, 
urinary and salivary nitrite after ingestion of a dietary nitrate load (Govoni et al., 2008; 
Webb et al., 2008c; Petersson et al., 2009a). In actual fact this process of nitrate 
reduction may not be completely dependent on bacteria but may be a process 
facilitated by mammalian nitrate reductases (Jansson et al., 2008). Indeed a recent 
study compared functional nitrate reductase activity in conventional and germ-free 
mice. Nitrate (NaNO₃, 10mg/kg) or placebo (NaCl) was given intraperitoneally. In germ-
free animals receiving nitrate, plasma nitrite concentration was approximately 3-fold 
higher than conventional animals receiving nitrate. This pattern was also reflected in 
the liver, kidney and gastro-intestinal tissues. Interestingly, pretreatment with 
allopurinol (100mg/kg/day via the drinking water) for 3 days significantly attenuated 
circulating nitrite concentration by approximately 50%. This implicates XOR as 
potentially a key enzyme in mammalian nitrate reduction (Huang et al., 2010). 
Reduction of nitrate to nitrite by mammalian nitrate reductases was shown in this 
study with elevations of nitrite noted in numerous tissues, however whether this 
correlates to human nitrate reductase activity in nitrate processing in the oral cavity is 
not fully understood. The possibility of mammalian nitrate reductases in the oral cavity 
contributing to nitrate processing should not be completely disregarded.     
 
Following nitrate reduction in the oral cavity salivary nitrite is swallowed and in the 
acidic environment of the stomach is protonated to form nitrous acid (HNO₂), which 
decomposes further to form NO and other nitrogen oxides (Benjamin et al., 1994; 
Lundberg et al., 1994). However, some of that nitrite is thought to escape the acidic 
environs of the stomach and enter the blood stream. Nitrite reduction to NO is greatly 
enhanced by reducing compounds such as vitamin C and polyphenols, both found 
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abundantly in the diet (Peri et al., 2005; Gago et al., 2007). A schematic providing an 
overview of the enterosalivary circuit is shown in figure 1.7. 
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Figure 1.9: The enterosalivary circulation showing the conversions and locations that occur in the 
activation of nitrate to nitrite and nitrite to NO.  
1.17 Sources of nitrate and nitrite 
In the body there are 2 main sources of nitrate and nitrite, the diet and endogenous 
NO generation. The L-arginine/NOS pathway contributes through the rapid oxidation 
of NO to nitrate and nitrite. In the circulation NO oxidation is facilitated by the 
multicopper oxidase, ceruloplasmain (Shiva et al., 2006). However, nitrate is the 
dominant final oxidation product in plasma with concentrations (micromolar) normally 
at least 2 orders of magnitude higher than nitrite (nanomolar) (Moncada et al., 1991). 
In eNOS KO mice, plasma concentrations of nitrite are reduced by up to 70% 
(Kleinbongard et al., 2003). The other major source of nitrate, and to a lesser extent 
nitrite, is our everyday diet. Vegetables are the predominant daily dietary source of 
nitrate (~80-85%) (Susin et al., 2006; Hord et al., 2009), and cured meats contain some 
nitrite, which is commonly used as a preservative against bacterial contamination as 
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well as a colour enhancer (Lundberg, 2009). Green leafy vegetables e.g. spinach, rocket 
and beetroot, are particularly high in nitrate and 1 serving of such a vegetable contains 
more nitrate than what is endogenously formed by all the 3 NOS isoforms during a day 
(Lundberg et al., 2009). 
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Figure 1.10: The L-arginine:NOS pathway and the nitrate-nitrite pathway of NO generation. The L-
arginine:NOS pathway requires molecular oxygen to produce NO. The nitrate-nitrite pathway is 
gradually activated as oxygen tension falls therefore can be viewed as a back-up system to ensure that 
there is sufficient NO formation when oxygen supply is limited.  
1.18 Effect of elevation of nitrite by a dietary nitrate strategy 
In 2006 Larsen et al. first demonstrated the functional effects on the cardiovascular 
system of elevating plasma nitrite concentration using nitrate. They observed that in 
17 physically active, healthy volunteers, a 3-day dietary nitrate supplementation 
significantly reduced diastolic blood pressure and mean arterial pressure by 3.7 and 
3.2mmHg respectively (Larsen et al., 2006). These effects were coupled to increases in 
plasma nitrate (placebo=26±11µM; post nitrate ingestion=178±51µM) and plasma 
nitrite (placebo=0.138±0.038µM; post nitrate ingestion=219±105µM). The daily nitrate 
dose used in the study was equivalent to the amount found in 150 to 250g of a nitrate-
rich vegetable such as spinach, beetroot or lettuce (Larsen et al., 2006). Since this work 
the beneficial effects of dietary nitrate supplementation, through conversion to nitrite, 
have been shown in numerous studies. These beneficial actions are not just limited to 
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lowering blood pressure but also include effects on platelet reactivity as well 
endothelial function. 
 
Work from our group showed that ingestion of a dietary nitrate load, this time in the 
form of 500ml beetroot juice (45.0±2.6mM) significantly lowered blood pressure 
(Webb et al., 2008c). This effect was correlated with rises in plasma nitrite 
concentration. In addition endothelial function was assessed by measuring brachial 
artery diameter (in the nondominant arm) in response to the endothelium-dependent 
reactive hyperaemia response before and after an ischaemic insult (Webb et al., 
2008c). Nitrate ingestion prevented ischaemia-induced endothelial dysfunction. 
Furthermore, in this study it was shown that nitrate intake attenuated the platelet 
aggregation response induced by ADP or collagen. These effects were mediated 
through nitrite since prevention of nitrite elevation in the circulation (by blocking the 
enterosalivary circuit by asking volunteers to spit out saliva before juice intake) 
abolished the beneficial effects seen (Webb et al., 2008c). 
 
Using nitrate salt supplementation (a potassium nitrate (KNO₃) capsule) these effects 
were shown to be dose-dependent with 4mmol being a threshold dose in terms of rise 
in plasma nitrite concentration (1.3 fold) and blood pressure decrease (Kapil et al., 
2010). In this study the rise in plasma nitrite was shown to be accompanied by a rise in 
cGMP the most sensitive indicator of NO bioactivity thereby providing strong evidence 
for the generation of bioactive NO (Kapil et al., 2010). The peak effect on BP reduction 
was with the highest dose of inorganic nitrate tested i.e. 24mmol (9.4±1.6mmHg for 
SBP, 6.0±1.1mmHg for DBP). Post hoc analyses in this study demonstrated that the 
magnitude of the blood pressure response was directly related to the baseline blood 
pressure i.e. the higher the baseline blood pressure the greater the peak in blood 
pressure reduction achieved. This analyses uncovered the potential benefit that nitrate 
might be more effective when it is required i.e. in people with a high normal blood 
pressure or hypertension (Kapil et al., 2010). 
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1.19 Aims 
Recently, it has emerged that the NO metabolites, nitrite and nitrate can be chemically 
reduced in vivo to biologically active NO. This novel means of generating 
cytoprotective NO depends on reduction of nitrate to nitrite by facultative anaerobes 
on the dorsal surface of the tongue, entry of the nitrite into the enterosalivary 
circulation, transit to the stomach and absorption through the gut wall (Lundberg et 
al., 2008). Conversion of nitrite to NO is then facilitated by a family of proteins that 
exhibit ‘nitrite reductase’ activity including the globins (Basu et al., 2007; Hendgen-
Cotta et al., 2008; Tiso et al., 2011), eNOS (Gautier et al., 2006; Webb et al., 2008a) 
and XOR (Zhang et al., 1998a; Li et al., 2001b; Webb et al., 2004a). The nitrate-nitrite-
NO pathway has been shown to exert a number of beneficial effects, including 
lowering systemic blood pressure and protecting against I/R injury (Webb et al., 2004a; 
Larsen et al., 2006; Hendgen-Cotta et al., 2008; Webb et al., 2008c). Indeed, ingestion 
of (inorganic) nitrate may underlie the cardioprotective phenotype of a diet rich in 
fruits and vegetables (Lundberg et al., 2006; Kapil et al., 2010). 
 
In the context of disease it is unknown whether the distribution of nitrate and nitrite is 
affected by CVD and if so to what extent, therefore in my PhD I have investigated 
whether it is possible to elevate circulating (and tissue) concentrations of nitrite 
through dietary nitrate or dietary nitrite supplementation. In addition I have 
investigated whether or not nitrite reductase pathways are altered by CVD. Finally, 
through its reduction to nitrite and thence NO I have investigated whether dietary 
nitrate might be used as a strategy to alter the inflammatory response therefore my 
specific aims were: 
1. To determine whether the distribution of nitrite and nitrate differs between 
healthy animals and animals with hypertension or atherosclerosis. 
2. To determine whether the nitrite reductase pathways within the cardiovascular 
system differ in health and disease. 
3. To determine whether dietary nitrate might influence disease outcome by 
modulating inflammatory responses. 
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2.1 Animals 
2.1.1 Mice 
All experiments were conducted in accordance with the Animals (Scientific Procedures) 
Act 1986, UK and approved by the UK Home Office. Male mice 12-14 weeks were used 
in all experiments. C57BL/6J wild-type (WT) and apolipoprotein E (ApoE) knockout (KO) 
(on a C57BL/6J background) mice breeding pairs were purchased from Charles River 
and mice bred in house. 
   
Heterozygotic mice with targeted disruption of 1 ApoE allele were brother-sister 
mated to give offspring deficient in ApoE. Genotype was confirmed by polymerase 
chain reaction (PCR). The ApoE KO strain was chosen as the defect renders the mice 
incapable of producing ApoE, a glycoprotein essential for the transport and 
metabolism of lipids (Plump et al., 1992). ApoE KO mice have been shown to develop 
lesions of atherosclerosis similar in appearance and distribution to those found in 
humans (Nakashima et al., 1994). All animals were fed a standard chow diet (Special 
Diet Services, Rat and Mouse No.1 Maintenance), were allowed water ad libitum and 
kept on a normal 12/12 light cycle. 
2.1.2 Rats 
Spontaneously hypertensive rats (SHR) were first developed in 1963 by Okamoto and 
Aoki (Okamoto et al., 1963). A male Wistar strain rat with persistent high blood 
pressure (150 to 175mmHg) showing spontaneous hypertension was mated with a 
female rat (blood pressure range 130 to 140mmHg) of the same strain. From the 
subsequent generations the SHR model was developed (Pinto et al., 1998). SHR and 
Wistar Kyoto (WKY) controls (14-16 weeks) were purchased from Charles River, UK. 
The raised blood pressure of the SHR and WKY animals used in this study were 
confirmed by blood pressure measurements in anaesthetized animals made in our 
laboratory by Dr Bubb, giving mean arterial pressure of 126.8±3.3mmHg for SHR 
(n=16) and 95.6±3.6mmHg for WKY (n=12). Animals were kept for 1 week for 
acclimatisation prior to use.  
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2.2 Genotyping 
2.2.1 Tissue processing 
To confirm the genetic status of the ApoE KO and WT mice genotyping was conducted. 
Mouse tail snips (1cm length) were cut into several pieces and DNA was extracted 
using a commercially available kit (Qiagen, UK). Tissue lysis buffer (ATL; 180μl) and 
20μl proteinase K (>600mAU/ml) was added to tail snips and left to incubate overnight 
(16h) in a water bath at 56°C. Samples were then mixed with 200μl lysis buffer (AL) 
and 200μl ethanol (96-100%). The resultant mixture was pipetted into DNeasy mini 
spin columns placed in a 2ml collection tube. The column was then centrifuged at 
8,000g for 1min following which the collection tube and flow through were discarded. 
The mini spin column was then placed into a new collection tube and 500μl wash 
buffer 1 (AW1 diluted in 96-100% ethanol) was added. This was then centrifuged for 
1min at 6,000g. The flow through and collection tube were again discarded and the 
mini spin column placed into a new collection tube, 500μl wash buffer 2 (AW2 diluted 
in 96-100% ethanol) was added and the tube centrifuged for 3min at 20,000g to dry 
the DNeasy membrane.  The flow through and collection tube were discarded. A final 
elution step was conducted where the mini spin column was placed into a 1.5ml 
microcentrifuge tube, 200μl of buffer AE (Elution Buffer) added to the spin column 
membrane and incubated at room temperature for 1min followed by a final spin for 
1min at 6,000g.  The final elution step was repeated to increase overall DNA yield.     
2.2.2 DNA quantification 
DNA was quantified using the nanodrop ND-1000 UV/visible spectrophotometer 
(NanoDrop Technologies, USA), the device being controlled by computer-run ND-1000 
software version 3.3.0. DNA absorbs ultra violet (UV) light and this property is used as 
the basis for quantification. To measure DNA concentration (and purity) the intensity 
of absorbance of DNA was measured at 260nm (A₂₆₀) and 280nm (A₂₈₀).  DNA quantity 
was measured on the basis that a pure DNA sample has an A₂₆₀/A₂₈₀ ratio of 1.8. Any 
samples with a ratio lower than this were excluded. For measurement, 2µl of each 
sample was placed into the measuring point and after calibration of the nanodrop an 
automated ratio and ng/µl concentration were provided.  
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2.2.3 Polymerase chain reaction 
Polymerase chain reaction (PCR) amplifies a specific segment of DNA multiple times so 
that the DNA segment can be visualized on a gel to confirm the absence/presence of 
the gene of interest. There are 4 steps of the PCR: 
1. Denaturation step - DNA is heated to high temperatures causing the hydrogen 
bonds between strands to break, therefore the DNA ‘melts’ and single stranded 
DNA (ssDNA) is yielded. 
2. Annealing step - the reaction temperature is lowered to assist the annealing 
(‘joining’) of primers to their target sequences on the DNA template. 
3. Extension/elongation step - formation of new complimentary strands of DNA, a 
reaction catalysed by DNA polymerase. 
4. Final elongation - this step is required to ensure extension of any remaining 
ssDNA. 
The ApoE gene contains 4 exons and is located on mouse chromosome 7. In ApoE KO 
mice the gene has been disrupted by insertion of a neomycin cassette sequence.  The 
sequence replaces exon 2 and a part of exon 3 (Piedrahita et al., 1992). Determination 
of the presence of ApoE or the neomycin cassette was utilised to distinguish between 
ApoE KO and WT mice. Specific forward and reverse primers were used (Table 2.1). A 
master mix of 10X PCR buffer (Applied Biosystems), deoxynucleoside triphosphates 
(dNTPS - Invitrogen), primers (Integrated DNA Technologies – IDT) and TaqPolymerase 
(Taq - Applied Biosystems) was made. The volume of each reaction component 
required for a single reaction is shown in table 2.2. For each reaction, 10μl of master 
mix was added to 2μl of DNA. The cycling conditions for the PCR are shown in table 
2.3. 
 
 
 
 
[85] 
 
 
Primer Sequence 5' --> 3' Primer Type PCR product size, base pairs 
(bp) 
oIMR0180 GCC TAG CCG AGG GAG AGC 
CG 
Common 
Forward 
Heterozygote ~ 155 and ~ 
245 
oIMR0181 TGT GAC TTG GGA GCT CTG 
CAG C 
Wild type 
Reverse 
WT ~ 155 
oIMR0182 GCC GCC CCG ACT GCA TCT Mutant Reverse ApoE KO ~ 245 
Table 2.1: The gene specific primer sequences that were used in the PCR amplifications. 
 
Reaction Components Volume for 1 reaction/μl 
10X PCR buffer 1 
Magnesium chloride (MgCl2) 25mM 0.8 
dNTPs 5mM 0.4 
Forward (F) Primer 10μM 0.5 
Reverse (R) Primer 10μM 0.5 
Forward (F) Primer2 10μM 0.5 
Taq 5U/μl 0.05 
Water 5.25 
Table 2.2: List of the reaction components in the PCR master mix required for 1 reaction. 
 
Step Temperature Time Note 
1 94°C 10min  
2 94°C 30s  
3 68°C 40s  
4 72°C 1min Repeat steps 2-4 for 35 cycles 
5 72°C 2min  
6 10°C  hold 
Table 2.3: The cycling times and conditions used for the amplification of the ApoE region of DNA as used 
on the Peltier Thermal Cycler (MJ Research). 
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2.2.4 Visualization of PCR products 
PCR products were resolved by agarose gel electrophoresis. A 1.5% wt/vol agarose gel 
(multi-purpose molecular grade; Bioline, UK) was dissolved by heating in 1X tris-
borate-EDTA (TBE) buffer (0.01M Tris base; 0.01M Boric acid; 0.004M EDTA – pH 8.0) 
mixed with GelRed (Biotium - 10μg/ml) and then allowed to set. In a cast 10μl of 
sample was added to 2μl of 6X DNA coloured loading buffer (GibcoBRL - 3g Ficoll 400; 
4ml EDTA, pH 8.0; 5ml 1% bromophenol blue; made up to 20ml dH₂O).  A ladder (4μl of 
a 100bp) was run and the PCR bands were visualised using a High Performance 
Ultraviolet Transilluminator (Bioimaging Systems). Figure 2.1 shows a representative 
image of the analysis of PCR products from DNA of ApoE KO and WT mice. 
1       2        3       4       5        6         7
300bp
200bp
Lane number:
~ 245bp ApoE KO band
~ 155bp WT band
 
Figure 2.1: An example gel from electrophoretic analysis of PCR products from genomic DNA of WT mice 
and ApoE KO mice. Lanes 1 and 7 represent a 100 bp ladder with the 300 and 200 bp markers shown, 
lane 2 a heterozygote, lanes 3, 4 and 5 a WT mouse whilst lane 6 represents the band for an ApoE KO 
mouse. 
2.2.5 Dietary nitrate supplementation 
WT mice were randomly assigned to 1 of 6 different treatment groups and ApoE KO 
mice were split into 1 of 3 groups (table 2.4): 
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WT mice ApoE KO mice 
Control Control 
KNO₂ 0.6mM KNO₂ 0.6mM 
KNO₂ 1.0mM KNO₃ 15mM 
KNO₃ 0.5mM   
KNO₃ 15mM   
KNO₃ 45mM   
Table 2.4: The list of treatment groups WT and ApoE KO mice were assigned to. 
 
For dietary nitrate supplementation potassium nitrite (KNO₂, Sigma-Aldrich, UK) or 
potassium nitrate (KNO₃, Sigma-Aldrich, UK) was dissolved in 1 litre (L) of 18MΩ dH₂O. 
This dH₂O had undetectable (<50nmol/L) levels of nitrite or nitrate. The drinking water 
was made fresh and replaced every 2 days for 2 weeks. 
2.3 Sample collection 
2.3.1 Blood and tissue collection 
Blood and tissue were collected from animals for nitrite and nitrate (collectively 
termed NOx) analyses. Animals were anaesthetized using isoflurane (2%, vapourised in 
100% oxygen at 0.4L/min, Baxter, UK).  Blood was extracted by cardiac puncture into 
heparin (25units/ml of blood) or citrate (0.109M sodium citrate) coated 23-gauge 
needles and immediately centrifuged at 4°C, 12,000 g for 5min. The plasma and blood 
were separated and both were snap frozen in liquid nitrogen until use. 
 
Following collection of blood the left ventricle of the heart was exposed and a cannula 
inserted and the animal then perfused with phosphate buffered saline (PBS, Sigma-
Aldrich, UK) at a pressure of 100mmHg, until all blood had been flushed from the 
system.  The internal organs (heart, lungs, liver, kidneys, spleen, mesentery and aorta) 
were then harvested and snap frozen in liquid nitrogen. All samples were stored at -
80°C until use for biochemical analyses. 
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2.3.2 RBC collection 
Blood was immediately centrifuged at 1,600g for 5min at room temperature. The 
plasma and buffy coat layer were removed, the plasma aliquoted and snap frozen in 
liquid nitrogen. RBCs were washed in PBS and the centrifuge/wash process repeated to 
generate a compacted RBC pellet. 
2.4 Preparation of samples for biochemical analyses 
2.4.1 Plasma preparation for NOx analysis  
In order to measure only circulating free NOx levels all plasma samples were 
deproteinated. This is necessary for several reasons. Firstly during measurement of 
NOx the bubbling of protein-containing samples results in frothing. Secondly, it is 
possible that nitrite will react to form either RSNO or RNNO groups and deproteination 
prevents this. 
 
For deproteination plasma samples were centrifuged at 4°C, 14,000g for 60min 
through Microcon® Ultracel YM-3 (3kDa) filters (Millipore Corporation, Billerica, USA).  
The filters were then discarded and the filtrate snap frozen in liquid nitrogen and the 
samples stored at -80°C until use for analysis. Prior to use all filters were washed 2 
times with low NOx containing 18MΩ dH₂O to remove any potential contaminants 
prior to addition of the plasma sample. 
2.4.2 Tissue preparation for NOx analysis 
Prior to homogenisation each organ was weighed and then diluted with a protease 
inhibitor cocktail made in PBS (table 2.5). Using a Precellys homogenizer (Bertin 
Technologies, France) samples were then homogenised at 4°C. The homogenate was 
then centrifuged at 4°C, 10,000g for 5min. Protein concentration of the resultant 
supernatant was determined (see section 2.4.3) before being passed through a washed 
microcon YM-3 filter at 4°C, 14,000g for 90min. The filters were discarded and the 
filtrates snap frozen and stored at -80°C until use. 
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2.4.3 Protein determination 
Protein concentration of tissue supernatant was determined using a Bradford protein 
assay (Bradford, 1976). A standard curve was generated from bovine serum albumin 
(BSA, 2mg/ml) by serial dilution at 0.0625-1mg/ml (figure 2.2) and then 10µl of each 
standard and 10µl of each sample was loaded in duplicate on a 96-well plate. Reagent 
(200µl; Bio-Rad, UK; diluted 1:5 in MQ H₂O) was then added to each of the wells. The 
light absorbance was measured using a spectrophotometric plate reader (MRX-TC 
Revelation, Dynex Technologies, UK) at wavelength 570nm. The protein concentration 
was determined by comparing the light absorbance of the unknown samples to the 
standards. 
0.00 0.25 0.50 0.75 1.00 1.25
0.0
0.2
0.4
0.6
0.8
Protein Conc. (g/l)
A
b
s
o
rb
a
n
c
e
 a
t 
5
7
0
n
m
 
Figure 2.2: Typical standard curve generated from the Bradford protein assay. 
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Inhibitor Target Stock conc. Made up in Final conc. 
Benzamidine 
Potent inhibitor of thrombin 
and trypsin 
1mg/ml 
(5.7mM) 
water 
1mg/L 
(5.7µM) 
Antipain 
Reversible inhibitor of serine 
and cysteine proteases. 
Inhibits papain and trypsin 
more specificity than 
leupeptin. Plasmin is inhibited 
only slightly. Also involved in 
inhibition of RNA synthesis 
1mg/ml 
(1.5mM) 
water 
1mg/L 
(1.5µM) 
Aprotinin 
Basic single-chain polypeptide 
that inhibits numerous serine 
proteases by binding to the 
active site of the enzyme, 
forming tight complexes. It 
inhibits above all plasmin, 
kallikrein, trypsin, 
chymotrypsin and urokinase, 
but not carboxypeptidase A 
and B, papain, pepsin, 
subtilisin, thrombin and 
factor X. Used in cell culture 
to prevent proteolytic 
damage to cells and to extend 
lifetime of cells. 
1mg/ml 
(0.15mM) 
water 1mg/L 
Leupeptin 
Tripeptide aldehyde. 
Reversible competitive 
inhibitor of serine and 
cysteine proteases. Inhibits 
also phospholipase D and C 
activation in rat hepatocytes. 
1mg/ml 
(2.1mM) 
water 
2mg/L 
(4.2µM) 
Pepsatin A 
Pentapeptide derivative. 
Reversible inhibitor of 
aspartic proteases, e.g. 
pepsin, cathepsin D, 
chymosin, renin 
1.5mM 
(0.7mg/ml) 
solubilised in 10% 
(v/v) acetic acid in 
methanol (9:1  
methanol:acetic 
acid at 100%) 
1µM 
AEBSF 
Irreversible inhibitor of 
Thrombin and other serine 
proteases. Inhibits by 
acylation of the active site of 
the enzyme. Much less toxic 
than PMSF and DFP 
100mg/ml water 400µM 
Table 2.5: List of all protease inhibitors used to make up cocktail. 
2.4.4 RBC preparation for NOx measurement 
RBCs were prepared according to published validated protocols (Dejam et al., 2005).  
Briefly a compacted RBC pellet was resuspended 1:4 in nitrite preserving stop solution. 
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The stop solution consisted of 0.8M potassium ferricyanide (K₃Fe(CN)₆, Sigma, UK) and 
0.1M N-ethylmaleimide (NEM, Sigma, UK) dissolved in 4.5ml MQ H₂O to which 500µl 
Nonidet P-40 (NP-40, Sigma, UK) was added.  Ice-cold methanol was then added to the 
resultant mix in a 1:1 ratio to deproteinate the sample. The sample was then 
centrifuged at 13,000g for 5min at 4°C. The supernatant was collected and used for 
biochemical analyses. 
2.5 Measurement of plasma, tissue and RBC nitrite and nitrate levels 
To determine the concentration of nitrite and/or nitrate in a given sample the 
technique of ozone chemiluminescence was used. For this technique an NO analyser 
(NOA 280A, Sievers) was used to measure NO based on the gas-phase 
chemiluminescent reaction between NO and ozone (O₃). Essentially the levels of nitrite 
and nitrate in any sample are reduced to NO.  Then NO is measured by the NOA and 
since for every one mole of nitrite or nitrate one mole of NO is generated one can 
assess accurately the levels of both anions in a given sample. When NO gas is mixed 
with ozone (O₃) it generates nitrogen dioxide in an excited state (equation 2.1). 
NO O₃ NO₂* O₂+ +
 
Equation 2.1: Reaction of NO with ozone (O₃) to produce excited nitrogen dioxide (NO₂*). 
 
The excess energy of NO₂* can be taken up by reaction with other gas molecules (M, 
equation 2.2) or released as a photon (equation 2.3) when the NO₂* spontaneously 
returns to a stable ‘ground’ state (NO₂), which releases energy as a photon (hv). 
NO₂* M NO₂ M+ +
 
Equation 2.2: Reaction of excited nitrogen dioxide (NO₂*) with other molecules. 
 
NO₂* NO₂ hv+
 
Equation 2.3: Stabilisation of excited nitrogen dioxide. 
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The release of the photon (emitted in proportion to the NO concentration) is detected 
by the NOA. 
 
For sample measurements 2 main components are required, the purge vessel and the 
NOA (figure 2.3). An inert gas i.e. 100% N₂ bubbles through the reducing agent inside 
the purge vessel to purge any NO from the solution contained within the vessel.  
Standards and biological samples are added through the liquid sample inlet into the 
purge vessel where, depending upon the reducing agent, nitrite and/or nitrate is 
reduced to NO. The NO produced, which is in the gas phase, is then carried through 
the purge vessel to the NOA for quantification. 
 
To determine the nitrite concentration samples were added to 0.09M potassium 
iodide (KI) in glacial acetic acid refluxing under N₂ at room temperature (equation 2.4). 
Initially a calibration curve is made based on the final dilutions from a stock solution of 
sodium nitrite (NaNO₂). Figure 2.4 shows an example trace that is obtained from 
different injection volumes and concentrations of standards. Figure 2.5 shows a 
calibration curve after integration of each peak to the correct standard. 
N2 gas in
Sample 
injection port
Purge vessel 
containing reducing 
reagent
Sievers 
280i,
NOA
Computer
Amplified signal
NO produced 
quantified by 
analyser
 
Figure 2.3: Diagram of the ozone chemiluminescence setup for nitrite determination. 
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Figure 2.4: An example trace that is produced when standards of known concentration are injected into 
the purge vessel. 
Amt (pmoles)
Area
 
Figure 2.5: A typical standard curve produced prior to the measurement of nitrite in liquid samples 
(slope=6.5; intercept=-1.2; R²=0.9999). 
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In the presence of protons (H⁺) from the acid, nitrite (NO₂⁻) is converted to the 
nitrosonium ion (NO⁺, equation 2.4). 
NO₂⁻ 2H⁺ NO⁺ H₂O+ +
 
Equation 2.4: Reaction of nitrite (NO₂⁻) with protons (H⁺).  
The NO⁺ associates rapidly with anions but in the presence of iodide (I⁻) NO⁺ is 
converted to NO via a nitrosyl iodide (ONI) intermediate (equation 2.5). 
NO⁺ I⁻ ONI+
 
2ONI 2NO I₂+
 
Equation 2.5: The conversion of the nitrosonium ion (NO⁺) to NO via a nitrosyl iodide intermediate. 
 
Thus the overall reaction chain for the reduction of 1 mole of nitrite gives one mole of 
NO (equation 2.6). 
NO₂⁻ 2H⁺ NO H₂O+ ++ e⁻
 
Equation 2.6: The overall reduction reaction of nitrite to NO.  
 
These conditions are specific for the reduction of nitrite since the reduction of nitrate 
requires a much stronger reducing environment. The level of nitrate can be 
determined by placing samples in a much stronger reducing environment that will 
reduce all nitrate and nitrite. To measure the total NOx samples were added to 0.1M 
vanadium (III) chloride (VCl₃) in 1M hydrochloric acid (HCl) refluxing under N₂ at 95°C 
to achieve high conversion efficiency. These conditions result in the reduction of all 
nitrate (equation 2.7) and nitrite (equation 2.6) to NO to give a total NOx value.  
NO₃⁻ 4H⁺ NO 2H₂O+ ++ 3e⁻
 
Equation 2.7: The overall reduction reaction of nitrate (NO₃⁻) to NO. 
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By subtracting the amount of nitrite measured from the NOx value a measure of the 
nitrate can be obtained. To accommodate the more powerful reducing environment 
required the setup is adjusted slightly (figure 2.6).  
N2 gas in
Liquid sample inlet
Purge vessel 
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Figure 2.6: Diagram of the ozone chemiluminescence setup for NOx determination. A gas bubbler 
containing 1M sodium hydroxide (NaOH) was installed between the purge vessel and the NOA to 
prevent HCl vapour damaging the NOA. 
2.5.1 Data analysis 
For determination of NOx levels in samples all plasma samples are expressed as a 
concentration whilst all tissue/RBC samples are normalized to protein concentration. 
2.6 Measurement of nitrite reductase activity 
Prior to use for nitrite reductase assessment protein concentration was determined 
using a Bradford protein assay (Bradford, 1976) on tissue supernatant or RBCs diluted 
1:1000 (see section 2.4.3). For the measurement of the nitrite reductase activity of 
tissue and RBC samples gas phase chemiluminescence was used. Experiments were 
performed in a sealed 10ml glass reaction chamber containing citric acid-sodium 
phosphate dibasic (Na₂HPO₄) (Sigma, UK) buffer at pH 7.4 (physiological levels) or pH 
6.8 (representing acidosis) and KNO₂ (10-300 µmol/l) in a total volume of 1ml (figure 
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2.7). Confirmation of correct pH was checked using a pH meter (Jenway, Staffordshire, 
UK). The pH meter was calibrated to solutions of known pH. The citric acid-Na₂HPO₄ 
solution was bubbled with 100% N₂ gas by means of an NO· scrubbing air filter 
(Sievers, Boulder, USA). The headspace NO· concentration was measured in parts per 
billion (ppb) by continuous sampling by ozone chemiluminescence (NOA 280A, 
Sievers).   
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Figure 2.7: Diagram of the ozone chemiluminescence setup for the measurement of nitrite reductase 
activity. 
 
In all experiments under each condition a baseline NO level was obtained prior to 
addition of 300-500µg of protein for tissues (calculated from the injection volume and 
protein concentration) or 20µl of RBC sample.  The impact of biological tissue samples 
on NO production was determined firstly by adding washed RBCs/tissue supernatant 
to the glass reaction chamber, then adding nitrite and measuring NO production from 
nitrite over the following 2min. From this, the rate of NO· production (nmol per g of 
tissue per s) was calculated from the area under the curve (see figure 2.8 for a typical 
trace with just the addition of nitrite, figure 2.9 for a typical trace with just the addition 
of tissue supernatant and figure 2.10 with the addition of nitrite followed by the 
addition of tissue supernatant). 
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Figure 2.8: Typical trace of sampling of NO production following the addition of just nitrite (300µM) at 
pH 6.8 under anaerobic conditions. 
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Figure 2.9: Typical trace of sampling of NO production following the addition of just tissue supernatant 
at pH 6.8 under anaerobic conditions. 
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Figure 2.10: Typical trace of sampling of NO production following the addition of rat aorta supernatant 
and then nitrite (300µM) at pH 6.8 under anaerobic conditions. 
 
To determine whether XOR might be involved in any nitrite reductase activity 
allopurinol (100µM) or vehicle (1M NaOH diluted in PBS) was incubated with the tissue 
sample for 30min prior to addition to the NO sampling chamber. 
2.6.1 Data analysis 
To normalize data to enable comparison between treatments, all data were corrected 
for protein amount therefore the rate of NO· production was converted from ppb per s 
to nmol per g per s: 
The protein amount was calculated from the injection volume (µL) and the protein 
concentration (µg/µL) obtained from the protein assay. The protein amount was 
therefore the result of the values multiplied together to give a value in µg.  As an 
example for a 300µg sample one would determine the reductase activity as follows -  
The NOA samples at a rate of 0.228Lmin-1 and therefore 0.0038Ls-1. 
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Under standard laboratory conditions (25°C and 1 atmosphere) 1 mole of an ideal gas 
has a volume of 24.47L, therefore the amount of pure gas in 1s=0.0038=1.5529x10⁻⁴ 
mol. 
              
For 1ppb over 1s, 1ppb=1x10-9 the rate of NO· production from 1ppb=1.5529x10-
4x1x10-9. 
Calculate rate=1.5529x10⁻¹³mols⁻¹. 
The value is then normalized for the amount of protein that was injected into the 
reaction chamber – 
So for a 300µg sample the rate of NO· production=1.5529x10-13÷3.0 x 10-4  
                                                                                   = 0.5176x10-9molg-1s-1 
2.7 Western blotting 
Expression of XOR in washed RBCs was determined using western blotting. Western 
blotting of the abundant cytoskeletal housekeeping protein actin was also performed 
to estimate protein loading. Western blotting comprised of 3 main steps; sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE), gel transfer and 
incubation and detection of proteins with the appropriate antibodies. 
2.7.1 Sample Preparation 
Cell pellets were lysed using a stock solution of tissue lysis buffer (table 2.6) and 0.5M 
NaF, 1% Triton X-100, 0.2M Na₃VO₄ as well as 1µg/ml each of the protease inhibitors 
benzamidine, aprotinin, antipain, leupeptin, pepstatin A and AEBSF. 
 
Chemical Final concentration 
(mM) 
Action 
10mM Tris-HCl 10 Buffer 
50mM NaCl 50 Buffer 
30mM NaPPi 30 Excess phosphate, 
phosphatase inhibitor 
2mM EDTA 2 Chelator of metal ions 
Table 2.6: Composition of tissue lysis buffer. 
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2.7.2 Protein Determination 
To quantify the amount of protein in each sample a Bradford Assay (Bradford, 1976) 
was performed as previously described (see section 2.4.3 Protein Determination).  The 
protein concentration of each sample was then adjusted to 10µg/µl in tissue lysis 
buffer to enable equal amounts of protein to be loaded in each well of the gel.   
2.7.3 SDS-PAGE 
Samples were diluted 1 in 5 in Laemmli’s loading buffer (final concentration 0.05M 
Tris-HCl, 6% glycerol, 0.002% bromophenol blue, 1.7% SDS and 1.55% DTT) and 
denatured by boiling at 95°C for 5min to break disulphide bonds therefore destroying 
the tertiary (and quaternary) structure, linearising protein in its primary structure so 
that proteins were separated by weight and charge. 
2.7.4 Preparation of Gels 
Precast gels, 10% Mini-PROTEAN® TGX™ (Bio-Rad, Hertfordshire, UK) were used.  The 
precast gel was securely locked in to a casting stand. From the gel, the comb was 
removed and the casting stand was placed inside a Mini-PROTEAN® TGX™ Tetra 
System gel tank. Running buffer (25mM Tris-Base, 192mM glycine, 0.1% SDS) was then 
added to the gel tank until all wells were fully submerged and no air bubbles were 
present inside any well.  Following addition of loading buffer 10µl of protein marker 
(Precision Plus Protein™ Dual Colour Standards, 10 - 250kDA, Bio-Rad, Hertfordshire, 
UK) was loaded in to the first well followed by 50µl of sample in to the subsequent 
wells and separated at 200V for 30min i.e. until the dye was visible at the bottom of 
the gel. 
2.7.5 Transfer of Proteins 
A piece of blot paper (PROTEAN®XL Size extra thick, Bio-Rad, Hertforshire, UK) and a 
Hybond™ Enhanced Chemiluminescence (ECL)™ nitrocellulose membrane (Amersham 
Biosciences, UK) were soaked in positive buffer (100ml methanol + 18.3g Tris-base, 
made up to 500ml with water) for 20min.  Another piece of blot paper was soaked in 
negative buffer (100ml methanol + 1.5g Tris-base + 2.6g 6-amino-n-caprioic acid, made 
up to 500ml with water) for 20min. On to a platinum anode, the positive blot paper 
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was added followed by the nitrocellulose membrane, then the gel and finally the 
negative blot paper (figure 2.11). In order to ensure homogenous transfer of proteins 
the ‘stack’ was rolled to ensure removal of air bubbles. A cathode was then placed on 
to the ‘stack’ and the proteins were then transferred to the membrane by 
electrotransfer at 100mA using a Trans-Blot® SD semi-dry transfer cell (Bio-Rad, 
Herforshire, UK) for 60min. Following this the membrane was stained with 0.1% 
Ponceau S Solution. Ponceau S reversibly stains proteins so that the membrane can be 
visually inspected to ensure equal loading and transfer. With distilled water the 
Ponceau S was washed 3-5 times with gentle agitation on a Luckham R100 Rotatest 
Shaker (Ecomat, Reading, UK) for 3min per wash step. 
Cathode (-ve)
Anode (+ve)
Filter paper
Gel
Nitrocellulose 
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Filter paper
Cathode (-ve)
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Figure 2.11: The different layers required in the transfer of proteins from a gel to a nitrocellulose 
membrane. The gel and nitrocellulose membrane are ‘sandwiched’ between 2 pieces of filter paper and 
placed in between electrodes. Electrotransfer (at 100mA) for 60min was required to fully transfer the 
proteins from the gel onto the nitrocellulose membrane.    
2.7.6 Detection 
To detect proteins of interest specific antibodies were added after the membrane had 
been blocked (required to prevent non-specific background binding of the primary 
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and/or secondary antibodies to the membrane, which has a high capacity at binding 
proteins and therefore antibodies). To prevent non-specific binding each membrane 
was blocked for 1h at room temperature with gentle agitation with 5% non-fat milk 
(Marvel®, Dublin, Republic of Ireland) in Tween-20 buffer (150mM NaCl, 10mM Tris-
HCl pH 7.6 and 0.05 % (w/v) Tween-20) and then washed with Tween-20 buffer. The 
membranes were incubated overnight at 4°C with anti-XOR primary antibody (1:2000, 
Abcam, Cambridge, UK) diluted in 0.05% (w/v) Tween-20 buffer. The membranes were 
then incubated with polyclonal goat anti-mouse antibody (1:5000, Dako, Denmark) 
conjugated to horseradish peroxidase (HRP), diluted in Tween-20 buffer, for 1h at 
room temperature (figure 2.12). 
Primary antibody
Nitrocellulose membrane containing transferred protein
Enzyme-conjugated 
secondary antibody
Enzyme substrate
Target/transferred 
protein
 
Figure 2.12: Detection of proteins using a primary antibody specific to the target protein of interest and 
a labelled secondary antibody. 
 
In order to visualise the membrane the Clarity™ Western ECL kit was used (Bio-Rad, 
Hertfordshire, UK). Solution A (peroxide solution) and solution B (Luminol / enhancer 
solution) were mixed in a 1:1 ratio and the membrane incubated in the mixture for 
2min. The excess was then drained and the membrane covered in Saran Wrap. 
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2.7.7 Data analysis 
Densitometric analysis was performed on bands using the Gel Analyzer software 
(www.gelanalyzer.com) using the FluorChem™ E chemiluminescent western blot 
imaging system (ProteinSimple, Santa Clara, CA, USA). The levels of protein were 
expressed relative to β-actin expression.  
2.8 Murine peritonitis 
2.8.1 Induction of inflammation 
Mice were injected intraperitoneally (i.p.) with 0.5ml of a pro-inflammatory stimulus of 
IL-1β (5ng), TNFα (300ng) or Zymosan (1mg).  These doses were chosen as they have 
been shown to induce polymorphonuclear (PMN) leukocyte and monocyte 
accumulation into a site of acute inflammation (Perretti et al., 1993; Dangerfield et al., 
2005; Cash et al., 2009). Sterile PBS was used as a control.  After 4 or 24h post injection 
the mice were anaesthetized using isoflurane (2%, vapourised in 100% oxygen at 
0.4l/min, Baxter, UK).  Blood was extracted by cardiac puncture prepared as described 
in section 2.3.1 for NOx analysis. For the collection of peritoneal lavage fluid a small 
incision was made around the lower abdomen and the skin pulled apart to expose the 
underneath muscle without compromising the integrity of the peritoneal cavity.  Using 
a 23-gauge needle 4ml of sterile ice cold PBS was injected in to the cavity. The cavity 
was thoroughly massaged for a minute and the wash retrieved using the same needle. 
The volume of wash was recorded and kept on ice. Tissue collection was conducted as 
described previously (see section 2.3.1).   
2.8.2 Cell counting 
Total white blood cell (WBC) count of the collected lavage fluid was assessed by 
dilution of sample with Turks solution (Merck, Germany). Turks solution haemolyses 
RBCs and stains the nuclei of WBCs blue to enable counting of leukocytes only. The 
total count was determined using a Neubauer haemocytometer (Hawksley, Sussex, UK) 
as recommended by the manufacturer using a x10 objective lens on the microscope 
(Eclipse TS100, Nikon, Surrey, UK). 
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2.8.3 Preparation for flow cytometry analysis 
The lavage fluid was centrifuged for 5min, 4°C at 800g. The supernatant was then 
aliquoted for biochemical analysis and the cell pellet resuspended in a volume of FACS 
buffer (0.2% BSA in PBS) to yield 5 x 10⁶cells/ml. A 100µl aliquot of each sample was 
added to FACS tubes and then centrifuged at 13,000g for 1 min at 4°C and the 
supernatant discarded. To block non-specific binding 20µl of Fc receptor antibody 
(1µg) was added to the cell pellets, vortexed to resuspend and incubated at 4°C for 
15min. To each tube 10µl of the appropriate antibody was then added and the 
samples incubated in the dark at 4°C for 30 min. The cells were washed with 500µl of 
PBS then flow cytometry was performed to identify the cells. To exclude dead cells 5µl 
of the viability marker 7-AAD was added to all samples.  
2.8.4 Flow cytometry 
Flow cytometry is a technique that simultaneously measures multiple physical 
characteristics of single cells/particles as they flow in single file in a fluid stream (figure 
2.13). The technique enables the user to gather detailed quantitative information on 
cells in a large population. After passing through a beam of light data such as relative 
size, relative granularity/internal complexity and relative fluorescence intensity, about 
a particle’s properties are collated. These properties are determined using an optical-
to-electron coupling system that records how the particle scatters incident laser light 
and emits fluorescence (figure 2.14). Samples were acquired and recorded on the 
LSRFortessa II Cell Analyzer (BD Biosciences, San Jose, CA, USA) using BD FACSDiva 
Software (BD Biosciences, San Jose, CA, USA).  
 
The flow cytometer analysed deflected light from each cell, which is recorded as 
forward-scatter (FSC; proportional to the size of the cell) and side-scatter (SSC; relative 
to granularity and internal complexity of the cell) on a FSC/SSC dot-plot graph (Figure 
2.15). Fluorochromes conjugated to antibodies can bind to specific cell surface markers 
and the presence of these markers can be quantified by measuring the fluorescence 
emission. 
[105] 
 
 
Laser light  source
Sheath fluid
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Sample (homogenous solution of stained cells)
Hydrodynamic focussing 
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Figure 2.13: Diagram of the basic internal structure of a flow cytometer. Sheath fluid passing down the 
nozzle aids the cells to fall in single file allowing the acquisition of data for each individual cell to be 
done. 
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Figure 2.14: Determination of cell specific properties by an optical-to-electron coupling system. Forward 
and side scatter detection means information about the size and internal complexity of a cell is 
acquired. 
[106] 
 
 
Lymphocytes
Monocytes
Granulocytes
 
Figure 2.15: Dot plot showing the FSC vs. SSC characteristics of leukocyte subpopulations derived from 
mouse lavage fluid. Lymphocytes are the smallest leukocytes with little granularity in the cytoplasm. 
They are identified by having a low FSC and SSC (P1 gate; red).  Monocytes (P2 gate; green) are bigger 
and therefore distinguished by a larger FSC. Granulocytes (predominantly neutrophils) are the largest 
cell type and contain many granules within their cytoplasm and therefore have a larger FSC and SSC (P3 
gate; blue). The black dots with low FSC and SSC represent dead cells and/or debris. 
 
The different leukocyte subtypes express different patterns of markers that enable 
characterization, and were further identified by their distinct expression profiles of 
F4/80 and Gr1 i.e. resident monocytes (F4/80+, Gr1-), inflammatory monocytes 
(F4/80+, Gr1+) and neutrophils (F4/80-, Gr1+). Furthermore the expression of the 
inflammatory markers CD62L, CD162 and CD11b on the surfaces of these cells was 
investigated. Tables 2.7 and 2.8 give a more detailed account of the information 
elucidated from using these particular markers. 
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Figure 2.16: Quadrant scheme for the identification of different leukocyte subsets. Subsets include Q1 
resident monocytes (F4/80
+
, Gr1
-
), Q2 inflammatory monocytes (F4/80
+
, Gr1
+
) and Q4 neutrophils 
(F4/80
-
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). 
 
Antigen Cell Type Fluorochrome Conjugated With Antibody 
Gr1 neutrophils Fluorescein isothiocyanate (FITC) 
F4/80 
resident 
monocytes 
Allophycocyanin (APC) 
GR1 + F4/80 
inflammatory 
monocytes 
  
Table 2.7: The fluorochrome conjugated antibodies used to identify specific inflammatory cells. 
[108] 
 
 
 
Antigen 
Alternative 
Name 
Role Of Surface Marker 
Fluorochrome Conjugated With 
Antibody 
CD62L L-selectin 
Expressed by activated 
macrophages, monocytes 
and neutrophils. Important 
for leukocyte rolling 
APC-eFluor 780 
CD162 
P-selectin 
glycoprotein 
ligand-1 
(PSGL-1) 
Expressed by activated 
leukocytes, PSGL-1 is the 
high affinity receptor for P-
selectin (expressed by 
platelets and endothelial 
cells, important for 
leukocyte rolling) 
Phycoerythrin (PE) 
CD11b 
Integrin 
alpha-M beta-
2 (αMβ2) 
Expressed by activated 
leukocytes. Aids in leukocyte 
adhesion and migration 
eFluor 450 
Table 2.8: The fluorochrome conjugated antibody used to identify specific cell surface markers. 
 
Combined with FSC and SSC data the staining pattern of each leukocyte was used to 
calculate the relative percentage of cells expressing each inflammatory marker, as well 
as their respective median fluorescence intensity (MFI). MFI is a measure of the 
number of markers present on each cell. By isolating sub-populations of leukocytes, it 
was possible to determine what percentage of total leukocytes was made up of each 
inflammatory cell type. To ensure that the fluorescence recorded was due to specific 
primary antibody binding to the desired marker, and not due to non specific binding 
(i.e. Fc receptors), isotype-matched control antibodies were used. Figure 2.17 shows 
an example of the histograms obtained from the antibody marker and its respective 
isotype control. 
[109] 
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Figure 2.17: An example histogram of cells stained positively for Gr1 and the isotype control for Gr1. The 
top graph shows an example histogram of cells positively stained for Gr1. The bottom graph shows and 
example of cells positively stained for the isotype control for Gr1. This analysis was set up individually 
for each antibody. 
 
Flow cytometry data were analysed using the BD FACSDiva 6.0 software. During flow 
cytometry the fluorochromes are excited by light which causes the emission of 
fluorescent light at a longer wavelength. The fluorochromes do not emit light at a 
specific wavelength but over a fairly wide range known as emission spectra.  
Overlapping of emission spectra between fluorochromes can occur therefore when 
using multiple fluorochromes, the emitted light from the leading and trailing tails from 
a neighbouring fluorochrome is registered. Since 5 different fluorochromes were used 
spectral overlap had to be accounted for by manual compensation to allow accurate 
data analysis. In order to manually compensate, single staining of samples with each 
antibody conjugated fluorochrome was recorded on the flow cytometer. 
[110] 
 
 
2.8.5 Data analysis 
Analysis of cell population size and fluorescent intensities of the different leukocytes 
were achieved by constructing dot plots and histograms. In order to segregate 
leukocyte populations accurately, gates had to be set-up on the dot-plots. The 
quadrant boundaries between cells that stained positive and negative for a particular 
leukocyte population was determined according to the fluorescence distribution of 
positively stained cell relative to the unstained sample. 
2.9 Myeloperoxidase assay 
Myeloperoxidase (MPO) is a protein abundantly expressed by neutrophils and 
produces hypochlorous acid (HOCl) from hydrogen peroxide (H₂O₂) and the chloride 
anion (Cl⁻) during the neutrophils respiratory burst. Measurement of MPO is 
standardly taken as a good indicator of neutrophil recruitment to a particular site of 
interest. This assay was used to confirm whether neutrophils were recruited in 
response to i.p. administration of inflammogens. 
 
Mesentery samples from PBS, zymosan, TNFα or IL-1β treated mice were homogenised 
in 1 ml of 0.5% hexadecyltrimethylammonium bromide (HTAB) using a precellys 
homogeniser (Bertin Technologies, France) and CK14 beaded tubes (Stretton Scientific, 
Derbyshire, UK). Samples were centrifuged 2 times at 5,000rpm for 30s with 15s 
between centrifugations. Following homogenisation samples were then centrifuged at 
10,000g for 5min at 4°C to generate a supernatant, which was then collected and the 
pellet discarded. A standard curve was generated using purified MPO in PBS (2U/ml) 
by serial dilution at 0.03125-1U/ml). Standard and sample (20µl) were loaded in 
triplicate on a 96-well plate and 160µl of reagent (Tetramethylbenzidine (TMB) 
4mg/ml in DMSO then diluted 1:8 in PBS just before use) was added to each of the 
wells along with 20µl of H₂O₂ (0.1mM diluted 1:30 in PBS just before use). The plate 
was protected from light using tin foil and left to incubate for 5min. Light absorbance 
was measured using a spectrophotometric plate reader (MRX-TC Revelation, Dynex 
Technologies, UK) at 620nm and sample MPO concentration determined from the 
[111] 
 
 
standard curve. In addition, as previously described (section 2.4.3) a protein assay was 
conducted to determine the protein concentration of each supernatant sample. 
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Figure 2.18: Typical standard curve generated from the MPO assay. 
2.9.1 Data analysis 
To normalize data to enable comparison between treatments, all data were corrected 
for protein amount therefore the final units of MPO activity were expressed as U per 
mg. 
2.10 Statistical analysis 
All data were analysed using GraphPad Prism version 5.0 for Windows (GraphPad 
Software, San Diego, CA; www.graphpad.com). All values are expressed as 
mean±standard error of the mean (SEM) with the n value representing the number of 
animals or patient in that particular treatment group unless otherwise stated. A 
statistically significant result was indicated by a probability level, p, of less than 0.05. 
  
For the analysis in WT mice 1-way analysis of variance (ANOVA) was used to compare 
means as the means of more than 2 unmatched treatment groups was being tested. A 
Dunnett’s multiple comparison post-test was applied to compare the mean of each 
treatment group with the control mean. When examining the effect that 
atherosclerosis had on NOx distribution a 2-way ANOVA was used as the mean 
differences between groups split on 2 independent variables (in this case genotype 
and dietary treatment) was being examined. The Bonferroni post-test was applied.  
[112] 
 
 
Unpaired students t-tests were used for comparisons between baseline statistics as 
samples were collected from different animals. A 2-tailed test was used as it was not 
clear as to how means would differ. 
 
For the assessment of nitrite reductase activity, when comparing concentration-
response curves between health and disease (i.e. WT vs. ApoE KO or WKY vs. SHR) or 
in the absence or presence of enzyme inhibitors, statistical significance was 
established with 2-way ANOVA followed by Bonferroni’s post-tests. 
 
For the peritonitis studies 1-way ANOVA with Dunnett’s multiple comparison test was 
used for comparison of the 2 nitrate treatments with baseline control. 
[113] 
 
 
 
 
Chapter 3: 
Investigation of the 
distribution of nitrite and 
nitrate in models of 
cardiovascular disease 
[114] 
 
 
3.1 Introduction 
CVD is associated with a deficiency of NOx therefore strategies that aim to restore 
levels might have therapeutic utility. Previous studies have demonstrated that an 
approximate doubling of circulating nitrite levels is associated with significant 
biological activity. In healthy volunteers, a 24mmol dose of inorganic nitrate (given in 
500ml of beetroot juice) caused a 2-fold elevation in plasma nitrite concentration 
(Webb et al., 2008c). This elevation in plasma nitrite levels was paralleled with 
significant reductions in blood pressure and improvement in endothelial function 
(Webb et al., 2008c). In a similar vein inorganic nitrate supplementation in the form of 
potassium nitrate capsules also exerted blood pressure lowering and endothelial 
effects (Kapil et al., 2010) in a dose-dependent manner associated with dose-
dependent increases in plasma nitrate and nitrite concentration (Kapil et al., 2010). 
However, whether similar elevation of both anions might occur in tissues and whether 
the distribution of these anions at baseline and following supplementation might be 
altered in CVD has not been systematically investigated. 
 
The aim of this study was to: 
1. Determine whether nitrite and/or nitrate levels are altered in the 
cardiovascular system between health and disease. 
2. Determine whether nitrite or nitrate might be used effectively to elevate NOx 
levels throughout the cardiovascular system in both health and CVD. 
[115] 
 
 
3.2 Assessment of the effect of nitrite and nitrate supplementation on basic 
parameters in WT mice  
3.2.1 Testing the stability of the drinking water 
Before administering nitrite/nitrate through the drinking water it was first necessary to 
determine the stability of the anions in the water over time. In all cases the 
concentration of either the nitrate or nitrite ion remained constant for no more than 2 
days (figure 3.1) before declining and becoming significantly reduced at 8 days. 
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Figure 3.1: The effect of time on the stability of either nitrite or nitrate anion in the drinking water. Data 
are expressed as mean±SEM (0.6mM nitrite n=4; 1.0mM nitrite n=4; 15mM nitrate n=4; 45mM nitrate 
n=4). 
 
Based on these initial studies it was decided that the drinking water would be made up 
fresh and replaced every 2 days. 
[116] 
 
 
3.2.2 Food and water consumption 
Nitrite or nitrate supplementation appeared to have no impact on food (figure 3.2A) or 
water consumption (figure 3.2B). An estimate of the amount of nitrite or nitrate 
consumed per day demonstrated that the doses used were equivalent to 7.00 and 
13.56mg/kg/day nitrite and 7.59, 207.00 and 698.90mg/kg/day nitrate (table 3.1). 
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Figure 3.2: The effect of drug treatment on food (A) and water (B) consumption. Data are expressed as 
the average amount consumed per day per animal. Data are expressed as mean±SEM (control group 
n=11; 0.6mM nitrite n=12; 1.0mM nitrite n=8; 0.5mM nitrate n=8; 15mM nitrate n=9; 45 mM nitrate 
n=9). Data analysed using a one-way ANOVA Dunnett’s multiple comparison statistical test.  
 
  
Amount nitrite consumed Amount nitrate consumed 
Treatment 
Water 
consumed 
(ml/day) 
(mg/kg/day) (mmol/kg/day) (mg/kg/day) (mmol/kg/day) 
Control 6.41±0.41 <0.001 <0.001 <0.001 <0.001 
0.6mM Nitrite 8.46±0.80 7.00±0.20 0.15±0.01 <0.001 <0.001 
1.0mM Nitrite 8.85±0.84 13.56±0.43 0.29±0.01 <0.001 <0.001 
0.5mM 
Nitrate 
6.31±0.59 <0.001 <0.001 7.59±0.35 0.12±0.01 
15mM Nitrate 7.11±1.36 <0.001 <0.001 207.00±11.25 3.34±0.18 
45mM Nitrate 7.20±0.55 <0.001 <0.001 698.90±38.73 11.27±0.62 
Table 3.1: The amount of nitrite and nitrate consumed by WT mice during the 2 week treatment period. 
Values are expressed as mean±SEM. 
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3.2.3 Weight gain over time 
Neither nitrite nor nitrate affected weight gain during the treatment period (figure 3.3, 
table 3.2). 
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Figure 3.3: The effect of nitrite/nitrate supplementation on weight gain throughout the 2 week feeding 
period. Data are expressed as the average mean±SEM (control group n=11; 0.6mM nitrite n=12; 1.0mM 
nitrite n=8; 0.5mM nitrate n=8; 15mM nitrate n=9; 45 mM nitrate n=9).  
 
Treatment n value Weight prior to 
study (g) 
Weight at the 
end of the 
study (g) 
Overall weight 
change (g) 
Control 11 25.7±0.51 27.7±0.83 2.0±0.32 
0.6mM nitrite 12 26.9±0.54 28.2±0.79 1.4±0.25 
1.0mM nitrite 8 26.7±0.69 27.6±0.82 0.9±0.13 
0.5mM nitrate 8 26.6±0.43 29.3±0.78 2.7±0.35 
15mM nitrate 12 26.3±0.65 27.5±0.76 1.2±0.12 
45mM nitrate 8 27.1±0.75 28.5±0.81 1.4±0.06 
Table 3.2: Summary of the average weight of the WT mice prior to and at the end of the study. Data are 
expressed as mean±SEM. 
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3.3 Effect of nitrite/nitrate supplementation on plasma NOx in WT mice 
In WT mice nitrite supplementation appeared to slightly elevate plasma nitrite but not 
plasma nitrate concentration (figure 3.4A + 3.4B). Nitrate treatment caused a 
concentration dependent rise in both plasma nitrite and nitrate concentration (figure 
3.4A + 3.4B), which reached significance at the 15 and 45mM concentrations. 
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Figure 3.4: The effect of dietary nitrite and dietary nitrate supplementation on plasma nitrite (A) and 
nitrate (B) concentration in WT mice. Data are expressed as mean ± SEM (control group n=11; 0.6mM 
nitrite n=12; 1.0mM nitrite n=8; 0.5mM nitrate n=8; 15mM nitrate n=12; 45mM nitrate n=8). A 
significant difference is shown as ***p<0.001 vs. control group using a one-way ANOVA Dunnett’s 
multiple comparison statistical test. 
 
From these studies it was decided that all further investigations in mice would be 
conducted with only a single dose of each anion for supplementation i.e. 0.6mM nitrite 
and 15mM nitrate. These doses were chosen since they caused rises in circulating 
nitrite that was commensurate with rises associated with biological activity in healthy 
volunteers (Kapil et al., 2010). 
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3.4 Comparison of baseline NOx levels between WT vs. ApoE KO mice in the blood 
There was no statistical difference in baseline plasma and RBC nitrite levels between 
WT and ApoE KO mice however, there was a significant reduction in nitrate levels 
(table 3.3). 
  Nitrite Nitrate 
  WT ApoE KO p value WT ApoE KO p value 
Plasma 
(µM) 
0.56±0.10 
(n=11) 
0.45±0.06 
(n=12) 
0.18 
37.68±2.26 
(n=11) 
19.99±2.80 
(n=12) 
<0.0001 
RBC 
(nmoles/g 
protein) 
0.41±0.05 
(n=5) 
0.33±0.05 
(n=5) 
0.26 
13.06±1.40 
(n=5) 
6.33±1.34 
(n=5) 
<0.01 
Table 3.3: Comparison of baseline levels of nitrite and nitrate in plasma and blood. Statistical 
comparison using unpaired t-test.  
3.4.1 The effects of dietary supplementation on distribution of NOx in the blood 
Nitrite supplementation caused slight elevations in plasma nitrite levels for both 
genotypes but these were not significant, however nitrate supplementation 
significantly elevated plasma nitrite levels (figure 3.5A). In addition a dietary nitrite 
strategy appeared to have no effect on nitrate levels, however dietary nitrate 
supplementation significantly elevated nitrate levels in both WT and ApoE KO mice 
(figure 3.5B).  
 
 
 
 
 
 
 
 
Figure 3.5: The effect of dietary nitrite and dietary nitrate supplementation on plasma nitrite (A) and 
nitrate (B) levels in WT vs. ApoE KO mice (WT control n=11; 0.6mM nitrite n=12; 15mM nitrate n=12, 
ApoE KO control n=12; 0.6mM nitrite n=11; 15mM nitrate n=11). Data shown as mean±SEM of levels 
normalized to baseline. A significant difference is show as ***p<0.001 vs. control group using a 1-way 
ANOVA Dunnett’s multiple comparison statistical test. 
N
it
ri
te
 le
ve
l r
e
la
ti
ve
to
 b
as
e
lin
e
Control Nitrite Nitrate
0
1
2
3
4
5
Nitrite
A
WT
ApoE KO
***
***
N
it
ra
te
 le
ve
l r
e
la
ti
ve
to
 b
as
e
lin
e
Control Nitrite Nitrate
0
1
2
3
4
5
6
7
8
9
10
Nitrate
B
WT
ApoE KO ***
***
Plasma
[120] 
 
 
Dietary nitrite and nitrate supplementation significantly elevated nitrite levels for WT 
and ApoE KO mice (figure 3.6A). Furthermore dietary nitrite supplementation 
appeared to have no effect on nitrate levels, however dietary nitrate supplementation 
did cause significant elevations of nitrate levels for both genotypes (figure 3.6B). 
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Figure 3.6: The effect of dietary nitrite and dietary nitrate supplementation on RBC nitrite (A) and 
nitrate (B) levels in WT vs. ApoE KO mice (WT control n=5; 0.6mM nitrite n=5; 15mM nitrate n=5, ApoE 
KO control n=5; 0.6mM nitrite n=5; 15mM nitrate n=5). Data shown as mean±SEM of levels normalized 
to baseline. A significant difference is show as ***p<0.001 and **p<0.01 vs. control group using a 1-way 
ANOVA Dunnett’s multiple comparison statistical test. 
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3.5 Comparison of baseline NOx levels between WT vs. ApoE KO mice in the tissues 
There was no statistical difference between the genotypes in baseline tissue nitrite 
levels, however baseline tissue nitrate levels were significantly reduced in ApoE KO vs. 
WT mice (table 3.4). This was applicable for all tissues apart from the mesentery in 
which nitrite levels were significantly raised in the ApoE KO and nitrate levels were 
also raised in the ApoE KO although this did not reach significance. Interestingly, for 
both nitrite and nitrate the aorta had the highest levels, whilst the rest of the tissues 
had similar levels of nitrite and nitrate. 
 
  
Nitrite  
(nmoles/g protein) 
Nitrate  
(nmoles/g protein) 
  WT ApoE KO p value WT ApoE KO p value 
Aorta 
102.51±7.28 
(n=10) 
112.85±10.11 
(n=13) 
0.44 
1014.44±142.53 
(n=10) 
503.73±51.60 
(n=13) 
<0.01 
Kidney 
4.93±0.66 
(n=13) 
5.19±0.73 
(n=10) 
0.80 
352.58±36.89 
(n=13) 
105.11±13.80 
(n=10) 
<0.0001 
Lung 
12.57±1.43 
(n=11) 
17.38±1.82 
(n=11) 
0.05 
349.05±33.33 
(n=11) 
148.37±31.94 
(n=11) 
<0.001 
Heart 
4.73±0.67 
(n=11) 
3.29±0.58 
(n=11) 
0.12 
204.85±13.27 
(n=11) 
126.86±12.07 
(n=11) 
<0.001 
Liver 
5.01±0.65 
(n=13) 
4.37±0.67 
(n=12) 
0.50 
130.74±12.76 
(n=13) 
80.32±14.69 
(n=12) 
<0.05 
Mesentery 
29.24±1.89 
(n=11) 
55.96±5.16 
(n=8) 
<0.0001 
287.13±37.16 
(n=11) 
426.14±61.11 
(n=8) 
0.056 
Table 3.4: Comparison of baseline levels of nitrite and nitrate in tissue homogenates. Statistical 
comparison using unpaired t-test between WT and ApoE KO mice. 
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3.5.1 The effects of dietary supplementation on distribution of NOx in the tissues 
Aorta nitrite levels were not elevated by dietary nitrite supplementation but were 
significantly elevated by dietary nitrate supplementation for both genotypes (figure 
3.7A). As with nitrite, dietary nitrite appeared to have no effect on nitrate levels but 
nitrate supplementation significantly elevated nitrate levels for both genotypes (figure 
3.7B). 
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Figure 3.7: The effect of dietary nitrite and dietary nitrate supplementation on aorta nitrite (A) and 
nitrate (B) levels in WT vs. ApoE KO mice (WT control n=10; 0.6mM nitrite n=10; 15mM nitrate n=10, 
ApoE KO control n=13; 0.6mM nitrite n=13; 15mM nitrate n=13). Data shown as mean±SEM of levels 
normalized to baseline. A significant difference is show as ***p<0.001 and **p<0.01 vs. control group 
using a 1-way ANOVA Dunnett’s multiple comparison statistical test. 
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Kidney nitrite levels were not elevated by a dietary nitrite strategy but were 
significantly elevated by a dietary nitrate strategy for both genotypes (figure 3.8A). 
This was reflected in nitrate levels since dietary nitrite supplementation had no effect, 
however dietary nitrate supplementation significantly elevated nitrate levels for both 
genotypes (figure 3.8B).  
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Figure 3.8: The effect of dietary nitrite and dietary nitrate supplementation on kidney nitrite (A) and 
nitrate (B) levels in WT vs. ApoE KO mice (WT control n=13; 0.6mM nitrite n=10; 15mM nitrate n=10, 
ApoE KO control n=10; 0.6mM nitrite n=10; 15mM nitrate n=9). Data shown as mean±SEM of levels 
normalized to baseline. A significant difference is show as ***p<0.001 and **p<0.01 vs. control group 
using a 1-way ANOVA Dunnett’s multiple comparison statistical test. 
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For lung homogenates nitrite levels were significantly elevated by dietary nitrate 
supplementation but not dietary nitrite supplementation for both WT and ApoE KO 
mice (figure 3.9A). In addition, nitrate levels were significantly elevated by dietary 
nitrate supplementation but not by dietary nitrite supplementation for both genotypes 
(figure 3.9B). 
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Figure 3.9: The effect of dietary nitrite and dietary nitrate supplementation on lung nitrite (A) and 
nitrate (B) levels in WT vs. ApoE KO mice (WT control n=11; 0.6mM nitrite n=11; 15mM nitrate n=11, 
ApoE KO control n=11; 0.6mM nitrite n=11; 15mM nitrate n=11). Data shown as mean±SEM of levels 
normalized to baseline. A significant difference is show as ***p<0.001 and **p<0.01 vs. control group 
using a 1-way ANOVA Dunnett’s multiple comparison statistical test. 
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Statistically significant elevations of nitrite levels in heart homogenates were observed 
with both WT and ApoE KO mice that had been treated with dietary nitrate 
supplementation but not dietary nitrite supplementation (figure 3.10A). This was 
reflected in nitrate levels as well since dietary nitrate treatment caused statistically 
significant elevations of nitrate levels for both genotypes whereas dietary nitrite 
treatment had no effect (figure 3.10B).  
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Figure 3.10: The effect of dietary nitrite and dietary nitrate supplementation on heart nitrite (A) and 
nitrate (B) levels in WT vs. ApoE KO mice (WT control n=11; 0.6mM nitrite n=10; 15mM nitrate n=10, 
ApoE KO control n=11; 0.6mM nitrite n=11; 15mM nitrate n=11). Data shown as mean±SEM of levels 
normalized to baseline. A significant difference is show as ***p<0.001 vs. control group using a 1-way 
ANOVA Dunnett’s multiple comparison statistical test. 
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In liver homogenates, dietary nitrite supplementation had no effect on nitrite levels for 
both genotypes whereas dietary nitrate supplementation significantly elevated nitrite 
levels (figure 3.11A). Furthermore, dietary nitrite supplementation had no effect on 
nitrate levels but dietary nitrate supplementation significantly elevated nitrate levels 
for both WT and ApoE KO mice (figure 3.11B). 
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Figure 3.11: The effect of dietary nitrite and dietary nitrate supplementation on liver nitrite (A) and 
nitrate (B) levels in WT vs. ApoE KO mice (WT control n=13; 0.6mM nitrite n=13; 15mM nitrate n=13, 
ApoE KO control n=12; 0.6mM nitrite n=12; 15mM nitrate n=12). Data shown as mean±SEM of levels 
normalized to baseline. A significant difference is show as ***p<0.001 and **p<0.01 vs. control group 
using a 1-way ANOVA Dunnett’s multiple comparison statistical test.  
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Dietary nitrite supplementation had no effect on nitrite levels in WT mice but 
significantly elevated nitrite levels in mesentery homogenates of ApoE KO mice. 
Furthermore dietary nitrate supplementation significantly elevated nitrite levels in 
both genotypes (figure 3.12A). Interestingly, dietary nitrite supplementation appeared 
to have no effect on nitrate levels but dietary nitrate supplementation significantly 
elevated nitrate levels for both WT and ApoE KO mice (figure 3.12B). 
N
it
ri
te
 le
ve
l r
e
la
ti
ve
to
 b
as
e
lin
e
Control Nitrite Nitrate
0
1
2
3
4
5
6
7
8
9
10
Nitrite
A
WT
ApoE KO
**
***
*
N
it
ra
te
 le
ve
l r
e
la
ti
ve
to
 b
as
e
lin
e
Control Nitrite Nitrate
0
5
10
15
Nitrate
B
WT
ApoE KO
***
***
Mesentery
 
Figure 3.12: The effect of dietary nitrite and dietary nitrate supplementation on mesentery nitrite (A) 
and nitrate (B) levels in WT vs. ApoE KO mice (WT control n=11; 0.6mM nitrite n=11; 15mM nitrate 
n=11, ApoE KO control n=8; 0.6mM nitrite n=8; 15mM nitrate n=8). Data shown as mean±SEM of levels 
normalized to baseline. A significant difference is show as ***p<0.001, **p<0.01 and *p<0.05 vs. control 
group using a 1-way ANOVA Dunnett’s multiple comparison statistical test. 
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3.6 Comparison of baseline NOx levels between WKY vs. SHRs 
The first animal model of hypertension was developed in 1934 by Harry Goldblatt 
(Goldblatt et al., 1934). Rats are the most popular animal used to model hypertension 
with the spontaneously hypertensive rat (SHR) being the most often used (Pinto et al., 
1998). The SHR is characterized by progressively increasing arterial pressure, vascular 
dysfunction and eventual left ventricular hypertrophy (Sullivan et al., 2010). For the 
first 5-6 weeks SHRs are pre to mildly hypertensive with conscious systolic blood 
pressure being 120-150mmHg (Touyz et al., 1999) (spontaneous hypertension is 
characterized by blood pressure exceeding 150mmHg persistently over 4 weeks 
(Okamoto et al., 1963)). SHRs show clear sex differences in their progression of 
hypertension (female SHRs develop hypertension slower, although by 24 months of 
age blood pressures are similar (Chan et al., 2011)), therefore only males were used. At 
16 weeks of age, SHRs compared to WKY strain controls were hypertensive (table 3.5). 
In these experiments a comparison between baseline levels across the compartments 
between WKY and SHRs was made. Due to cost and availability the impact of dietary 
nitrite or nitrate was not feasible. 
 
Parameter WKY (n=12) SHR (n=16) p value 
SBP, mmHg 119.3±2.6 154.4±3.9*** <0.0001 
DBP, mmHg 74.4±3.8 101.1±2.7*** <0.0001 
MAP, mmHg 95.6±3.6 126.8±2.3*** <0.0001 
HR, bpm 394.8±14.6 329.4±5.4*** <0.0001 
Table 3.5: Baseline hemodynamic parameters in WKY rats and SHRs. Data shown as mean±SEM. Mean 
with statistical significance determined by 1-way ANOVA with ***p<0.0001 vs. WKY with Bonferroni 
post hoc analysis. Bpm indicates beats per min; DBP, diastolic blood pressure; HR, heart rate; MAP, 
mean arterial pressure; SBP, systolic blood pressure. 
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3.6.1 Comparison of baseline NOx levels in the blood 
Plasma nitrite (figure 3.13A) and nitrate (figure 3.13B) concentration were similar in 
SHRs compared to WKY controls. 
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Figure 3.13: The concentration of nitrite (A) and nitrate (B) in the plasma of WKY (n=25) and SHRs 
(n=23). Data shown as mean±SEM. Comparison between 2 groups made using unpaired t-tests. 
 
In contrast the levels of both nitrite (figure 3.14A) and nitrate (figure 3.14B) in purified 
RBCs were significantly reduced in the SHR compared to the WKY animals. 
N
it
ri
te
 (
fm
o
l/
g 
p
ro
te
in
)
WKY SHR
0
20
40
60
80
Nitrite
A
***
***
N
it
ra
te
 (
fm
o
l/
g 
p
ro
te
in
)
WKY SHR
0
200
400
600
800
1000
Nitrate
B
***
*
RBCs
 
Figure 3.14: The levels of nitrite (A) and nitrate (B) in RBCs of WKY (n=4) and SHRs (n=7). Data shown as 
mean±SEM. Comparison between 2 groups using unpaired t-tests and shown as *** for p<0.001 and * 
for p<0.05. 
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3.6.2 Comparison of baseline NOx levels in the tissues 
Of all the organs the aorta had the highest levels of both nitrite and nitrate, followed 
by the heart and lung with 3x fewer levels in the kidney and liver. There were no 
differences in the levels of either of these anions between the WKY and SHRs. 
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Figure 3.15: The levels of nitrite (A) and nitrate (B) in the aortas of WKY (n=15) and SHRs (n=12). Data 
shown as mean±SEM. Comparison between 2 groups made using unpaired t-tests. 
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Figure 3.16: The levels of nitrite and nitrate in the heart, lung, kidney and liver (WKY n=10, SHR n=10). 
Data shown as mean±SEM. Comparison between 2 groups made using unpaired t-tests. 
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3.7 Summary 
Feeding C57BL/6J wild type mice with the dietary anions had no effect on weight gain 
over time. Interestingly, whilst there were no statistical differences in food and water 
consumption both the highest dose of nitrite and nitrate did appear to be associated 
with increases in food and water consumption.  
 
In healthy WT animals inorganic nitrite caused dose-dependent elevations in plasma 
nitrite, but no changes in plasma nitrate concentration. Administration of dietary 
inorganic nitrate caused dose-dependent elevations in both plasma nitrite and plasma 
nitrate. The fold elevations in plasma nitrite (seen with the 15 and 45mM nitrate 
doses) are similar to the fold elevations reported in healthy volunteer studies in which 
functional changes in blood pressure are seen. 
 
To investigate the effect that CVD has on the distribution of these 2 anions the ApoE 
KO model was used. As with the WT mice the mice were administered the drug in the 
drinking water for 2 weeks. The primary observation made was that basal levels of 
nitrate were significantly reduced in the ApoE KO compared to the WT across most of 
the tissues. The specific tissues affected were the plasma, RBCs, kidney, heart, liver 
aorta and lungs. For each of these tissues the most effective way in restoring nitrate 
and nitrite levels to baseline was through the administration of a dietary inorganic 
nitrate (15mM) intervention. This intervention consistently elevated nitrate levels 
above baseline in all the tissues. 
 
The nitrite profiles across the tissues are similar. Basal levels of nitrite appear not to be 
affected by early stage atherosclerosis. In addition, administration of inorganic nitrite 
does not significantly elevate nitrite across the tissues in either the WT or the ApoE KO 
mice. There are, however, 2 notable exceptions. In the RBCs, nitrite levels are 
significantly elevated in both genotypes. Interestingly in the mesentery, nitrite is 
significantly elevated in the ApoE KO compared to the WT animals. These results 
suggest perhaps some selective uptake of nitrite in these tissues. 
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Furthermore hypertension appeared to have no effect on the baseline distribution of 
nitrite and nitrate across the organs examined. The RBCs did, however, show 
significantly reduced levels of both anions with hypertension. This is possibly due to 
enhanced nitrite reductase activity seen at the level of the RBC, which is discussed in 
detail in the next chapter.  
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Chapter 4: 
Investigation of the 
nitrite reductase activity 
in models of 
cardiovascular disease 
and patients 
[135] 
 
 
4.1 Introduction 
CVD is associated with a reduction in bioavailable NO. This reduction in part is due to 
dysfunction of the classical L-arginine/NOS mediated pathway of NO generation 
(Moncada et al., 1991). Given the importance of NO in sustaining a healthy 
cardiovascular system much work currently focuses on identifying alternative 
strategies of NO generation. A recent point of focus has been assessing the possibility 
of utilizing nitrite and nitrate as endogenous sources of NO. NOS-independent 
formation of NO within the cardiovascular system was first reported in the ischaemic 
heart where it was demonstrated that endogenous nitrite was reduced to NO (Zweier 
et al., 1995). At that time the authors speculated that the conditions generated were a 
consequence of hypoxia i.e. acidosis, which resulted in the reduction of nitrite to NO. 
 
However, since that time it has been discovered that nitrite reductases operate to 
facilitate this reaction. In particular previous studies have suggested that XOR is an 
important nitrite reductase in the heart and kidney. Using ozone chemiluminescence it 
was reported that both rat and human myocardium under ischaemic conditions 
produce NO from nitrite that is dependent on XOR (Webb et al., 2004a). Similarly in rat 
kidney the XOR inhibitor allopurinol profoundly attenuated nitrite reductase activity 
(Tripatara et al., 2007). 
 
In the previous investigations the pre-clinical studies involved subjecting organs (in 
vitro or in vivo) to acute insults that mimic CVD i.e. animals were healthy prior to acute 
insult. Whether nitrite reductase activity is altered by disease is unknown. This is an 
important point to investigate since the utility of nitrite as a therapeutic in CVD might 
offer potential not only in acute scenarios such as I/R injury where nitrite reductase 
activity is upregulated but also in progressive CVD where environmental conditions are 
normal, such as hypertension and atherosclerosis. Both of these diseases are of 
particular interest with respect to the therapeutic potential of nitrite since both 
diseases have been associated with increased expression and activity of XOR (White et 
al., 1996b; Laakso et al., 1998b). 
 
[136] 
 
 
Therefore in this set of experiments the nitrite reductase activity in models of 
hypertension (SHR) and atherosclerosis (ApoE KO) have been investigated and 
compared with the nitrite reductase activity of the respective healthy controls i.e. WKY 
rats and C57BL/6J wild type mice respectively. In addition key sites/tissue for nitrite 
reductase activity have been assessed that are pertinent for XOR i.e. the liver, vascular 
tissue and the erythrocyte, which are all sites of prominent nitrite reductase capacity 
(Webb et al., 2004a; Duranski et al., 2005; Webb et al., 2008a). 
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4.2 Nitrite reductase activity in atherosclerosis 
4.2.1 Nitrite reductase activity in the liver 
The nitrite reductase activity of liver homogenates was significantly enhanced across 
the full concentration range of nitrite tested in ApoE KO vs. WT mice at pH 7.4 (figure 
4.1A). A similar trend was also evident at pH 6.8 (figure 4.1B). 
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Figure 4.1: Nitrite reductase activity of mouse liver homogenates. Comparison of the nitrite reductase 
activity at pH 7.4 ApoE KO vs. WT (A) and pH 6.8 ApoE KO vs. WT (B). Statistical significance between 
concentration response curves determined using 2-way ANOVA and shown as ### for p<0.001 followed 
by Bonferroni post tests shown as * for p<0.05. 
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4.2.2 Mechanism of nitrite reductase activity in the liver 
Incubation of liver homogenates with allopurinol did not alter the extent of nitrite-
derived NO generation from liver homogenates of WT mice at pH 7.4 (figure 4.2A) or 
pH 6.8 (figure 4.2B). In contrast, allopurinol significantly inhibited nitrite reduction at 
pH 7.4 (figure 4.2C) and pH 6.8 (figure 4.2D) in liver homogenates from ApoE KO mice. 
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Figure 4.2: XOR-dependent nitrite reductase activity of mouse liver homogenates. Both liver types were 
tested in the absence and presence of the XOR inhibitor allopurinol (100µmol/L) for WT (A + B) and 
ApoE KO (C + D) mice. Data are expressed as mean±SEM with n indicated on the graphs. Statistical 
significance between concentration response curves determined using repeated measures 2-way 
ANOVA and shown as ### for p<0.001 followed by Bonferroni post tests shown as * for p<0.05 and ** 
for p<0.01. 
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4.2.3 Nitrite reductase activity in the RBCs 
The nitrite reductase activity of mouse RBCs was significantly enhanced across the full 
concentration range of nitrite tested in ApoE KO vs. WT mice at pH 7.4 (figure 4.3A). A 
similar trend was also evident at pH 6.8 (figure 4.3B). 
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Figure 4.3: Nitrite reductase activity of mouse RBCs. Comparison of the nitrite reductase activity at pH 
7.4 ApoE KO vs. WT (A) and pH 6.8 ApoE KO vs. WT (B). Statistical significance between concentration 
response curves determined using 2-way ANOVA and shown as ## for p<0.01 followed by Bonferroni 
post tests shown as *** for p<0.001, ** for p<0.01 and * for p<0.05. 
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4.2.4 Mechanism of nitrite reductase activity in the RBCs 
Incubation of mouse RBCs with allopurinol did not alter the extent of nitrite-derived 
NO generation from RBCs of WT mice at pH 7.4 (figure 4.4A) or pH 6.8 (figure 4.4B). In 
contrast, allopurinol significantly inhibited nitrite reduction at pH 7.4 (figure 4.4C) and 
pH 6.8 (figure 4.4D) in RBCs from ApoE KO mice. 
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Figure 4.4: XOR-dependent nitrite reductase activity of mouse RBCs. Both RBC types were tested in the 
absence and presence of the XOR inhibitor allopurinol (100µmol/L) for WT (A + B) and ApoE KO (C + D) 
mice. Data are expressed as mean±SEM with n indicated on the graphs. Statistical significance between 
concentration response curves determined using 2-way ANOVA and shown as ### for p<0.001 and # for 
p<0.05 followed by Bonferroni post tests shown as *** for p<0.001 and ** for p<0.01. 
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4.3 Expression of XOR in atherosclerosis 
4.3.1 Expression of XOR in the liver 
XOR expression in mouse liver homogenates from ApoE KO mice was significantly 
enhanced compared to WT mice (figure 4.5A + B). 
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Figure 4.5: XOR expression levels of mouse liver homogenates for WT (n=8) and ApoE KO (n=8) mice as 
assessed by western blotting. Expression quantified by densitometry (normalized to control). Data 
shown as mean±SEM. Comparison between 2 groups using unpaired t-tests and shown as *p<0.05. 
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4.3.2 Expression of XOR in the RBCs 
XOR expression in mouse RBCs from ApoE KO mice was significantly enhanced 
compared to WT mice (figure 4.6A + B). 
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Figure 4.6: XOR expression levels of mouse RBCs for WT (n=8) and ApoE KO (n=8) mice as assessed by 
western blotting. Expression quantified by densitometry (normalized to control). Data shown as 
mean±SEM. Comparison between 2 groups using unpaired t-tests and shown as ***p<0.001. 
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4.4 Nitrite reductase activity in pre-clinical models of hypertension 
4.4.1 Nitrite reductase activity in aorta 
Nitrite-derived NO formation was similar in aortic homogenates of WKY (figure 4.7A) 
and SHR (figure 4.7B). Furthermore XOR inhibition had no effect on the ability of the 
blood vessel wall to reduce nitrite to NO in either the WKY (figure 4.7A) or the SHR 
(figure 4.7B). 
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Figure 4.7: Nitrite reductase activity of aortic homogenates of WKY at pH 7.4 and 6.8 (A) and SHR at pH 
7.4 and 6.8 (B) in the presence of nitrite (300µmol/L) and allopurinol (100µmol/L). Data shown as 
mean±SEM with n indicated on graphs. No significant differences in nitrite reductase activity using 1-
way ANOVA. 
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4.4.2 Nitrite reductase activity in RBCs 
Nitrite reductase activity of purified RBCs was significantly enhanced in SHR vs. WKY at 
pH 7.4 (Figure 4.8A). A similar trend was seen at pH 6.8 but this did not reach statistical 
significance (Figure 4.8B).  
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Figure 4.8: Nitrite reductase activity of rat RBCs. Comparison of the nitrite reductase activity at pH 7.4 
WKY vs. SHR (A) and pH 6.8 WKY vs. SHR (B). Data shown as mean±SEM. Statistical significance between 
concentration response curves determined using 2-way ANOVA and shown as ## for p<0.01 followed by 
Bonferroni post tests shown as * for p<0.05. 
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4.4.3 Mechanism of nitrite reductase activity in RBCs 
Incubation of RBCs with allopurinol did not alter the extent of nitrite-derived NO 
generation of RBCs of WKY animals at pH 7.4 (figure 4.9A) or pH 6.8 (figure 4.9B). In 
contrast, allopurinol significantly inhibited nitrite reduction at pH 7.4 (Figure 4.9C) and 
pH 6.8 (Figure 4.9D) in RBCs of SHRs. 
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Figure 4.9: XOR-dependent nitrite reductase activity of rat RBCs. Both RBC types were tested in the 
absence and presence of the XOR inhibitor allopurinol (allo, 100 µmol/L) for WKY (A + B) and SHR (C + 
D). Data are expressed as mean±SEM with n indicated on the graphs. Statistical significance between 
concentration response curves determined using 2-way ANOVA and shown as ### for p<0.001 followed 
by Bonferroni post tests shown as ** for p<0.01 and *** for p<0.001. 
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4.5 Expression of XOR in WKY vs. SHRs 
There was significantly enhanced XOR expression in rat liver homogenates from SHRs 
compared to WKY rats (figure 4.10). 
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Figure 4.10: XOR expression levels of liver homogenates. Comparison between WKY (n=7) and SHR 
(n=8). Data shown as mean±SEM. Comparison between 2 groups assessed using unpaired t-tests. 
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There was no difference in XOR expression in rat aorta homogenates from SHRs 
compared to WKY rats (figure 4.11). 
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Figure 4.11: XOR expression levels of mouse aorta homogenates. Comparison between WKY (n=8) and 
SHR (n=6). Data shown as mean±SEM. Comparison between 2 groups assessed using unpaired t-tests. 
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4.5.3 RBCs 
An approximate doubling of erythrocytic XOR expression was observed in the RBCs 
isolated from SHRs compared to control WKY animals (figure 4.12). 
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Figure 4.12: Expression of erythrocytic XOR determined by western blotting. Comparison between WKY 
(n=4) and SHR (n=6). Data are expressed as mean±SEM. Comparison between 2 groups using unpaired t 
tests and shown as **p<0.01. 
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4.6 Nitrite reductase activity in human hypertension 
In a proof-of-principle study, grade 1 drug-naïve hypertensive subjects (determined 
from previous 24-hour ambulatory blood pressure measurements conducted <1 
month before study date) were randomized in an open-label crossover design to 
receive 250ml of inorganic nitrate-rich beetroot juice (dietary nitrate; James White 
Drinks, UK or an equal volume of water (placebo; Zepbrook Ltd, UK)). On each visit 
clinic blood pressure measurements were made for 1 hour to provide baseline blood 
pressure before intervention. The baseline hemodynamic/biochemical parameters of 
the volunteers at screening are shown in table 4.2. 
 
Parameter Normotensives Hypertensives 
Subjects, n 20 15 
Systolic ABP, mmHg 110.1±3.4 151.5±1.5 
Diastolic ABP, 
mmHg 
70.1±2.3 89.7±2.2 
Table 4.1: Hemodynamic/biochemical parameters of volunteers at screening. Data are shown as 
mean±SEM values. ABP measurements were taken with a Spacelabs 90207 (Spacelabs Healthcare, 
Issaquah, WA). Ambulatory blood pressure (ABP) values adjusted as per British Hypertension Society 
guidelines (Williams et al., 2004). 
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4.6.1 Nitrite reductase activity in RBCs 
Nitrite reductase activity of purified RBCs was significantly enhanced in hypertensive 
vs. normotensive patients at pH 7.4 (figure 4.13A) and pH 6.8 (figure 4.13B). 
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Figure 4.13: Nitrite reductase activity of patient RBCs. Comparison of the nitrite reductase activity at pH 
7.4 normotensive vs. hypertensive (A) and pH 6.8 normotensive vs. hypertensive (B). Data shown as 
mean±SEM. Statistical significance between concentration response curves determined using 2-way 
ANOVA and shown as ### for p<0.001 and ## for p<0.01 followed by Bonferroni post tests shown as *** 
for p<0.001, ** for p<0.01 and * for p<0.05. 
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4.6.2 Mechanism of nitrite reductase activity in RBCs 
Previous studies with RBCs of human normotensives show no effect of allopurinol on 
nitrite reductase activity (Webb et al., 2008a). However, incubation of RBCs with 
allopurinol significantly inhibited nitrite-derived NO generation of RBCs from 
hypertensive patients at pH 7.4 (figure 4.14A) and 6.8 (figure 4.14B).  
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Figure 4.14: XOR facilitates nitrite-derived NO generation by erythrocytes of hypertensives. Comparison 
of the nitrite reductase activity of purified erythrocytes at pH 7.4 (A) and 6.8 (B) in the presence of 
vehicle or allopurinol (100µmol/L). Data are expressed as mean±SEM with n indicated on the graphs. 
Statistical significance between concentration response curves determined using 2-way ANOVA and 
shown as ### for p<0.001 followed by Bonferroni post tests shown as *** for p<0.001, ** for p<0.01 
and * for p<0.05. 
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4.7 Expression of XOR in human hypertension 
4.7.1 RBCs 
Raised nitrite reductase activity seen in patient erythrocytes was associated with 
significantly higher levels of XOR expression in erythrocytes of hypertensive patients 
compared to normotensive volunteers (figure 4.15). 
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Figure 4.15: The expression of XOR of erythrocytes purified from the blood of normotensive and 
hypertensive volunteers (n=4 for each) determined by western blotting. Data expressed as mean±SEM. 
Comparison between 2 groups using unpaired t tests and shown as *p<0.05. 
[153] 
 
 
4.8 Summary 
Within this chapter the potential significance of XOR in CVD has been investigated. 
Firstly using a mouse model of atherosclerosis it was shown that liver homogenates 
and RBCs taken from ApoE KO mice have enhanced nitrite reductase activity compared 
to WT controls. Furthermore, this enhanced activity was significantly attenuated by 
the XOR inhibitor allopurinol in both tissues. Western blotting demonstrated that XOR 
expression was raised in both the liver and RBCs of ApoE KO compared to WT mice. 
 
The second model of CVD used was the spontaneously hypertensive rat (SHR). Initially 
nitrite reduction was examined at the level of the blood vessel wall since in the 
literature there is evidence to suggest that key nitrite reductase activity occurs in this 
compartment (Li et al., 2008). While nitrite reductase activity of aortic homogenates 
was evidenced no difference in activity between the SHR and the WKY control was 
found. Moreover, this activity was not affected by XOR inhibition. In contrast washed 
RBCs showed significantly enhanced nitrite reduction in the SHR compared to the WKY. 
Furthermore XOR inhibition attenuated nitrite-derived NO generation in the RBCs of 
SHRs but had no impact in the WKY rats. Western blotting of tissues suggested that 
this increased activity was likely due to increased XOR expression. 
 
Erythrocytes isolated from the blood of 11 grade 1 hypertensive volunteers were 
assessed for nitrite reductase activity and compared to normotensive controls. Nitrite-
derived NO generation was significantly elevated in the hypertensive erythrocytes 
compared to the normotensive controls. Moreover, as seen with the rat RBCs, this 
increased activity was complemented by higher XOR expression in the hypertensive 
erythrocytes. Finally the nitrite reductase activity in the hypertensive erythrocytes was 
significantly inhibited by allopurinol. These findings fit well with previous work from 
the lab, which showed that at pH 7.4 allopurinol did not have an effect on nitrite-
derived NO generation by RBCs collected from healthy volunteers (Webb et al., 
2008a). 
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Chapter 5: 
Investigation of the effect 
of dietary nitrate on 
inflammatory cell 
recruitment 
[155] 
 
 
5.1 Introduction 
Acute inflammation is characterized by migration of inflammatory cells to the site of 
injury. NO which is constantly being produced by the endothelium, exerts important 
anti-inflammatory effects on this response mainly through prevention of leukocyte 
activation and adhesion (Kubes et al., 1991; Gaboury et al., 1993). Recent research has 
uncovered the potential for using inorganic nitrite and nitrate (either from 
endogenous or dietary sources) as alternative sources of NO (Lundberg et al., 2008). At 
the time of starting this work, whether dietary nitrate might influence inflammatory 
cell recruitment was unknown. To address this issue the effect of a dietary nitrate 
regimen on inflammatory cell recruitment induced by a range of stimuli (IL-1β, TNFα 
and zymosan) was investigated.  
 
Zymosan promotes a well characterized inflammatory response that is due to 
triggering of the complement cascade (Rawal et al., 1998; Mizuno et al., 2009) 
resulting in a substantial neutrophil recruitment. Classically the response to zymosan 
mimics an acute hypersensitivity response, although activation of the complement 
cascade has been demonstrated in certain CVD states including ischaemic heart 
disease (Langlois et al., 1988; Yasuda et al., 1990; Pedersen et al., 2004). 
 
First identified in 1975 (Carswell et al., 1975) TNFα is a potent cytokine that promotes 
inflammation and tissue destruction in rheumatic/immune mediated diseases. TNFα 
effects paracrine or autocrine regulation of leukocytes and endothelial cells and 
therefore serves as an important regulator of the inflammatory response. TNFα is 
important in CVD as it has been shown to increase in the myocardium after 
experimental ischaemia and reperfusion (Gulick et al., 1989; Herskowitz et al., 1995) 
and clinical myocardial infarction (Latini et al., 1994).  
 
IL-1β was first described in 1972 as a lymphocyte-activating factor (Gery et al., 1972) 
and is a trigger for neutrophil and monocyte recruitment. It has been shown to be 
involved in myocardial I/R injury (Li et al., 2004b) and ischaemic heart disease 
particularly coronary artery disease (Hasdai et al., 1996). 
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5.2 The effect of inflammatory stimuli on cell recruitment 
In comparison to PBS, IL-1β and TNFα did not cause a substantial increase in the total 
number of cells recruited to the peritoneal cavity of WT mice over a 4h period (figure 
5.1A). In contrast zymosan caused a substantial increase (~5-fold) in total cell count 
(figure 5.1A). After 24h these differences were still apparent although there was some 
evidence of the resolution of inflammation as the total cell number for zymosan had 
decreased to approximately 20x106 from 30x106 (figure 5.1B).  
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Figure 5.1: The effect of stimulus on total leukocyte count with PBS (n=9-10), IL-1β (n=7-10), TNFα 
(n=10) and zymosan (n=15-17) injected mice. Data shown as mean±SEM. A significant difference is 
shown as ***p<0.001 vs. PBS using 1-way ANOVA followed by Dunnett’s multiple comparison statistical 
test. 
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5.3 The effect of inflammatory stimuli on type of leukocyte recruited 
I.p. injection of control mice with PBS resulted in almost 100% of cells collected from 
the cavity being resident monocytes (figure 5.2A) with a small percentage being 
neutrophils (figure 5.2B) and inflammatory monocytes (figure 5.2C) 4h after the 
injection of stimulus. IL-1β and TNFα caused more of a response as a greater 
percentage of neutrophils (figure 5.2B) and inflammatory monocytes (figure 5.2C) was 
evident after 4h. The response to both IL-1β and TNFα was resolved after 24h as the 
profile for both stimuli reverted to the profile for PBS (figure 5.2E, F + G). In contrast, 
zymosan caused a substantial influx of neutrophils into the peritoneal cavity (figure 
5.2C) resulting in very few resident (0.42x10⁶; figure 5.2A + table 5.1) and 
inflammatory monocytes (1.0x10⁶; figure 5.2C + table 5.1) being present. After 24h, 
inflammation was not completely resolved as neutrophil percentage was still high 
(figure 5.2F), which was also reflected in the high cell count (table 5.1), although 
resident monocyte (figure 5.2E) and inflammatory monocyte (figure 5.2G) percentages 
and cell counts were rising (table 5.1). 
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Figure 5.2: The effect of stimulus on cell type with PBS (n=9), IL-1β (n=7-8), TNFα (n=10) and zymosan 
(17) injected mice. Data shown as mean±SEM. 
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Cell numbers (x10⁶) 
Time 
point 
Stimulus Total Neutrophils 
Resident 
Monocytes 
Inflammatory 
Monocytes 
4h PBS 5.95±0.33 0.20±0.12 5.53±0.23 0.22±0.12 
4h IL-1β 6.20±0.42 1.20±0.21 4.01±0.27 0.99±0.17 
4h TNFα 6.10±0.88 2.38±0.65 2.47±0.55 1.41±0.18 
4h Zymosan 32.91±2.26 30.23±1.36 0.42±0.12 1.03±0.31 
24h PBS 4.74±0.32 0.07±0.02 4.47±0.13 0.09±0.04 
24h IL-1β 5.97±0.26 0.13±0.04 5.58±0.09 0.24±0.06 
24h TNFα 6.25±0.71 0.23±0.05 4.87±0.50 0.47±0.11 
24h Zymosan 22.93±1.35 12.71±1.18 6.35±0.96 4.42±0.89 
Table 5.1: Total leukocyte sub-type numbers in the peritoneal cavity. 
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5.4 The effect of inflammatory stimuli on MPO levels in the cell pellet 
In comparison to PBS control MPO activity was raised for all stimuli 4h after the 
induction of inflammation (figure 5.3A). A substantial increase was seen with zymosan 
(figure 5.3A). After 24h activity was still raised in comparison to PBS although 
resolution of inflammation was evidenced with all stimuli as activity had decreased vs. 
4h (figure 5.3B). The substantial difference between zymosan and PBS was still present 
after 24h (figure 5.3B). 
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Figure 5.3: The effect of stimulus on MPO levels in the cell pellet with PBS, IL-1β, TNFα and zymosan 
(n=6) injected mice. Data shown as mean±SEM. A significant difference is shown as ***p<0.001, 
**p<0.01 or *p<0.05 vs. PBS using a 1-way ANOVA followed by Dunnett’s multiple comparison statistical 
test. 
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5.5 The effect of inflammatory stimuli on MPO levels in the mesentery 
In comparison to PBS control MPO level was raised for all stimuli 4h after the induction 
of inflammation (figure 5.4A). A substantial increase was seen with zymosan (figure 
5.4A). After 24h, activity was still raised in comparison to PBS although resolution of 
inflammation was evidenced with all stimuli as activity had decreased (figure 5.4B). 
The substantial difference between zymosan and PBS was still present after 24h (figure 
5.4B). 
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Figure 5.4: The effect of stimulus on MPO levels in the mesentery with PBS, IL-1β, TNFα and zymosan 
(n=6-10) injected mice. Data shown as mean±SEM. A significant difference is shown as ***p<0.001 vs. 
PBS using a 1-way ANOVA followed by Dunnett’s multiple comparison statistical test. 
[161] 
 
 
5.6 The effect of dietary nitrate on total cell number following i.p. injection of 
inflammatory stimuli 
Since previous studies from chapter 3 demonstrated that only dietary nitrate 
supplementation was effective in elevating tissue levels of nitrite the effect of dietary 
nitrate supplementation on cell recruitment was investigated.  
 
Dietary nitrate supplementation had no effect on total leukocyte count in the 
peritoneal lavage fluid collected from PBS control injected mice 4 (figure 5.5A) and 24h 
(figure 5.5B) following injection. 
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Figure 5.5: The effect of dietary nitrate on total leukocyte count 4 (A; n=9-10) and 24h (B; n=10) after 
i.p. injection of PBS (0.5ml). Data shown as mean±SEM. Data analysed using 1-way ANOVA followed by 
Dunnett’s multiple comparison statistical test.  
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Similarly there was no change in cell number with dietary nitrate treatment in IL-1β 
injected mice at 4 or 24h (figure 5.6A + B). 
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Figure 5.6: The effect of dietary nitrate on total leukocyte count 4 (A; n=8-10) and 24h (B; n=7) after i.p. 
injection of IL-1β (5ng). Data shown as mean±SEM. Data analysed using 1-way ANOVA followed by 
Dunnett’s multiple comparison statistical test. 
 
There did appear to be a trend to reduce total leukocyte count in the peritoneal lavage 
fluid collected from TNFα injected mice at 4 (figure 5.7A) and 24h (figure 5.7B) after 
the injection of stimulus. This reached significance at 4 but not 24h. 
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Figure 5.7: The effect of dietary nitrate on total leukocyte count 4 (A; n=9-10) and 24h (B; n=10) after 
i.p. injection of TNFα (300ng). Data shown as mean±SEM. Data analysed using 1-way ANOVA followed 
by Dunnett’s multiple comparison statistical test. 
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In contrast significant reductions in total leukocyte count were evident in nitrate 
supplemented mice compared to control in response to zymosan at both 4 (figure 
5.8A) and 24h (figure 5.8B), however this was only statistically significant at the higher 
45mM concentration. 
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Figure 5.8: The effect of dietary nitrate on total leukocyte count 4 (A; n=15-17) and 24h (B; n=17) after 
i.p. injection of zymosan (1mg). Data shown as mean±SEM. A significant difference is shown as *p<0.05 
vs. control group using a 1-way ANOVA followed by Dunnett’s multiple comparison statistical test. 
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5.7 The effect of dietary nitrate treatment on cell type following i.p. injection of 
inflammatory stimuli 
Dietary nitrate treatment had no effect on inflammatory cell type in PBS control 
injected mice with respect to resident monocytes (figure 5.9A + D), neutrophils (figure 
5.9B + E) and inflammatory monocytes (figure 5.9C + F) at 4 or 24h after the injection 
of PBS. 
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Figure 5.9: The effect of dietary nitrate on resident monocytes (A + D; n=9-10), neutrophils (B + E; n=9-
10) and inflammatory monocytes (C + F; n=9-10) 4 and 24h after i.p. injection of PBS (0.5ml). Data 
shown as mean±SEM. Data analysed using 1-way ANOVA followed by Dunnett’s multiple comparison 
statistical test. 
[165] 
 
 
Dietary nitrate treatment had no effect on IL-1β-induced changes in resident 
monocytes (figure 5.10A + D), neutrophils (figure 5.10B + E) and inflammatory 
monocytes (figure 5.10C + F) either at 4 or 24h after the injection of IL-1β. 
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Figure 5.10: The effect of dietary nitrate on resident monocytes (A + D; n=7-8), neutrophils (B + E; n=7-8) 
and inflammatory monocytes (C + F; n=7-8) 4 and 24h after i.p. injection of IL-1β (5ng). Data shown as 
mean±SEM. Data analysed using 1-way ANOVA followed by Dunnett’s multiple comparison statistical 
test. 
[166] 
 
 
Dietary nitrate treatment also had no effect on TNFα-induced changes in resident 
monocytes (figure 5.11A + D), neutrophils (figure 5.11B + E) and inflammatory 
monocytes (figure 5.11C + F) at either 4 or 24h after the injection of TNFα. 
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Figure 5.11: The effect of dietary nitrate on resident monocytes (A + D; n=9-10), neutrophils (B + E; n=9-
10) and inflammatory monocytes (C + F; n=9-10) 4 and 24h after i.p. injection of TNFα (300ng). Data 
shown as mean±SEM. Data analysed using 1-way ANOVA followed by Dunnett’s multiple comparison 
statistical test. 
[167] 
 
 
Dietary nitrate treatment had no effect on zymosan-induced changes in resident 
monocytes (figure 5.12A + D), neutrophils (figure 5.12B + E) and inflammatory 
monocytes (figure 5.12C + F) at either 4 or 24h after the injection of zymosan. 
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Figure 5.12: The effect of dietary nitrate on resident monocytes (A + D; n=17), neutrophils (B + E; n=17) 
and inflammatory monocytes (C + F; n=17) 4 and 24h after i.p. injection of zymosan (1mg). Data shown 
as mean±SEM. Data analysed using 1-way ANOVA followed by Dunnett’s multiple comparison statistical 
test. 
[168] 
 
 
5.8 The effect of dietary nitrate treatment on MPO levels in the cell pellet following 
i.p. injection of inflammatory stimuli 
Dietary nitrate supplementation had no effect on MPO levels in PBS stimulated mice 4 
(figure 5.13A) and 24h (figure 5.13B) after injection. 
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Figure 5.13: The effect of dietary nitrate on MPO activity 4 (A; n=6) and 24h (B; n=6) after i.p. injection 
of PBS (0.5ml). Data shown as mean±SEM. Data analysed using 1-way ANOVA followed by Dunnett’s 
multiple comparison statistical test. 
 
Dietary nitrate treatment had no effect on MPO levels in IL-1β stimulated mice 4 
(figure 5.14A) and 24h (figure 5.14B) after injection. 
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Figure 5.14: The effect of dietary nitrate on MPO activity 4 (A; n=6) and 24h (B; n=6) after i.p. injection 
of IL-1β (5ng). Data shown as mean±SEM. Data analysed using 1-way ANOVA followed by Dunnett’s 
multiple comparison statistical test. 
[169] 
 
 
Dietary nitrate supplementation caused dose-dependent decreases in MPO levels 4h 
after the injection of TNFα with significance being reached at the 45mM nitrate dose 
(figure 5.15A). This effect of nitrate was still evident 24h after injection (figure 5.15B). 
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Figure 5.15: The effect of dietary nitrate on MPO activity 4 (A; n=5-6) and 24h (B; n=6) after i.p. injection 
of TNFα (300ng). Data shown as mean±SEM. A significant difference is shown as **p<0.01 or *p<0.05 vs. 
control group using a 1-way ANOVA followed by Dunnett’s multiple comparison test. 
 
Dietary nitrate caused dose-dependent decreases in MPO levels 4h after the injection 
of zymosan with significance being reached at both nitrate doses (figure 5.16A). This 
effect of nitrate was still evident 24 after injection (figure 5.16B). 
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Figure 5.16: The effect of dietary nitrate on MPO activity 4 (A; n=6) and 24h (B; n=6) after i.p. injection 
of zymosan (1mg). Data shown as mean±SEM. A significant difference is shown as **p<0.01 or *p<0.05 
vs. control group using a 1-way ANOVA followed by Dunnett’s multiple comparison test. 
[170] 
 
 
5.9 The effect of dietary nitrate treatment on MPO levels in the mesentery following 
i.p. injection of inflammatory stimuli 
Dietary nitrate supplementation had no effect on MPO activity in PBS injected mice 4 
(figure 5.17A) and 24h (figure 5.17B) after the injection of stimulus. 
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Figure 5.17: The effect of dietary nitrate on MPO activity 4 (A; n=8-9) and 24h (B; n=6) after i.p. injection 
of PBS (0.5ml). Data shown as mean±SEM. Data analysed using 1-way ANOVA followed by Dunnett’s 
multiple comparison statistical test. 
 
Similarly to PBS injected mice dietary nitrate treatment had no effect on MPO activity 
in IL-1β stimulated mice 4 (figure 5.18A) and 24h (figure 5.18B) after injection. 
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Figure 5.18: The effect of dietary nitrate on MPO activity 4 (A; n=10) and 24h (B; n=9) after i.p. injection 
of IL-1β (5ng). Data shown as mean±SEM. Data analysed using 1-way ANOVA followed by Dunnett’s 
multiple comparison statistical test. 
[171] 
 
 
Interestingly dietary nitrate supplementation caused dose-dependent decreases in 
MPO activity 4h after the injection of TNFα with significance being reached at both 
doses of nitrate (figure 5.19A). This effect of nitrate was not apparent 24h after the 
injection of stimulus as no effect of dietary nitrate on MPO level was observed after 
24h (figure 5.19B). 
4 hours
Co
nt
ro
l
15
m
M
 N
itr
at
e
45
m
M
 N
itr
at
e
0.00
0.05
0.10
0.15
0.20
M
P
O
 a
ct
iv
it
y
(U
/m
g 
p
ro
te
in
)
A
**
*
24 hours
Co
nt
ro
l
15
m
M
 N
itr
at
e
45
m
M
 N
itr
at
e
0.00
0.05
0.10
0.15
0.20
M
P
O
 a
ct
iv
it
y
(U
/m
g 
p
ro
te
in
)
B
TNF
 
Figure 5.19: The effect of dietary nitrate on MPO activity 4 (A; n=10) and 24h (B; n=10) after i.p. 
injection of TNFα (300ng). Data shown as mean±SEM. A significant difference is shown as **p<0.01 or 
*p<0.05 vs. control group using a 1-way ANOVA followed by Dunnett’s multiple comparison test. 
 
Dietary nitrate caused dose-dependent decreases in MPO levels 4h after the injection 
of zymosan with significance being reached for both nitrate doses (figure 5.20A). This 
effect of nitrate was still evident 24h after injection (figure 5.20B). 
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Figure 5.20: The effect of dietary nitrate on MPO activity 4 (A; n=10) and 24h (B; n=10) after i.p. 
injection of zymosan (1mg). Data shown as mean±SEM. A significant difference is shown as ***p<0.001, 
**p<0.01 or *p<0.05 vs. control group using a 1-way ANOVA followed by Dunnett’s multiple comparison 
test. 
[172] 
 
 
5.10 The effect of dietary nitrate treatment on cell surface marker expression 
following i.p. injection of zymosan 
CD162 expression on the surface of resident monocytes (figure 5.21A + D), neutrophils 
(figure 5.21B + E) and inflammatory monocytes (figure 5.21C + F) was not altered by 
dietary nitrate supplementation when compared to control animals 4 and 24h after 
the injection of zymosan. 
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Figure 5.21: The effect of dietary nitrate on CD162 cell surface expression on resident monocytes (A + D; 
n=8), neutrophils (B + E; n=8) and inflammatory monocytes (C + F; n=8) 4 and 24h after i.p. injection of 
zymosan (1mg). Data shown as mean±SEM. Data analysed using 1-way ANOVA followed by Dunnett’s 
multiple comparison statistical test. 
[173] 
 
 
CD62L expression on the surface of resident monocytes (figure 5.22A + D), neutrophils 
(figure 5.22B + E) and inflammatory monocytes (figure 5.22C + F) was not altered by a 
dietary nitrate treatment when compared to control animals 4 and 24h after the 
injection of zymosan. 
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Figure 5.22: The effect of dietary nitrate on CD62L cell surface expression on resident monocytes (A + D; 
n=8), neutrophils (B + E; n=8) and inflammatory monocytes (C + F; n=8) 4 and 24h after i.p. injection of 
zymosan (1mg). Data shown as mean±SEM. Data analysed using 1-way ANOVA followed by Dunnett’s 
multiple comparison statistical test. 
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CD11b expression on the surface of resident monocytes (figure 5.23A + D) and 
inflammatory monocytes (figure 5.23C + F) was not altered by a dietary nitrate 
strategy when compared to control animals 4 and 24h after the injection of zymosan. 
Expression on the surface of neutrophils was dose-dependently reduced by dietary 
nitrate treatment 4 (figure 5.23B) and 24h (figure 5.23E) after injection. 
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Figure 5.23: The effect of dietary nitrate on CD11b cell surface expression on resident monocytes (A + D; 
n=8), neutrophils (B + E; n=8) and inflammatory monocytes (C + F; n=8) 4 and 24h after i.p. injection of 
zymosan (1mg). Data shown as mean±SEM. A significant difference is shown as *p<0.05 vs. control 
group using a 1-way ANOVA followed by Dunnett’s multiple comparison statistical test. 
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5.11 The effect of dietary nitrate treatment on lavage NOx following i.p. injection of 
inflammatory stimuli 
Inorganic dietary nitrate supplementation caused a concentration-dependent 
elevation of nitrate levels in the lavage fluid collected from PBS (figure 5.24A), IL-1β 
(figure 5.24B), TNFα (figure 5.24C) and zymosan (figure 5.24D) treated mice 4h after 
injection.  
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Figure 5.24: A comparison of the effect of dietary nitrate supplementation on lavage nitrate 
concentration with PBS (A), IL-1β (B), TNFα (C) and zymosan (D) injected mice 4h after i.p. injection of 
stimulus. Data shown as mean±SEM with n indicated on graphs. A significant difference is shown as 
***p<0.001 or **p<0.01 vs. control group using a 1-way ANOVA followed by Dunnett’s multiple 
comparison statistical test. 
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Inorganic dietary nitrate supplementation caused a concentration-dependent 
elevation of nitrate levels in the lavage fluid of PBS (figure 5.25A), IL-1β (figure 5.25B), 
TNFα (figure 5.25C) and zymosan (figure 5.25D) injected mice. This was evident in the 
lavage fluid collected 24 hours after the induction of inflammation. 
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Figure 5.25: A comparison of the effect of dietary nitrate supplementation on lavage nitrate 
concentration with PBS (A), IL-1β (B), TNFα (C) and zymosan (D) injected mice 24h after i.p. injection of 
stimulus. Data shown as mean±SEM with n indicated on graphs. A significant difference is shown as 
***p<0.001, **p<0.01 or *p<0.05 vs. control group using a 1-way ANOVA followed by Dunnett’s 
multiple comparison statistical test. 
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Inorganic dietary nitrate supplementation caused a concentration-dependent 
elevation of nitrite concentration in the lavage fluid collected from PBS injected mice 
(figure 5.26A). This elevation was also shown in IL-1β (figure 5.26B), TNFα (figure 
5.26C) and zymosan (figure 5.26D) stimulated animals with significance being reached 
at the 45mM dose for all stimuli. 
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 Figure 5.26: A comparison of the effect of dietary nitrate supplementation on lavage nitrate 
concentration with PBS (A), IL-1β (B), TNFα (C) and zymosan (D) injected mice 4h after i.p. injection of 
stimulus. Data shown as mean±SEM with n indicated on graphs. A significant difference is shown as 
***p<0.001, **p<0.01 or *p<0.05 vs. control group using a 1-way ANOVA followed by Dunnett’s 
multiple comparison statistical test. 
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Inorganic dietary nitrate supplementation caused a concentration-dependent 
elevation of nitrite concentration in the lavage fluid collected from PBS (figure 5.27A), 
IL-1β (figure 5.27B), TNFα (figure 5.27C) and zymosan (figure 5.27D) injected mice. This 
was evident in the lavage fluid collected 24h after the induction of inflammation. 
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Figure 5.27: A comparison of the effect of dietary nitrate supplementation on lavage nitrite 
concentration with PBS (A), IL-1β (B), TNFα (C) and zymosan (D) injected mice 24h after i.p. injection of 
stimulus. Data shown as mean±SEM with n indicated on graphs. A significant difference is shown as 
***p<0.001, **p<0.01 or *p<0.05 vs. control group using a 1-way ANOVA followed by Dunnett’s 
multiple comparison statistical test. 
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5.12 The effect of dietary nitrate treatment on plasma NOx following i.p. injection of 
inflammatory stimuli 
In WT mice inorganic dietary nitrate supplementation caused concentration-
dependent elevations of plasma nitrate in PBS injected mice (figure 5.28A). This 
elevation was also shown in IL-1β (figure 5.28B), TNFα (figure 5.28C) and zymosan 
(figure 5.28D) stimulated mice. 
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Figure 5.28: A comparison of the effect of dietary nitrate supplementation on plasma nitrate with PBS 
(A), IL-1β (B), TNFα (C) and zymosan (D) injected mice. Data shown as mean±SEM with n indicated on 
graphs. A significant difference is shown as ***p<0.001 or *p<0.05 vs. control group using a 1-way 
ANOVA followed by Dunnett’s multiple comparison statistical test. 
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In WT mice inorganic dietary nitrate supplementation caused concentration-
dependent elevations of plasma nitrite in PBS injected mice (figure 5.29A). This 
elevation was also shown in IL-1β (figure 5.29B), TNFα (figure 5.29C) and zymosan 
(figure 5.29D) stimulated mice. 
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Figure 5.29: A comparison of the effect of dietary nitrate supplementation on plasma nitrite with PBS 
(A), IL-1β (B), TNFα (C) and zymosan (D) injected mice. Data shown as mean±SEM with n indicated on 
graphs. A significant difference is shown as ***p<0.001 or *p<0.05 vs. control group using a 1-way 
ANOVA followed by Dunnett’s multiple comparison statistical test. 
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5.13 Summary 
In this chapter it was investigated whether dietary nitrate could affect inflammatory 
cell recruitment using the mouse peritonitis model of acute inflammation. Peritonitis 
was induced by various proinflammatory cytokines and the effect of dietary nitrate on 
markers of inflammation was investigated. In PBS-injected WT mice dietary nitrate 
(both 15 and 45mM doses) significantly elevated plasma nitrate and nitrite levels 
above baseline. This was applicable for all stimuli used. Elevations in plasma NOx were 
paralled with increases in lavage fluid NOx. 
 
After 4 hours, percent cell type following PBS injection was predominantly resident 
monocytes (93.79±3.06%) with few inflammatory monocytes (3.09±1.53%) and 
neutrophils (3.11±1.54%). Treatment with IL-1β elevated percentage of inflammatory 
monocytes (15.96±2.74%) and neutrophils (19.42±3.38%) 4 hours after injection. 
Treatment with TNFα resulted in an even greater percentage of inflammatory 
monocytes (21.29±1.72%) and neutrophils (44.13±5.84%) 4 hours after injection. 
Injection with zymosan caused the greatest percentage change in neutrophils 
(95.43±0.95%). After 24 hours IL-1β and TNFα had cell percent profiles that were 
similar to PBS, however zymosan still had a significant percentage of neutrophils 
(59.10±4.60%) present. For all stimuli dietary nitrate supplementation had no effect on 
percent cell type. Interestingly dietary nitrate supplementation did cause 
concentration-dependent reductions in total leukocyte count in TNFα (4 hours) and 
zymosan (4 and 24 hours) treated mice. The concentration-dependent reductions were 
also present in MPO levels assessed in the peritoneal infiltrate and mesentery.   
 
Finally, in zymosan treated mice, repression of neutrophil recruitment was associated 
with concentration-dependent decreases in the expression of the neutrophil activation 
marker CD11b, at both 4 and 24 hours. These findings suggest that inorganic dietary 
nitrate supplementation suppresses the acute inflammatory response. 
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Chapter 6: 
Discussion 
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The nitrate-nitrite-NO pathway has emerged as an alternative to the L-arginine-NOS 
pathway for the generation of NO. Bioactivation of nitrate occurs through its initial 
reduction to nitrite, a process catalysed by commensal bacteria in the mouth and GI 
tract (Lundberg et al., 2004). Subsequently, nitrite is then further metabolised to NO 
and other nitrogen oxides in blood and tissues (Lundberg et al., 2008). Interest in this 
alternative pathway stems from the view that it may provide an endogenous source of 
NO when defects in the production or activity of the conventional NO pathway due to 
endothelial dysfunction are present. This is important since the healthy endothelium 
exerts a number of vasoprotective effects such as vasodilation, suppression of smooth 
muscle cell growth and inhibition of inflammatory responses (Moncada et al., 1991). 
6.1 The distribution of nitrite and nitrate in health and models of CVD 
6.1.1 Baseline levels of nitrite in the plasma in health  
In healthy WT mice that were fed nitrite/nitrate-free water for 2 weeks plasma nitrite 
concentration was 0.56±0.10µM. These results are similar to previous work utilising 
similarly to this study low nitrite and nitrate-deplete water. Using 3 different analytical 
procedures, in 2003 Kleinbongard et al. determined basal plasma nitrite concentration 
in C57BL/6J mice to be 0.46±0.05µM (Kleinbongard et al., 2003). This level is also 
similar to the 0.29±0.05µM and 0.40µM concentrations found in previous work (Bryan 
et al., 2004; Stokes et al., 2009). Indeed, a relatively recent review comparing plasma 
nitrite concentrations across studies indicated that the vast majority of measurements 
estimate baseline plasma nitrite concentration, in healthy volunteers, to fall within 
0.20-0.50µM range (Grau et al., 2007a). However, published values range from non-
detectable or as low as ~0.02µM (Pannala et al., 2003a) to as high as 5µM (Moshage et 
al., 1995a). Such variability may reflect true levels in plasma but are also likely to 
reflect differences in techniques used for measurement of nitrite; an issue debated in 
several reviews (Pelletier et al., 2006b; Grau et al., 2007a; Tsikas, 2007b). 
6.1.2 The concentrations of nitrite used for nitrite supplementation 
Administration of inorganic nitrite has been proposed as an effective approach to 
elevate circulating concentrations of nitrite in eNOS KO mice (Bryan et al., 2008), 
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however whether it might be as effective in CVD is unknown. In chapter 3 I determined 
the effects of nitrite (and nitrate) administration as a potential strategy to elevate 
circulating and/or tissue nitrite levels in mice. I did this first in healthy mice to 
ascertain a dosing regimen in mice that would provide a rise in circulating nitrite levels 
similar to the levels achieved in humans that have been proposed to be bioactive, for 
future use in functional experiments.  
 
Animals were treated with 0.6 and 1.0mM nitrite in the drinking water. The 0.6mM 
nitrite concentration was chosen based on previous work where protective effects of 
this dose have been shown. Supplementation in the drinking water for 7 days elevated 
plasma levels of nitrite and this was associated with significantly reduced infarct size 
after myocardial I/R injury (Bryan et al., 2007). The 1.0mM nitrite dose was chosen to 
investigate whether a dose-dependent change could be seen. Previous work has 
shown that nitrite given intravenously immediately before reperfusion can protect 
from I/R injury (Duranski et al., 2005) but due to the relatively short circulating half-life 
of nitrite in blood (110 seconds) (Kelm, 1999), it was previously unclear as to whether 
nitrite administered subchronically in the drinking water could affect blood and tissue 
nitrite concentrations.  
 
Nitrite in the diet serves a multitude of purposes such as fixing meat colour, 
contributing to the cured meat flavour and inhibiting the growth of microorganisms 
(specifically Clostridium botulinum) on foods. The concentrations chosen in this study 
equate to doses ingested in the mice of 7.00±2.00 and 13.56±0.43mg/kg/day. The 
main source of nitrite in the diet in western societies is processed meat and for 
example the amount obtained from cured, cooked sausage on average is 
7.6mg/kg/day (Sindelar et al., 2012). Thus the doses administered in this study reflect 
those consumed in the diets of humans.  
6.1.3 Dietary nitrite supplementation elevates plasma nitrite 
These concentrations of nitrite (0.6 and 1.0mM) in the drinking water resulted in 
concentration-dependent rises of nitrite in the plasma of 1.50- and 1.76-fold 
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respectively. Assessment of basal levels of nitrite in the tissues indicated that uptake of 
nitrite was greatest in the aorta. Indeed the aorta had ~20-fold higher levels of nitrite 
compared to the kidney, heart and liver and ~9-fold higher compared to the lung. The 
aorta, being a conduit vessel has a primary function of transportation therefore the 
difference in nitrite levels could be attributed to increased consumption by the other 
tissues. Indeed in 2004, Bryan et al. showed a similar disparity in nitrite levels found in 
the aorta compared to other organs including the kidney, heart, liver and lung (Bryan 
et al., 2004). The dosing regimen had a similar effect throughout the cardiovascular 
system causing concentration-dependent increases in nitrite levels for all organs 
tested. Indeed the fold elevations seen in all organs were similar to the fold elevations 
to those observed in the plasma. 
 
Baseline tissue concentrations of nitrite tend to be greater than those measured in 
plasma. Recent studies analysing nitrite levels in various organs in the rat measured 
the highest concentrations of nitrite in the vasculature (~12-23µM) in comparison with 
most other tissues; levels fell between 0.2-0.5µM in the heart, brain, liver, kidney and 
lung (Bryan et al., 2004; Bryan et al., 2005), a similar difference observed in my data. 
Variation in the literature does exist e.g. in the rat heart levels of up to 10µM have 
been measured (Zweier et al., 1995) although these may be due to differences in 
dietary intake, rather than reflecting differences in endogenous production, or may 
simply be a reflection of differences in techniques of measurement.  
 
Previous studies investigating distribution of nitrite stores in the rat have shown that 
supplementation of nitrite by systemic injection results in a rapid (steady-state 
concentrations achieved within 5 min) distribution throughout the body (Bryan et al., 
2005). However, feeding animals a low nitrate diet resulted in substantial decreases in 
tissue levels throughout the body with the notable exception of plasma and aorta, 
where levels were maintained at those observed in animals fed a standard chow diet. 
The authors suggested that these observations, taken together, intimate the existence 
of 2 distinct processes involved in nitrite distribution. Acute elevation results in passive 
transport of nitrite across membranes while, in contrast, slow changes in plasma 
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nitrite are sensed by the NOS within circulating cells and the vascular wall, the activity 
of which alters to maintain basal levels (Bryan et al., 2005).    
 
With regard to the distribution of nitrite throughout the organs, questions still remain 
as to the mechanism of uptake into the cells since the charged nature of nitrite has 
prompted speculation that specific uptake mechanisms for nitrite must exist or that 
nitrite utlilises anion exchangers to enter cells. Studies using equine RBC ghost 
demonstrated nitrite exchange (export) with bicarbonate in the place of chloride via 
the anion exchange transporter-1 (AE-1), since it was blocked by the non-selective 
inhibitor 4,4’-diisothiocyanatostilbene-2,2’-disulphonate (Shingles et al., 1997). It has 
also been suggested that the Na-Pi transporter plays a role in nitrite uptake in RBCs, 
since addition of phosphate and removal of sodium, to the extracellular media bathing 
isolated human RBCs, inhibited nitrite uptake by ~25% (May et al., 2000).  
 
In eukaryotic cells it has been proposed that conversion of nitrite to nitrous acid 
(HNO₂) underlies nitrite entry into cells, however with a pKa of 3.3-3.4 for HNO₂ a very 
acidic pH is required for such a phenomenon. Whilst it is likely that this pathway 
contributes to nitrite transport from the acidic environment of the gastric lumen, 
where the pH is between 1.0-2.5 (Evans et al., 1988), to the circulation, it is unlikely 
that this accounts for substantial transport within the cells of the cardiovascular 
system, where the pH of the blood drops to 6.8 only under the most severe acidotic 
conditions (Williamson et al., 1976) and perhaps to 5.5 deep within ischaemic tissues 
(Zweier et al., 1995). Whether the pathways identified in RBCs might also have a role 
to play in tissue nitrite uptake is uncertain and warrants further investigation. 
6.1.4 Baseline levels of nitrate in the plasma in health 
In healthy mice that were fed nitrate-free water for 2 weeks baseline levels of nitrate 
were 37.68±2.26µM. Plasma levels of nitrate in health have been suggested to be in 
the 20-40µM range (Lundberg et al., 2004; Webb et al., 2008c; Kapil et al., 2010). This 
is a key observation as nitrate levels have been proposed to be up to 100 times more 
than nitrite levels (Webb et al., 2008c; Kapil et al., 2010). In this study baseline plasma 
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nitrate concentration was measured to be ~67 fold more than baseline plasma nitrite 
concentration, which is in agreement with most previous work. In humans baseline 
plasma nitrate levels in healthy volunteers is thought to derive from dietary nitrate 
(75%) (Lundberg et al., 2004) and endogenous NO oxidation (Moncada et al., 1993; 
Kelm, 1999). 
6.1.5 The concentration of nitrate used for nitrate supplementation 
I investigated whether dietary nitrate supplementation in mice would increase steady-
state plasma and tissue levels of nitrite and nitrate. The doses of nitrate were chosen 
based on data obtained in studies in animal models and healthy volunteers 
demonstrating that the sustained elevation of plasma nitrite at low micromolar 
concentrations is associated with functional effects of NO (Bryan et al., 2008; Webb et 
al., 2008c; Kapil et al., 2010). The concentrations of nitrate in the drinking water used 
in this study were chosen to cover the range of nitrate concentrations used previously 
in these human experiments.  
6.1.6 Dietary nitrate supplementation elevates plasma nitrite and nitrate 
My studies show that in mice as in humans there is a concentration-dependent effect 
on both plasma nitrite and nitrate levels. Dietary feeding with 0.5, 15 and 45mM 
nitrate supplemented water led to 1.43, 2.68 and 2.75 fold increases in plasma nitrite 
and 1.50, 6.80 and 18.37 fold increases in plasma nitrate. This finding suggests that as 
in humans the enterosalivary circuit is intact. In this study I did not confirm that 
disruption of the oral microbiota blocked this rise, however, this has been 
demonstrated by others (Govoni et al., 2008; Kapil et al., 2010). In addition the ratios 
suggest that there is likely a saturation of nitrate to nitrite conversion. This might 
suggest that in mice the oral conversion is saturated and that uptake of nitrite in the 
gut is limited. The ratios of nitrite:nitrate of 0.95, 0.39 and 0.15 suggest that with 
increasing amounts of nitrate relatively less nitrite is formed. Interestingly 45mM 
nitrate only caused a marginal increase in nitrite above 15mM (2.75 vs. 2.68) and thus 
the 15mM concentration was chosen for all future experiments.  
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The dosing regimen had a similar effect throughout the cardiovascular system causing 
concentration-dependent increases in nitrite and nitrate levels for all organs tested. 
Indeed the fold elevations seen in all organs were similar to the fold elevations to 
those observed in the plasma. Interestingly, as demonstrated with nitrite levels, 
baseline nitrate uptake was most efficiently evident in the aorta, which had ~4.41 fold 
more nitrate than other tissues tested. This was a difference that was also previously 
observed by Bryan et al. who found ~10-fold more levels of nitrate in the aorta 
compared to other tissues (Bryan et al., 2004).  
6.1.7 The effect of atherosclerosis on nitrite and nitrate distribution 
Similar to humans, ApoE KO mice are characterised by endothelial dysfunction caused 
by their propensity to spontaneously develop hypercholesterolaemia associated with 
atherosclerotic lesions (Meyrelles et al., 2011). Although, whether this dysfunction 
translates to variations in circulating levels of NOx is uncertain with evidence 
demonstrating increases, decreases or no effect in humans with atherosclerosis 
(Maejima et al., 2001; Vanizor et al., 2001; Pekdemir et al., 2004; Loffredo et al., 2007; 
Binh et al., 2011). In my study I have shown that at baseline and in the blood 
compartments nitrite levels were not significantly altered compared to WT littermates, 
whereas nitrate levels were reduced ~50% in the ApoE KO compared to the WT mice in 
plasma (53.05%) and in the RBCs (48.47%). These effects on nitrite and nitrate levels at 
baseline were evident across the tissues as well i.e. no apparent change in nitrite but 
statistically significant reductions in nitrate (aorta (49.66%); kidney (29.81%); lung 
(42.51%); heart (61.93%); liver (61.43%)). Previous work intimates that nitrite is a 
better reflection of eNOS activity (Kelm et al., 1999; Kleinbongard et al., 2003), 
however the data presented in this thesis does not support this. My data suggests that 
as baseline nitrate levels are significantly reduced in ApoE KO mice and that perhaps 
nitrate is a better reflection of endothelial dysfunction since not only are nitrate levels 
significantly reduced across the tissues but indeed most NO is oxidised to nitrate 
(Moncada et al., 1993). 
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6.1.8 The effect of dietary nitrite or nitrate supplementation in atherosclerosis 
For further investigations, the 0.6mM nitrite and 15mM nitrate doses were chosen 
since they caused rises in circulating nitrite that were commensurate with rises 
associated with biological activity in healthy volunteers (Kapil et al., 2010) and 
increasing nitrate dose further did not increase nitrite levels substantially above the 
15mM nitrate dose. As shown with WT mice, in ApoE KO mice baseline plasma nitrite 
(0.45±0.06µM) and baseline plasma nitrate (19.99±2.80µM) concentrations were 
comparable to previous work in which concentrations of plasma nitrite and nitrate 
were measured (Bryan et al., 2004; Stokes et al., 2009). Administration of 0.6mM 
nitrite caused a 2.29-fold (compared to 1.50 fold in WT mice) increase in plasma nitrite 
concentration in ApoE KO mice. Furthermore, administration of 15mM nitrate caused 
a 5.39-fold (compared to 2.68 fold in WT mice) increase in plasma nitrite 
concentration. This disparity in fold elevation was also reflected in plasma nitrate 
concentration as administration of 0.6mM nitrite (WT vs. ApoE KO; 1.27 vs. 1.85) and 
15mM nitrate (WT vs. ApoE KO; 6.80 vs. 12.90) caused greater fold elevations than 
those observed in WT mice. Interestingly the nitrite:nitrate ratios were almost 
identical (0.6mM – 1.19 vs. 1.24; 15mM nitrate – 0.39 vs. 0.42). These data suggest 
that not only is the enterosalivary circuit intact but both the oral conversion and gut 
uptake pathways are potentially upregulated in atherosclerosis. The fact that the 
nitrite:nitrate ratio is identical in ApoE KO mice compared to WT mice suggest that the 
oral conversion and gut pathways are upregulated to the same extent.  
 
In WT and ApoE KO mice dietary nitrate supplementation significantly elevated nitrite 
and nitrate levels in RBCs to a similar degree.  Further investigations revealed that 
elevation of nitrite and nitrate levels was also possible in other tissues of the 
cardiovascular system. In ApoE KO mice dietary nitrate supplementation was 
consistently a more efficient method of elevation of nitrite across the tissues. This 
suggests 2 important points. Firstly, in the ApoE KO model of atherosclerosis the 
enterosalivary circuit is intact. The similar ratios of nitrite/nitrate in WT and ApoE KO 
mice support this view. Secondly, the enterosalivary circuit is functioning efficiently 
enough that it can be utilised to elevate circulating levels of nitrite and nitrate back up 
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to and even past baseline to potentially replenish depleted NO. This is important as 
strategies that look to elevate NO generation by targeting conventional NO synthesis 
are inherently problematic due to the constraints imposed by endothelial dysfunction 
and disturbed eNOS function (Wilson et al., 2007). In addition the organic nitrates, 
such as glyceryl trinitrate (GTN) and isosorbide mononitrate, represented the first class 
of NO donors to reach the clinical setting however, the utility of these drugs has been 
severly limited due to 2 main issues. The generation of NO from some of these drugs is 
associated with the concomitant generation of other reactive O₂ species (in particular 
O₂⁻), which feeds back and inhibits the very pathways responsible for NO generation 
by these drugs (Mayer et al., 2008). This phenomenon is thought to underlie the 
development of tolerance due to both the pro-oxidant effects and induction of 
endothelial dysfunction associated with continuous treatment (Bellisarii et al., 2003). 
These effects explain both the mechanism of tachyphylaxis which limits their 
therapeutic use (Munzel et al., 2005a) and perhaps partly explains the lack of efficacy 
of organic nitrates in large-scale clinical trials (Group, 1995). 
 
Regular intake of nitrate-containing food, such as green leafy vegetables, may ensure 
that blood and tissue levels of nitrate and NO pools are maintained at a level sufficient 
to compensate for any disturbances in endogenous NO synthesis (Lundberg et al., 
2006). The dietary pathway may provide not only essential nutrients for NO 
production but also a rescue or protective pathway for people with CVD (Bryan, 2006). 
6.1.9 The effect of hypertension on baseline levels of nitrite and nitrate 
Endothelial dysfunction is a phenomenon common to hypertension as well as 
atherosclerosis. To investigate whether the distribution of nitrite and nitrate might 
also be altered in hypertension I measured the NOx levels in plasma, RBC, kidney, 
heart, aorta, liver and lung from WKY rats and SHRs. My data shows that whilst 
plasma, kidney, heart, aorta, liver and lung levels of both nitrite and nitrate were 
unaltered in the SHR, RBC NOx was substantially reduced in the SHR. The SHRs used in 
this study did present with hypertension as demonstrated by their hemodynamic 
parameters (WKY vs. SHR; SBP 119.3±2.6 vs. 154.4±3.9; DBP 74.4±3.8 vs. 101.1±2.7). 
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Interpretation of NOx data is challenging because of the fact that multiple pathways for 
the generation and destruction of NOx and NO exist (Lundberg et al., 2008). Indeed, 
changes in plasma nitrite and/or nitrate concentration may reflect not only endothelial 
NO synthase activity (Lauer et al., 2001), NO oxidation (Ignarro et al., 1993), nitrate 
reduction (Lundberg et al., 2004; Webb et al., 2008c) or all 3 at once. The differences 
in the effect of atherosclerosis and hypertension on the nitrite and/or nitrate profiles 
across the tissues could relate to differences in these pathways or may be species 
specific. 
 
Interestingly the baseline levels did show similar profiles in mice compared to rats in 
that the aorta had the highest levels of both metabolites, the heart, lung and kidney 
had similar levels and the liver had the lowest levels in both species. This could be a 
reflection as suggested earlier of the degree of consumption and utilisation of these 
anions by the tissues, or to differences in the uptake pathways into the different 
tissues.  
6.2 Nitrite reductase activity in hypertension and atherosclerosis 
Elevation of systemic nitrite levels has been shown to be associated with dose-
dependent decreases in blood pressure in both healthy animals and in healthy 
volunteers, as well as in SHRs, demonstrating clear functional effects that have been 
attributed to NO. However the vascular nitrite reductase that accounts for these 
effects has as yet not been clearly established (Vleeming et al., 1997a; Cosby et al., 
2003a; Dejam et al., 2007a). Difficulty in isolating the vascular nitrite reductase stems, 
in part from the fact that nitrite reduction is enhanced with decreasing pH and oxygen 
tension (Zweier et al., 1995) and that biochemical measurement of activity is limited in 
sensitivity. Therefore, often, measurement needs to be made in conditions that act in 
concert to upregulate the activity/expression of a number of nitrite reductase 
candidates including XOR, deoxyhaemoglobin and eNOS (Webb et al., 2008a). Despite 
this it is important to appreciate that the blood pressure lowering effect of nitrite 
occurs under normal physiological conditions such as normoxia and pH 7.4. Whether 
an environment of CVD might alter nitrite reductase capacity is unknown and in 
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chapter 4 I investigated this question by measuring activity firstly in the compartment 
demonstrating the most consistent differences in NOx levels in the SHR and ApoE KO, 
the RBC, a key site of nitrite reduction (Cosby et al., 2003a), as well as in other tissues. 
6.2.1 In vivo nitrite reductase activity is enhanced in CVD and mediated by XOR    
Nitrite was reduced to NO by RBCs of WKY rats in a concentration-dependent manner. 
This activity was enhanced by reducing pH. Such a profile fits with previous studies 
demonstrating a dependence on pH (Zweier et al., 1995; Webb et al., 2004a; Webb et 
al., 2008a). These experiments were all conducted in N₂ i.e. anoxia. Due to the 
limitations of the assay it is not possible to pick up NO under oxygenated conditions. In 
RBCs of SHRs nitrite caused concentration-dependent NO generation that was 
evidenced at pH 7.4 and enhanced by reducing pH. Importantly however, the nitrite 
reductase activity of SHR RBCs was almost double that of the WKY. Previous studies 
suggest that a key nitrite reductase on RBCs is XOR (Webb et al., 2008a).  
 
Indeed, incubation of RBCs with the XOR inhibitor allopurinol near-abolished the 
nitrite reductase activity of RBCs purified from SHRs but interestingly not WKY rats. 
Thus, suggesting that XOR located at the level of the RBC is a key site for nitrite 
reduction in hypertension. This fits with previous work in the lab, which has shown 
that nitrite causes dose-dependent decreases in blood pressure in SHRs with 
significant decreases being evident at concentrations of nitrite of approximately 
1µmol/L within the circulation. At this dose (as well as at higher doses) nitrite had 
minimal effects on blood pressure in the normotensive strain control rats (Ghosh et al., 
2013). My data suggest that XOR located at the level of the RBC underlies the nitrite 
reduction occurring in vivo and therefore is likely associated with the blood pressure-
lowering effects of nitrite.  
 
The enhancement of XOR activity in hypertension may be attributed to an increase in 
the levels of RBC XOR expression as demonstrated by a doubling of levels measured by 
western blotting. This is in line with previous studies where XOR expression was found 
to be enhanced in the liver of SHR (Laakso et al., 1998b; Suzuki et al., 1998a). The liver 
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is one of the major sites for XOR synthesis releasing XOR into the circulation (Martin et 
al., 2004) especially after periods of metabolic stress (Terada et al., 1992b). This XOR is 
then carried to distant parts of the circulatory tree where it binds to 
glycosaminoglycans (GAGs) found on the surfaces of circulating cells, including RBCs, 
and on the endothelium. Indeed assessment of XOR levels in the livers of SHRs also 
demonstrated a doubling in expression relative to the WKY. Thus, it seems likely that 
elevated expression in the liver results in increased levels entering the circulation and 
that at least some of this circulating XOR binds to GAGs on the RBCs. Further 
experiments testing this theory would be of value. Perhaps by interfering with GAG 
expression one could test whether this then might result in a loss of acute bioactivity   
 
Interestingly the results in hypertensive rats were mirrored in ApoE KO mice. In both 
liver tissue and RBCs nitrite reduction was enhanced in the ApoE KO mice compared to 
WT controls. Furthermore, the enhanced nitrite reductase activity observed in the 
ApoE KOs was attenuated by allopurinol. In addition, western blot analysis of both 
compartments revealed that XOR expression was increased in ApoE KO mice compared 
to WT mice thus suggesting the enhanced nitrite reductase activity in ApoE KO mice is 
due to increased XOR expression and activity. This finding is similar to observations in 
patients with atherosclerosis where both XO expression and endothelium-bound XOR 
activity is substantially increased (Spiekermann et al., 2003a; Guzik et al., 2006a). 
 
Previous work has shown that nitrite was reduced to NO by RBCS of normotensive 
patients in a concentration-dependent manner. This activity was enhanced with 
reducing pH. These experiments were also conducted in N₂ (Webb et al., 2008a). My 
work showed that in RBCs of hypertensive patients nitrite also caused concentration-
dependent NO generation that was evidenced at pH 7.4 and enhanced by reducing pH. 
Importantly, however, the nitrite reductase activity was almost doubled that of the 
normotensive patients. 
 
RBCs isolated from hypertensive patients also expressed nitrite reductase activity that 
was attenuated by XOR inhibition at pH 7.4. Previous work in the lab has 
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demonstrated that RBC-facilitated nitrite reduction was unaffected by XOR inhibition 
at physiological pH of normotensive healthy volunteers; a role for XOR only occurring 
under severely acidic pH (Webb et al., 2008a). This work is complemented by studies in 
which it was demonstrated that nitrite-induced vasodilation in the forearm of healthy 
volunteers was unaffected by allopurinol (Dejam et al., 2007a). The observations that I 
have made in chapter 4 suggest that XOR activity is upregulated in human 
hypertension similarly to the situation in the SHR and the ApoE KO mice therefore XOR 
does not seem to contribute to nitrite reduction in health but mediates nitrite 
reduction in pathological scenarios. Moreover RBC XOR expression was doubled in 
hypertensives in comparison with normotensives a pattern that mimics the findings in 
the rat model of hypertension and the mouse model of atherosclerosis. Importantly, 
RBC nitrite and nitrate levels were found to be significantly lower in SHR compared 
with WKY as well in ApoE KO compared to WT mice. This could be due to an increased 
consumption of nitrite basally in the SHR and ApoE KO mouse attributed to an 
upregulation of nitrite reductase pathways, a phenomenon proposed to underlie the 
arteriovenous gradient in RBC nitrite concentrations in humans (Gladwin et al., 2000; 
Dejam et al., 2005). Together, the findings suggest a CVD-specific elevation of nitrite 
reductase capacity, which is in part dependent on XOR. These results also suggest that 
the pre-clinical models of CVD are useful models to explore the pathways involved in 
the increased XOR expression and activity that is also evident in human disease. 
6.2.2 The enhanced nitrite reductase activity in hypertension has translational 
potential 
That nitrite and nitrite reductase activity might similarly be more potent in 
hypertensive patients is supported by proof-of-principle studies demonstrating that 
elevation of circulating nitrite, to levels previously shown to be insufficient to cause 
significant blood pressure-lowering in healthy volunteers (Kapil et al., 2010), caused 
substantial reductions in blood pressure (Ghosh et al., 2013). Previous work has shown 
that dietary nitrate lowers blood pressure in healthy volunteers (Larsen et al., 2006; 
Webb et al., 2008c; Kapil et al., 2010). More recently, this observation has been 
extended to patients presenting with hypertension. It has now been shown that 
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following oral ingestion of a dietary nitrate load, the plasma levels of both nitrate and 
nitrite anions rise in stage 1 hypertensive patients (Ghosh et al., 2013). As 
demonstrated previously in healthy volunteers, the rise in plasma nitrite in the 
patients is slow-developing with the peak effect occurring 4h post nitrate 
consumption. This time-lag (relative to the very rapid (30min) appearance of nitrate) 
reflects the dependence upon the enterosalivary circuit for the conversion of nitrate to 
nitrite in the body. The patient studies showed that the time-course for the 
bioactivation and appearance within the circulation of nitrite and nitrate is similar 
between normotensive and stage 1 hypertensives (Kapil et al., 2010; Ghosh et al., 
2013). However, this study also demonstrated an important increased potency of 
nitrate in patients. Previous studies have shown that oral inorganic nitrate ingestion 
(4-24mmol in the form of a potassium nitrate capsule) causes a dose-dependent rise in 
plasma nitrite levels and decreases in blood pressure in healthy volunteers (Kapil et al., 
2010) with a 4mmol dose of nitrate representing a threshold dose for blood pressure 
lowering, and causing a 1.4-fold peak increase (from baseline) of plasma nitrite. Of 
particular significance in the hypertension patient study is that the dose administered 
to the patient was of approximately 3.3mmol. This lead to a peak fold increase of 
plasma nitrite of 1.5±0.1-fold suggesting similar processing of nitrate to nitrite in 
hypertensives, although a prospective study comparing age-matched normotensives 
and hypertensives is needed to confirm this. However, despite this the rise in nitrite 
resulted in a ≥12mmHg reduction in systolic blood pressure. With regards to the 
processing of nitrate the levels follow a similar pattern between normotensives and 
hypertensives. This similarity indicates that hypertension per se does not result in 
substantial changes in the bioconversion rate and extent of nitrate processing via the 
enterosalivary circuit but that the extent of nitrite reduction to NO, as reflected by the 
RBC activity is enhanced. 
 
The potential importance of these data is considerable particularly when one considers 
that hypertension is associated with endothelial dysfunction, which is characterised by 
decreased bioavailability of eNOS-derived NO (Brunner et al., 2005). In hypertensives, 
decreased levels of both nitrite and nitrate in the circulation and urine are thought to 
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reflect endothelial dysfunction and reduced NO synthesis (Brunner et al., 2005). The 
findings with dietary nitrate suggest that interventions targeting NO generation via the 
nitrate-nitrite-NO generating pathway remain intact and can be utlilised to correct NO 
levels in hypertension. My data complement these findings as they indicate that the 
nitrite reductase pathways that facilitate the reduction of nitrite to NO are enhanced 
in hypertension leading to the increased potency of nitrite in hypertension and 
possibly other CVDs. Whether my observations in ApoE KO mice might translate to 
patients with atherosclerosis is uncertain. However, recent assessment of this 
possibility has been investigated with the completion of a randomised placebo 
controlled double blind clinical trial in which 67 hypercholesterolaemics were 
randomised to receive nitrate-deplete beetroot juice or nitrate-rich beetroot juice. 
Measurements of platelet and endothelial function were conducted before and after 6 
weeks of juice ingestion, and publication of the findings are eagerly awaited 
(ClinicalTrials.gov Identifier: NCT01493752)  
 
The benefits of a high nitrate i.e. fruit and vegetable rich diets, in populations at risk of 
CVD are well recognised. However, investigation of the constituent elements of such 
diets has not replicated the same beneficial outcomes (Bjelakovic et al., 2007; 
Bjelakovic et al., 2012). The enhanced nitrite reductase activity in CVD however, 
demonstrates that a dietary nitrate load at a dose that is safe and achievable, 
sufficiently elevating plasma nitrite levels does cause significant resultant reductions in 
blood pressure. It is important to note that the dietary approaches to stop 
hypertension (DASH) diet, which has been shown to lower blood pressure (Appel et al., 
1997), is thought to deliver ~20mmol of nitrate  (Hord et al., 2009). Importantly in a 
70kg adult this would equate to ~4.2mmol. This dose exceeds the acceptable daily 
intake limit for nitrate, which currently is 3.7mg/kg/day (EFSA, 2008). However, the 
dietary nitrate load (~3.3mmol) given in the hypertensive cohort mentioned (Ghosh et 
al., 2013) sits below this level and thus suggests that the blood pressure lowering 
effects of fruit and vegetable rich diets might be best achieved by consuming nitrate-
rich vegetables. Given that ~50% of treated hypertensive subjects fail to achieve their 
target blood pressure (Egan et al., 2010), an additional strategy based on nitrate-rich 
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foods i.e. green leafy vegetables, may prove to be both cost-effective and favourable 
for public health. Thus further elucidation of the mechanisms involved and the long 
term therapeutic potential of inorganic dietary nitrate is warranted. Indeed a clinical 
trial assessing a sustained once daily dietary nitrate load for 4 weeks in hypertensive 
patients (ClinicalTrials.gov Identifier: NCT01405898) has just been completed and 
again the results eagerly awaited.  
6.3 Investigating the effect of dietary nitrate on inflammatory cell recruitment 
Recruitment of immune cells from the circulation to tissues is fundamental for host 
defence against pathogens. Increases in cell activation contribute to many chronic 
diseases including atherosclerosis and hypertension (Hansson et al., 2006). Indeed 
such disorders are associated with sustained low-grade inflammation, thought to be 
critical in disease progression (Mocsai, 2013). Among various important functions the 
healthy vascular endothelium maintains a leukocyte-free surface, which is necessary 
for the preservation of vascular homeostasis. NO is one of the most important humoral 
mediators produced by the endothelium (Moncada et al., 1991) and influences 
vascular integrity by preventing adherence of platelets and leukocytes e.g. neutrophils, 
to the vascular endothelium (Kubes et al., 1991; Gauthier et al., 1995). This 
relationship between NO and cell adhesion molecule expression therefore has 
important implications for health and disease (Freedman et al., 1996). One can see 
that supplementation of NO under circumstances in which there is insufficient NO 
production, such as those seen in CVD, might have therapeutic utility particularly in 
the modulation of leukocyte recruitment. Therefore in chapter 5 I investigated 
whether dietary inorganic nitrate might influence leukocyte recruitment. 
6.3.1 Proinflammatory cytokines IL-1β, TNFα and zymosan effectively stimulate cell 
recruitment into the peritoneal cavity 
Initial investigations set out to determine the effect of inflammatory stimuli on cell 
recruitment. In terms of total leukocyte count and in comparison to PBS (vehicle) 
control (5.67±0.26x10⁶ cells), i.p. injection with IL-1β (6.20±0.42x10⁶ cells) or TNFα 
(6.92±0.73x10⁶ cells) caused recruitment of more leukocytes into the peritoneal cavity. 
However zymosan (32.91±2.26x10⁶ cells) caused a particularly abundant number of 
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cells to be recruited. At 24h following PBS injection resolution of inflammation was 
evident from the total leukocyte count (4.72±0.23x10⁶). Furthermore, at 24h following 
injection, IL-1β- (5.97±0.26x10⁶ cells), TNFα- (6.06±0.58x10⁶ cells) and zymosan-
induced (25.96±1.92x10⁶ cells) leukocyte infiltration appeared also to be undergoing 
resolution of the inflammation as evident from the total leukocyte count. 
 
Interestingly, flow cytometric analysis indicated that after 4h IL-1β and TNFα caused 
predominantly neutrophils to be recruited, 30-40% with 20-30% of the peritoneal cells 
being inflammatory monocytes. In comparison, in PBS-treated mice >95% of the cells 
were resident monocytes and <5% neutrophils and inflammatory monocytes. Injection 
of zymosan also produced a time-dependent cell accumulation into mouse peritoneal 
cavities which followed a typical profile of acute inflammation. In accordance with 
previous studies there was a large predominance of neutrophils (>90%) (Ajuebor et al., 
1998). With regards to the time points tested, leukocyte influx was maximal at 4h post-
zymosan and this was followed by an accumulation of monocytes (resident and 
inflammatory), which in previous studies have been shown to peak at 24h (Getting et 
al., 1997). Furthermore, as demonstrated by previous work (Getting et al., 1997), by 
24h inflammation had not fully resolved as indicated by flow cytometric analysis as 
well as the total leukocyte count. A similar profile was evident in this study. The 
differences in the cell profiles in response to the inflammatory stimuli relates to 
differences in the pathways activated by the respective stimuli. Zymosan activation of 
the complement cascade (Rawal et al., 1998; Mizuno et al., 2009) resulted in a 
predominantly neutrophil-dependent response whilst the cytokines TNFα and IL-1β 
triggered both neutrophil and monocyte recruitment. 
 
The recruitment of neutrophils by all 3 proinflammatory cytokines was further 
substantiated by measurement of MPO in whole mesentery homogenates and in cell 
pellets. In the mesentery 4h after treatments, zymosan caused substantial neutrophil 
recruitment compared to IL-1β and TNFα. After 24h IL-1β and TNFα displayed MPO 
levels that had almost reverted back to PBS control levels whereas for zymosan-
treated animals mesenteric MPO analysis indicated that by 24h the acute 
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inflammatory response had not fully resolved. These results were reflected in MPO 
levels analysed in the cell pellet indicating recruitment of neutrophils into the cavity 
itself as well as into the mesenteric vasculature. 
  
NO has previously been shown to reduce leukocyte activity and adhesion (Kubes et al., 
1991; Gaboury et al., 1993), however whether dietary nitrite/nitrate could similarly 
affect inflammatory processes is uncertain. As part of my work in chapter 5 I explored 
the possibility that dietary nitrate may be used to modulate vascular inflammation by 
delivering NO. 
6.3.2 Dietary nitrate attenuates inflammatory cell recruitment 
My studies indicate that a dietary nitrate strategy may be an effective way to 
modulate the acute inflammatory response. For the 2 most potent stimulators of cell 
recruitment, concentration-dependent reductions in total leukocyte count were 
observed. In TNFα-treated animals this was only evident at 4h whereas for zymosan-
treated animals the suppressive effect of nitrate treatment was evident at 4 and 24h. 
Previously it has been shown that acute nitrite treatment can reduce infiltration of 
leukocytes in response to microvascular inflammation (Jadert et al., 2012; Samal et al., 
2012). Furthermore, in a model of NSAID-induced intestinal injury leukocyte infiltration 
has been shown to be reduced in mice that were pretreated with 10mM dietary 
nitrate (administered in the drinking water for 1 week) (Jadert et al., 2012). Treatment 
of mice with antiseptic mouthwash during the week of dietary nitrate pretreatment 
resulted in loss of nitrate-induced attenuation of leukocyte infiltration. These data 
along with my results provide strong evidence for the utility of the nitrate-nitrite-NO 
pathway in influencing leukocyte infiltration, a finding that could be of particular 
importance for diseases in which the inflammatory response becomes dysfunctional. 
6.3.3 Dietary nitrate attenuates neutrophil-mediated acute inflammation 
Interestingly mice treated with either TNFα or zymosan responded most sensitively to 
dietary nitrate treatment. Furthermore these mice were characterized by the most 
abundant (in terms of cell percent, mesenteric and cell pellet MPO) levels of neutrophil 
recruitment. Concentration-dependent reductions in mesenteric and cell pellet MPO 
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levels were seen with dietary nitrate treatment 4h post zymosan treatment. This is 
comparable to previous work in which control treated diclofenac-challenged mice (to 
mimic intestinal injury) exhibited similar levels of MPO to those seen in the control 
treated zymosan-challenged mice in this study (Jadert et al., 2012). As observed in my 
study a statistically significantly lower MPO level was found in tissue from diclofenac-
challenged mice pretreated with dietary nitrate compared with the control group 
given only diclofenac. This pattern of dietary nitrate-mediated attenuation was also 
extended to MPO levels analysed in the cell pellet supporting the view that nitrate 
specifically targets the neutrophil. 
 
Interestingly the concentration-dependent reductions in MPO levels were also shown 
in the TNFα-treated mice but not the IL-1β-treated mice. Although after 4 and 24h cell 
numbers were comparable between the 2 stimuli (IL-11β vs. TNFα; 4h – 6.20±0.42x10⁶ 
vs. 6.92±0.73x10⁶; 24h – 5.97±0.26x10⁶ vs. 6.06±0.58x10⁶), as previously mentioned 
flow cytometric analysis showed a greater percentage of neutrophils recruited in the 
TNFα-treated mice compared to the IL-1β-treated mice. Furthermore quantification of 
MPO levels in the cell pellet revealed exactly the same observations that were noted in 
mesenteric MPO levels. Assessment of neutrophil recruitment demonstrated clear 
concentration-dependent suppression of MPO levels in the mesentery and cellular 
infiltrate indicating that dietary nitrate supplementation not only prevented 
recruitment of cells into the peritoneal cavity but also likely reduced the number of 
cells adhering to the vascular wall. 
6.3.4 Dietary nitrate suppresses neutrophilic adhesion molecule expression 
To investigate whether the altered cell recruitment evident in the peritoneal cavity 
might be due to a dietary nitrate-dependent suppression of a specific step in the 
recruitment paradigm, I measured expression of specific inflammatory adhesion 
molecules on the surface of the leukocytes. 
 
Leukocyte recruitment to sites of tissue injury is a dynamic, multistep process involving 
leukocyte rolling, adhesion and emigration (Ley et al., 2007). Initial leukocyte-
[201] 
 
 
endothelial cell interactions are mediated by the selectin family of adhesion molecules. 
L-selectin (CD62L) is expressed constitutively on the leukocyte surface and is believed 
to play a pivotal role in the initial rolling of leukocytes along the endothelial layer. In 
my studies dietary nitrate treatment did not alter expression of this adhesion 
molecule. This is not surprising since as mentioned this molecule is constitutively 
expressed. Early leukocyte rolling in vivo is mediated by the interaction of endothelial 
(particularly P-selectin) and leukocyte adhesion molecules (particularly PSGL-1). P- and 
E-selectins are subsequently expressed in a matter of minutes and hours, respectively, 
to aid this process (Bevilacqua et al., 1993; Springer, 1994; Tedder et al., 1995). 
Unfortunately due to the nature of my experiments I was unable to measure 
endothelial P-selectin. It is likely however that P-selectin expression is a target for 
nitrate-derived NO since it is well established that NO, via cGMP elevation, suppresses 
endothelial P-selectin. Indeed recent assessment of platelet P-selectin has shown a 
suppressive effect of nitrate in platelets of healthy volunteers activated with 
adenosine diphophate (Velmurugan et al., 2013). I found no effect of nitrate on PSGL-1 
expression. 
 
Firm adhesion of leukocytes to the endothelium depends predominantly on the 
expression of β₂-integrin (CD11b/CD18) on the leukocyte surface and ICAM-1 on the 
endothelial cells (von Andrian et al., 1991; Bevilacqua et al., 1993; Kubes et al., 1996). 
CD11b is expressed on natural killer cells and a subset of lymphocytes in addition to 
neutrophils and different types of monocytes (Springer, 1990) and plays a central role 
in the migration of leukocytes from peripheral blood to sites of inflammation during 
the process of host defense (Springer, 1990; Nielsen et al., 1994a). Moreover the 
protein contributes to firm leukocyte adhesion, not only to the endothelium via ICAM-
1 but also to the underlying subendothelium and interstitial extracellular matrix by 
binding diverse ligands such as fibronectin, collagens and laminins (Smith et al., 1989; 
Thompson et al., 1992; Ding et al., 1999).  
 
The neutrophil, one of the first cell types emerging after an acute inflammatory 
stimulus, is considered to be a major player in CVD aetiology. Injury of the 
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microvascular endothelium causes upregulation of adhesion molecules such as P-
selectin and ICAM-1, which leads to recruitment of neutrophils through interactions 
with PSGL-1 and CD18 respectively. Neutrophils are therefore considered one of the 
most important effector cells in acute inflammation. Prevention of neutrophil 
activation and recruitment, processes partly mediated in healthy individuals by 
endogenously produced NO (Kubes et al., 1991; Gaboury et al., 1993; Lefer et al., 
1999; Ignarro, 2002), is therefore desirable. My studies did show that dietary nitrate 
induced a neutrophil specific down-regulation of the expression of CD11b. 
Furthermore suppression of CD11b expression was concentration-dependent. The 
repressive effects of nitrite/nitrate on adhesion molecule expression have been 
demonstrated in other studies as well. For example, acute pretreatment with a bolus 
dose of nitrite (1.3mg/kg) was shown to decrease neutrophil adhesion and emigration 
in the mouse cremaster muscle stimulated with the neutrophil specific chemokine 
MIP-2. These effects however, were attributed to down regulation of ICAM-1 
expression (Jadert et al., 2012) although CD11b expression was not measured. In 
addition, supplementation with dietary nitrate was shown to reduce the number of 
emigrated and rolling cells in MIP-2 superfused cremaster muscle, an effect attributed 
to prevention of P-selectin expression (Jadert et al., 2012). As demonstrated in chapter 
5 the ability of dietary nitrate supplementation to manipulate adhesion molecule 
expression but more pertinently CD11b expression on neutrophils indicates a 
previously uncharacterised role for dietary nitrate in the process of firm adhesion of 
the neutrophil to the endothelium. Arguably more importantly it suggests the use of a 
potent anti-inflammatory agent that could be administered and managed through the 
diet and may be of considerable therapeutic benefit in the treatment of inflammatory 
cardiovascular disorders.   
    
Other studies demonstrating anti-inflammatory effects of dietary nitrate and nitrite 
are emerging in different experimental inflammatory diseases e.g. by reducing vascular 
pathology (Kevil et al., 2011). In addition dietary nitrite supplementation has been 
demonstrated to prevent inflammation induced by hypercholesterolaemia, with 
reduced leukocyte adhesion and emigration (Stokes et al., 2009). Additionally, 
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Carlstrom et al. recently demonstrated potent anti-inflammatory and antioxidant 
effects of dietary nitrate in a rat model of chronic hypertension with concomitant renal 
and cardiac inflammation (Carlstrom et al., 2011). Observations in inflammatory bowel 
disease and in DSS-induced colitis also suggest that oral therapeutic nitrite and nitrate 
supplementation may influence the inflammatory response (Jadert et al., 2014). Along 
with these data, the results I have provided in chapter 5 provide support for the 
potential modulatory effect of a dietary nitrate strategy in inflammatory disorders. 
However, whether nitrate/nitrite might reduce CD11b or P-selectin in CVD models of 
atherosclerosis and hypertension is unknown. Assessment of the inflammatory 
response in ApoE KO mice and in SHR would address this issue. 
 
Much evidence now supports the notion that leukocyte recruitment is likely to be 
pathogenic in atherosclerotic disease. Indeed, circulating neutrophil numbers and 
levels of neutrophil chemokines (Zineh et al., 2008) are correlated with severity in 
acute coronary syndromes as well as being evident in thrombi and at sites of plaque 
and rupture in patients (Naruko et al., 2002; Weber et al., 2008; Naruko et al., 2010). 
Furthermore a relationship between hypertension and WBC count has been 
demonstrated with one population-based study finding an association between 
elevated WBC count and incident hypertension (Shankar et al., 2004). In addition, 
leukocytes have been identified at lesional sites in the early stages of plaque 
formation, and neutrophil depletion is associated with decreased atherosclerotic load 
in mouse models of disease (van Leeuwen et al., 2008; Zernecke et al., 2008; Hazen, 
2010). As leukocyte recruitment has been implicated in CVD and the findings 
presented here suggest that leukocyte recruitment can be attenuated in acute 
inflammation, the effects of dietary nitrate on leukocyte recruitment may in part 
explain the cardioprotective effects seen with green leafy vegetables. 
6.4 Conclusions 
The results of this thesis offer insight into how conditions associated with depleted NO 
production (e.g. atherosclerosis and hypertension) affect the distribution of nitrite and 
nitrate in the tissues. In most tissues it was observed that nitrate levels were 
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significantly reduced in disease models associated with cardiovascular inflammation. 
Moreover, my studies show that an efficient method of elevating nitrate/nitrite back 
to baseline levels is through dietary inorganic nitrate supplementation. My results 
have important implications for future investigations and also potentially offer 
evidence for the development of a diagnostic marker of atherosclerosis based upon 
nitrate. In addition my data advocates the administration of inorganic dietary nitrate in 
both hypertension and atherosclerosis. The use of a dietary intervention in this way 
represents an option that is cheap, effective and readily available. 
 
CVD causes 1/3 of all deaths in the UK with coronary heart disease being responsible 
for ~50% of these deaths and 28% from stroke. Hypertension is a major risk factor for 
CVD and is predicted to reach a global prevalence of 30% by 2025 (Kearney et al., 
2005). Whilst the lipid lowering drugs, the statins, and aspirin have substantially 
reduced the incidence of mortality from such disease (Baigent et al., 2005; Patrono et 
al., 2005) a significant mortality remains and with increasing levels of morbidity a 
substantial health burden persists. There is, therefore, a need to find therapies to 
further reduce this health burden. Since CVD is characterised by a pathogenic state of 
inflammation identification of agents that might improve this state is an area of great 
interest and potential therapeutic utility. Previous work suggests that a dietary nitrate 
approach might underlie the benefits of fruit- and vegetable-rich diets, in part by 
suppressing inflammatory phenomena occurring at the level of the endothelium. The 
research carried out in this thesis largely advocates the consumption of a diet high in 
nitrate i.e. a natural and low cost strategy, which may be useful in protecting 
individuals from atherosclerotic and hypertensive disease and diseases associated with 
cardiovascular inflammation, thereby ultimately decreasing both healthcare costs and 
the number of adverse events.  
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